WO2006102342A2 - Production of carotenoids in oleaginous yeast and fungi - Google Patents

Production of carotenoids in oleaginous yeast and fungi Download PDF

Info

Publication number
WO2006102342A2
WO2006102342A2 PCT/US2006/010271 US2006010271W WO2006102342A2 WO 2006102342 A2 WO2006102342 A2 WO 2006102342A2 US 2006010271 W US2006010271 W US 2006010271W WO 2006102342 A2 WO2006102342 A2 WO 2006102342A2
Authority
WO
WIPO (PCT)
Prior art keywords
fungus
polypeptide
carotenoid
carotenogenic
oleaginic
Prior art date
Application number
PCT/US2006/010271
Other languages
French (fr)
Other versions
WO2006102342A3 (en
Inventor
Richard Bailey
Kevin T. Madden
Joshua Trueheart
Original Assignee
Microbia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP06748522A priority Critical patent/EP1866428A2/en
Application filed by Microbia, Inc. filed Critical Microbia, Inc.
Priority to JP2008502155A priority patent/JP2008537878A/en
Priority to CA2602183A priority patent/CA2602183C/en
Priority to KR1020077021286A priority patent/KR101482081B1/en
Priority to EA200701974A priority patent/EA016258B1/en
Priority to AU2006227165A priority patent/AU2006227165B2/en
Priority to CN2006800088162A priority patent/CN101218352B/en
Priority to BRPI0609040-0A priority patent/BRPI0609040B1/en
Publication of WO2006102342A2 publication Critical patent/WO2006102342A2/en
Priority to IL185713A priority patent/IL185713A0/en
Priority to ZA2007/07651A priority patent/ZA200707651B/en
Priority to NO20075200A priority patent/NO20075200L/en
Publication of WO2006102342A3 publication Critical patent/WO2006102342A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A23L31/10—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P23/00—Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes

Definitions

  • Carotenoids are organic pigments ranging in color from yellow to red that are naturally produced by certain organisms, including photosynthetic organisms (e.g., plants, algae, cyanobacteria), and some fungi. Carotenoids are responsible for the orange color of carrots, as well as the pink in flamingos and salmon, and the red in lobsters and shrimp. Animals, however, cannot produce carotenoids and must receive them through their diet.
  • Carotenoid pigments e.g., ⁇ -carotene and astaxanthin
  • Carotenoid pigments are used industrially as ingredients for food and feed stocks, both serving a nutritional function and enhancing consumer acceptability.
  • carotenoids are also precursors of vitamin A.
  • carotenoids have antioxidant properties, and may have various health benefits (see, for example, Jyonouchi et al., Nutr, Cancer 16:93, 1991; Giovannucci et al., /. Natl. Cancer Inst. 87:1767, 1995; Miki, Pure Appl. Chem 63:141, 1991; Chew et al., Anticancer Res. 19:1849, 1999; Wang et al., Antimicrob. Agents Chemother. 44:2452, 2000).
  • Some carotenoids such as ⁇ -carotene, lycopene, and lutein are currently sold as nutritional supplements.
  • the present invention provides improved systems for the biological production of carotenoids.
  • the invention encompasses the discovery that it is desirable to produce carotenoids in oleaginous organisms.
  • the present inventors propose that biological systems may be able to accumulate higher levels of carotenoids if the compounds are sequestered in lipid bodies. Regardless of whether absolute levels are higher, however, carotenoids that are accumulated within lipid bodies in oleaginous organisms are readily isolatable through isolation of the lipid bodies.
  • the present invention therefore provides oleaginous fungi (including, for example, yeast or other unicellular fungi) that produce one or more carotenoids.
  • the present invention also provides methods of constructing such yeast and fungi, methods of using such yeast and fungi to produce carotenoids, and methods of preparing carotenoid-containing compositions, such as food or feed additives, or nutritional supplements, using carotenoids produced in such oleaginous yeast or fungi.
  • the present invention provides systems and methods for generating yeast and fungi containing one or more oleaginic and/or carotenogenic modifications that increase the oleaginicity and/or alter their carotenoid- producing capabilities as compared with otherwise identical organisms that lack the modif ⁇ cation(s).
  • the present invention further encompasses the general recognition that lipid- accumulating systems are useful for the production and/or isolation of lipophilic agents (such as, but not limited to isoprenoids, or isoprenoid-derived compounds).
  • lipophilic agents such as, but not limited to isoprenoids, or isoprenoid-derived compounds.
  • Figure IA-I D depicts certain common carotenoids.
  • Figure 2 depicts how sufficient levels of acetyl-CoA and NADPH may be accumulated in the cytosol of oleaginous organisms to allow for production of significant levels of cytosolic lipids.
  • Enzymes 1, pyruvate decarboxylase; 2, malate dehydrogenase; 3, malic enzyme; 4, pyruvate dehydrogenase; 5, citrate synthase; 6, ATP-citrate lyase; 7, citrate/malate translocase.
  • Figures 3 A and 3B depict the mevalonate isoprenoid biosynthesis pathway, which typically operates in eukaryotes, including fungi.
  • Figure 4 depicts the mevalonate-independent isoprenoid biosynthesis pathway, also known as the DXP pathway, which typically operates in bacteria and in the plastids of plants.
  • Figure 5 depicts intermediates in the isoprenoid biosynthesis pathway and how they feed into biosynthetic pathways of other biomolecules, including carotenoids as well as non-carotenoid compounds such as sterols, steroids, and vitamins, such as vitamin E or vitamin K.
  • Figures 6A-6D illustrate various carotenoid biosynthetic pathways.
  • FIG. 6A highlights branches leading to various cyclic and acyclic xanthophylls;
  • Figure 6B shows certain X. dendrorhous pathways that generate dicyclic and monocyclic carotenoids, including astaxanthin;
  • Figure 6C shows interconnecting pathways for converting ⁇ -carotene into any of a variety of other carotenoids, including astaxanthin;
  • Figure 6D depicts possible routes of synthesis of cyclic carotenoids and common plant and algal xanthophylls from neurosporene.
  • Figures 7A-7C show an alignment of certain representative fungal HMG-
  • CoA reductase polypeptides show very high identity across the catalytic region, and also have complex membrane spanning domains. In some embodiments of the invention, these membrane-spanning domains are disrupted or are removed, so that, for example, a hyperactive version of the polypeptide may be produced.
  • Figures 8A-8D depict schematic representations of plasmids generated and described in detail in the exemplification.
  • Carotenogenic modification refers to a modification of a host organism that adjusts production of one or more carotenoids, as described herein.
  • a carotenogenic modification may increase the production level of one or more carotenoids, and/or may alter relative production levels of different carotenoids.
  • an inventive carotenogenic modification may be any chemical, physiological, genetic, or other modification that appropriately alters production of one or more carotenoids in a host organism produced by that organism as compared with the level produced in an otherwise identical organism not subject to the same modification.
  • the carotenogenic modification will comprise a genetic modification, typically resulting in increased production of one or more selected carotenoids.
  • the selected carotenoid is one or more of astaxanthin, ⁇ -carotene, canthaxanthin, lutein, lycopene, phytoene, zeaxanthin, and/or modifications of zeaxanthin or astaxanthin (e.g., glucoside, esterif ⁇ ed zeaxanthin or astaxanthin).
  • the selected carotenoid is one or more xanthophylls, and/or a modification thereof (e.g., glucoside, esterif ⁇ ed xanthophylls).
  • the selected xanthophyl is selected from the group consisting of astaxanthin, lutein, zeaxanthin, lycopene, and modifications thereof.
  • the selected carotenoid is one or more of astaxanthin, ⁇ -carotene, canthaxanthin, lutein, lycopene, and zeaxanthin and/or modifications of zeaxanthin or astaxanthin.
  • the carotenoid is ⁇ -carotene.
  • the selected carotenoid is astaxanthin.
  • the selected carotenoid is other than ⁇ -carotene.
  • Carotenogenic polypeptide refers to any polypeptide that is involved in the process of producing carotenoids in a cell, and may include polypeptides that are involved in processes other than carotenoid production but whose activities affect the extent or level of production of one or more carotenoids, for example by scavenging a substrate or reactant utilized by a carotenoid polypeptide that is directly involved in carotenoid production.
  • Carotenogenic polypeptides include isoprenoid biosynthesis polypeptides, carotenoid biosynthesis polypeptides, and isoprenoid biosynthesis competitor polypeptides, as those terms are defined herein. The term also encompasses polypeptides that may affect the extent to which carotenoids are accumulated in lipid bodies.
  • Carotenoid The term "carotenoid” is understood in the art to refer to a structurally diverse class of pigments derived from isoprenoid pathway intermediates. The commitment step in carotenoid biosynthesis is the formation of phytoene from geranylgeranyl pyrophosphate. Carotenoids can be acyclic or cyclic, and may or may not contain oxygen, so that the term carotenoids include both carotenes and xanthophylls.
  • carotenoids are hydrocarbon compounds having a conjugated polyene carbon skeleton formally derived from the five-carbon compound IPP, including triterpenes (C 30 diapocarotenoids) and tetraterpenes (C 40 carotenoids) as well as their oxygenated derivatives and other compounds that are, for example, C 35 , C 50 , C 6 o, C 70 , C 80 in length or other lengths.
  • C 2 oo- C 30 diapocarotenoids typically consist of six isoprenoid units joined in such a manner that the arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1 ,6-positional relationship and the remaining non-terminal methyl groups are in a 1,5- positional relationship.
  • Such C 30 carotenoids may be formally derived from the acyclic C 30 H 42 structure, having a long central chain of conjugated double bonds, by: (i) hydrogenation (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v) esterification/glycosylation, or any combination of these processes.
  • C 40 carotenoids typically consist of eight isoprenoid units joined in such a manner that the arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1,6-positional relationship and the remaining non-terminal methyl groups are in a 1,5- positional relationship.
  • Such C 40 carotenoids may be formally derived from the acyclic C 40 H 56 structure, having a long central chain of conjugated double bonds, by (i) hydrogenation, (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v) esterification/glycosylation, or any combination of these processes.
  • the class of C 40 carotenoids also includes certain compounds that arise from rearrangements of the carbon skeleton, or by the (formal) removal of part of this structure. More than 600 different carotenoids have been identified in nature; certain common carotenoids are depicted in Figure 1.
  • Carotenoids include but are not limited to: antheraxanthin, adonirubin, adonixanthin, astaxanthin, canthaxanthin, capsorubrin, ⁇ -cryptoxanthin, ⁇ -carotene, ⁇ -carotene, ⁇ , ⁇ - carotene, ⁇ -carotene, ⁇ -carotene, echinenone, 3-hydroxyechinenone, 3'-hydroxyechinenone, ⁇ - carotene, ⁇ -carotene, 4-keto- ⁇ -carotene, ⁇ -carotene, ⁇ -cryptoxanthin, deoxyflexixanthin, diatoxanthin, 7,8-didehydroastaxanthin, didehydrolycopene, fucoxanthin, fucoxanthinol, isorenieratene, ⁇ -isorenieratene, lactucaxanthin, lutein, lycopene, myx
  • carotenoid compounds include derivatives of these molecules, which may include hydroxy-, methoxy-, oxo-, epoxy-, carboxy-, or aldehydic functional groups. Further, included carotenoid compounds include ester (e.g., glycoside ester, fatty acid ester) and sulfate derivatives (e.g., esterified xanthophylls).
  • ester e.g., glycoside ester, fatty acid ester
  • sulfate derivatives e.g., esterified xanthophylls
  • Carotenoid biosynthesis polypeptide refers to any polypeptide that is involved in the synthesis of one or more carotenoids.
  • these carotenoid biosynthesis polypeptides include, for example, polypeptides of phytoene synthase, phytoene dehydrogenase (or desaturase), lycopene cyclase, carotenoid ketolase, carotenoid hydroxylase, astaxanthin synthase, carotenoid epsilon hydroxylase, lycopene cyclase (beta and epsilon subunits), carotenoid glucosyltransferase, and acyl CoA:diacyglycerol acyltransferase.
  • Gene generally refers to a nucleic acid encoding a polypeptide, optionally including certain regulatory elements that may affect expression of one or more gene products (i.e., RNA or protein).
  • Heterologous refers to genes or polypeptides, refers to a gene or polypeptide that does not naturally occur in the organism in which it is being expressed. It will be understood that, in general, when a heterologous gene or polypeptide is selected for introduction into and/or expression by a host cell, the particular source organism from which the heterologous gene or polypeptide may be selected is not essential to the practice of the present invention. Relevant considerations may include, for example, how closely related the potential source and host organisms are in evolution, or how related the source organism is with other source organisms from which sequences of other relevant polypeptides have been selected.
  • Host cell As used herein, the "host cell” is a yeast or fungal cell that is manipulated according to the present invention to accumulate lipid and/or to express one or more carotenoids as described herein.
  • a "modified host cell”, as that term is used herein, is a host cell that contains at least one oleaginic modification and/or at least one carotenogenic modification according to the present invention.
  • Isolated means that the isolated entity has been separated from at least one component with which it was previously associated. When most other components have been removed, the isolated entity is “purified”. Isolation and/or purification may be performed using any techniques known in the art including, for example, fractionation, extraction, precipitation, or other separation.
  • Isoprenoid biosynthesis competitor polypeptide The term “isoprenoid biosynthesis competitor polypeptide”, as used herein, refers to a polypeptide whose expression in a cell reduces the level of geranylgeranyl diphosphate (GGPP) available to enter the carotenoid biosynthesis pathway.
  • GGPP geranylgeranyl diphosphate
  • isoprenoid biosynthesis competitor polypeptides include enzymes that act on isoprenoid intermediates prior to GGPP, such that less GGPP is generated (see, for example, Figure 5).
  • Squalene synthase is but one isoprenoid biosynthesis competitor polypeptide according to the present invention; representative squalene synthase sequences are presented in Table 16.
  • Prenyldiphosphate synthase enzymes and/? ⁇ r ⁇ -hydroxybenzoate (PHB) polypreny transferase are yet additional isoprenoid biosynthesis competitor polypeptides according to the present invention; representative prenyldiphosphate synthase enzymes and PHB polyprenyltransferase polypeptides are presented in Table 29 and 30 respectively.
  • Isoprenoid biosynthesis polypeptide refers to any polypeptide that is involved in the synthesis of isoprenoids. For example, as discussed herein, acetoacetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, IPP isomerase, FPP synthase, and GGPP synthase, are all involved in the mevalonate pathway for isoprenoid biosynthesis.
  • Isoprenoid pathway The "isoprenoid pathway” is understood in the art to refer to a metabolic pathway that either produces or utilizes the five-carbon metabolite isopentyl pyrophosphate (IPP). As discussed herein, two different pathways can produce the common isoprenoid precursor IPP — the “mevalonate pathway” and the “non-mevalonate pathway”. The term “isoprenoid pathway” is sufficiently general to encompass both of these types of pathway.
  • Isoprenoid metabolites derived from IPP are of varying size and chemical structure, including both cyclic and acyclic molecules. Isoprenoid metabolites include, but are not limited to, monoterpenes, sesquiterpenes, diterpenes, sterols, and polyprenols such as carotenoids.
  • Oleaginic modification refers to a modification of a host organism that adjusts the desirable oleaginy of that host organism, as described herein.
  • the host organism will already be oleaginous in that it will have the ability to accumulate lipid to at least about 20% of its dry cell weight. It may nonetheless be desirable to apply an oleaginic modification to such an organism, in accordance with the present invention, for example to increase (or, in some cases, possibly to decrease) its total lipid accumulation, or to adjust the types or amounts of one or more particular lipids it accumulates (e.g., to increase relative accumulation of triacylglycerol).
  • the host organism may be non-oleaginous (though may contain some enzymatic and regulatory components used in other organisms to accumulate lipid), and may require oleaginic modification in order to become oleaginous in accordance with the present invention.
  • the present invention also contemplates application of oleaginic modification to non-oleaginous host strains such that their oleaginicity is increased even though, even after being modified, they may not be oleaginous as defined herein.
  • the oleaginic modification may be any chemical, physiological, genetic, or other modification that appropriately alters oleaginy of a host organism as compared with an otherwise identical organism not subjected to the oleaginic modification.
  • the oleaginic modification will comprise a genetic modification, typically resulting in increased production and/or activity of one or more oleaginic polypeptides.
  • the oleaginic modification comprises at least one chemical, physiological, genetic, or other modification; in other embodiments, the oleaginic modification comprises more than one chemical, physiological, genetic, or other modification. In certain aspects where more than one modification is utilized, such modifications can comprise any combination of chemical, physiological, genetic, or other modification (e.g., one or more genetic modification and chemical or physiological modification).
  • Oleaginic polypeptide refers to any polypeptide that is involved in the process of lipid accumulation in a cell and may include polypeptides that are involved in processes other than lipid biosynthesis but whose activities affect the extent or level of accumulation of one or more lipids, for example by scavenging a substrate or reactant utilized by an oleaginic polypeptide that is directly involved in lipid accumulation.
  • acetyl-CoA carboxylase, pyruvate decarboxylase, isocitrate dehydrogenase, ATP-citrate lyase, malic enzyme, and AMP deaminase are all involved in lipid accumulation in cells.
  • reducing the activity of pyruvate decarboxylase or isocitrate dehydrogenase, and/or increasing the activity of acetyl CoA carboxylase, ATP-citrate lyase, malic enzyme and/or AMP deaminase is expected to promote oleaginy.
  • Each of these proteins is an oleaginic polypeptide for purposes of the present invention, and sequences of representative examples of these enzymes are provided in Tables 1-6.
  • Oleaginous refers to the ability of an organism to accumulate lipid to at least about 20% of its dry cell weight.
  • oleaginous yeast or fungi accumulate lipid to at least about 25% of their dry cell weight.
  • inventive oleaginous yeast or fungi accumulate lipid within the range of about 20-45% of their dry cell weight.
  • oleaginous organisms may accumulate lipid to as much as about 70% of their dry cell weight.
  • oleaginous organisms may accumulate a large fraction of total lipid accumulation in the form of triacylglycerol.
  • the majority of the accumulated lipid is in the form of triacylglycerol.
  • the lipid may accumulate in the form of intracellular lipid bodies, or oil bodies.
  • the present invention utilizes yeast or fungi that are naturally oleaginous.
  • naturally oleaginous organisms are manipulated (e.g., genetically, chemically, or otherwise) so as to futher increase the level of accumulated lipid in the organism.
  • yeast or fungi that are not naturally oleaginous are manipulated (e.g., genetically, chemically, or otherwise) to accumulate lipid as described herein.
  • Xanthophyllomyces dendrorhous (Phaffia rhodo ⁇ ym ⁇ ) and Candida utilis are not naturally oleaginous fungi.
  • Polypeptide generally has its art- recognized meaning of a polymer of at least three amino acids. However, the term is also used to refer to specific functional classes of polypeptides, such as, for example, oleaginic polypeptides, carotenogenic polypeptides, isoprenoid biosynthesis polypeptides, carotenoid biosynthesis polypeptides, and isoprenoid biosynthesis competitor polypeptides. For each such class, the present specification provides several examples of known sequences of such polypeptides.
  • polypeptide is intended to be sufficiently general as to encompass not only polypeptides having the complete sequence recited herein (or in a reference or database specifically mentioned herein), but also to encompass polypeptides that represent functional fragments (i.e., fragments retaining at least one activity) of such complete polypeptides.
  • polypeptides generally tolerate some substitution without destroying activity.
  • highly conserved regions e.g., isocitrate dehydrogenase polypeptides often share a conserved AMP-binding motif
  • HMG-CoA reductase polypeptides typically include a highly conserved catalytic domain (see, for
  • Source organism refers to the organism in which a particular polypeptide sequence can be found in nature.
  • source organism refers to the organism in which a particular polypeptide sequence can be found in nature.
  • source organism the organism in which the polypeptides are expressed in nature (and/or from which their genes were originally cloned) is referred to as the "source organism".
  • source organism may be utilized for independent selection of each of the heterologous polypeptide(s). It will be appreciated that any and all organisms that naturally contain relevant polypeptide sequences may be used as source organisms in accordance with the present invention.
  • Representative source organisms include, for example, animal, mammalian , insect, plant, fungal, yeast, algal, bacterial, cyanobacterial, archaebacterial and protozoal source organisms.
  • the present invention encompasses the discovery that carotenoids can desirably be produced in oleaginous yeast and fungi.
  • strains that both (i) accumulate lipid, often in the form of cytoplasmic oil bodies and typically to at least about 20% of their dry cell weight; and (ii) produce carotenoid(s) at a level at least about 1%, and in some embodiments at least about 3-20%, of their dry cell weight, are generated through manipulation of host cells (i.e., strains, including, e.g., naturally-occurring strains, strains which have been previously modified, etc.). These manipulated host cells are then used to produce carotenoids, so that carotenoids that partition into the lipid bodies can readily be isolated.
  • host cells i.e., strains, including, e.g., naturally-occurring strains, strains which have been previously modified, etc.
  • this strategy involves engineering cells to be oleaginous; in other embodiments, it involves engineering cells to accumulate a higher level of lipid, particularly cytoplasmic lipid, than they would accumulate in the absence of such engineering even though the engineered cells may not become "oleaginous" as defined herein. In other embodiments, the extent to which an oleaginous host cell accumulates lipid is actually reduced so that remaining carbon can be utilized in carotenoid production.
  • yeast and fungal strains exist that are naturally oleaginous or that naturally produce carotenoids. Any of such strains may be utilized as host strains according to the present invention, and may be engineered or otherwise manipulated to generate inventive oleaginous, carotenoid- producing strains. Alternatively, strains that naturally are neither oleaginous nor carotenoid- producing may be employed. Furthermore, even when a particular strain has a natural capacity for oleaginy or for carotenoid production, its natural capabilities may be adjusted as described herein, so as to change the production level of lipid and/or carotenoid.
  • engineering or manipulation of a strain results in modification of a type of lipid and/or carotenoid which is produced.
  • a strain may be naturally oleaginous and/or carotenogenic, however engineering or modification of the strain may be employed so as to change the type of lipid which is accumulated and or to change the type of carotenoid which is produced.
  • a particular yeast or fungal strain for use in accordance with the present invention it will generally be desirable to select one whose cultivation characteristics are amenable to commercial scale production. For example, it will generally (though not necessarily always) be desirable to avoid filamentous organisms, or organisms with particularly unusual or stringent requirements for growth conditions. However, where conditions for commercial scale production can be applied which allow for utilization of filamentous organisms, these may be selected as host cells. In some embodiments of the invention, it will be desirable to utilize edible organisms as host cells, as they may optionally be formulated directly into food or feed additives, or into nutritional supplements, as desired.
  • some embodiments of the invention utilize host cells that are genetically tractable, amenable to molecular genetics (e.g., can be efficiently transformed, especially with established or available vectors; optionally can incorporate and/or integrate multiple genes, for example sequentially; and/or have known genetic sequence; etc), devoid of complex growth requirements (e.g., a necessity for light), mesophilic (e.g., prefer growth temperatures with in the range of about 25-32 0 C), able to assimilate a variety of carbon and nitrogen sources and/or capable of growing to high cell density.
  • various embodiments of the invention utilize host cells that grow as single cells rather than multicellular organisms (e.g., as mycelia).
  • any modifiable and cultivatable oleaginous organism may be employed.
  • yeast or fungi of genera including, but not limited to, Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Mucor, Phycomyces, Pythium, Rltodosporidium, Rliodotorula, Trichosporon, and Yarrow ia are employed.
  • organisms of species that include, but are not limited to, Blakeslea frispora, Candida pulcherrima, C. revkau ⁇ , C.
  • any organism that is naturally oleaginous and non-carotenoid- producing may be utilized as a host cell in accordance with the present invention.
  • the organism is a yeast or fungus from a genus such as, but not limited to, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Pythium, Trichosporon, and Yarrowia; in some embodiments, the organism is of a species including, but not limited to, Mortierella alpina and Yarrowia lipolytica.
  • the present invention may utilize any naturally oleaginous, carotenoid-producing organism as a host cell.
  • the present invention may be utilized to increase carbon flow into the isoprenoid pathway in naturally carotenoid-producing organisms (particularly for organisms other than Blakeslea and Phycomyces), and/or to shift production from one carotenoid (e.g., ⁇ -carotene) to another (e.g., astaxanthin).
  • one or more carotenogenic modifications e.g., increased expression of one or more endogenous or heterologous carotenogenic polypeptides
  • the utilized oleaginous, carotenoid- producing organism is a yeast or fungus, for example of a genus such as, but not limited to, Blakeslea, Mucor, Phycomyces, Khodosporidium, and Rhodotorula; in some embodiments, the organism is of a species such as, Mucor circinelloides and PJjodotorula glutinis.
  • genera of non-oleaginous yeast or fongi include, but are not limited to, Aspergillus, Botrytis, Cercospora, Fusarium (Gibberella), Kluyveromyces, Neurospora, Penicillium, Pichia (Hansenula), Puccinia, Saccharomyces, Sclerotium, Trichoderma, and Xanthophyllomyces (Phaffia); in some embodiments, the organism is of a species including, but not limited to, Aspergillus nidulans, A. niger, A.
  • Botrytis cinerea Cercospora nicotianae, Fusarium fujikuroi ⁇ Gibberella zeae), Kluyveromyces lactis, K. lactis, Neurospora crassa, Pichia pastoris, Puccinia distincta, Saccharomyces cerevisiae, Sclerotium rolfsii, Trichoderma reesei, and Xanthophyllomyces dendrorhous (Phaffia rhodozyma).
  • non-oleaginous encompasses both strains that naturally have some ability to accumulate lipid, especially cytoplasmically, but do not do so to a level sufficient to qualify as “oleaginous” as defined herein, as well as strains that do not naturally have any ability to accumulate extra lipid, e.g., extra-membranous lipid. It will further be appreciated that, in some embodiments of the invention, it will be sufficient to increase the natural level of oleaginy of a particular host cell, even if the modified cell does not qualify as oleaginous as defined herein.
  • Genera of naturally non-oleaginous fungi that do not naturally produce carotenoids may desirably be used as host cells in accordance with the present invention include, but are not limited to, Aspergillus, Kluyveromyces, Penicillium, Saccharomyces, and Pichia; species include, but are not limited to, Aspergillus niger and Saccharomyces cerevisiae.
  • Genera of naturally non-oleaginous fungi that do naturally produce carotenoids and that may desirably be used as host cells in accordance with the present invention include, but are not limited to, Botrytis, Cercospora, Fusarium (Gibberella), Neurospora, Puccinia, Sclerotium, Trichoderma, and Xanthophyllomyces (Phaffia); species include, but are not limited to, Xanthophyllomyces dendrorhous (Phaffia rhodozyma).
  • host cells will be Yarrowia lipolytica cells.
  • Advantages of 7. lipolytica include, for example, tractable genetics and molecular biology, availability of genomic sequence (see, for example. Sherman et al. Nucleic Acids Res. 32(Database issue):D315-8, 2004), suitability to various cost-effective growth conditions, and ability to grow to high cell density.
  • Y. lipolytica is naturally oleaginous, such that fewer manipulations may be required to generate an oleaginous, carotenoid-producing Y. lipolytica strain than might be required for other organisms.
  • Saccharomyces cerevisiae is also a useful host cell in accordance with the present invention, particularly due to its experimental tractability and the extensive experience that researchers have accumulated with the organism. Although cultivation of Saccharomyces under high carbon conditions may result in increased ethanol production, this can generally be managed by process and/or genetic alterations.
  • Additional useful hosts include Xanthophyllomyces dendrorhous (Phaffia rhodozyma), which is experimentally tractable and naturally carotenogenic.
  • Xanthophyllomyces dendrorhous (Phaffia rhodozyma) strains can produce several carotenoids, including astaxanthin.
  • Aspergillus niger and Mortierella alpina accumulate large amounts of citric acid and fatty acid, respectively; Mortierella alpina is also oleaginous.
  • Neurospora or Gibberella are also useful. They are not naturally oleaginous and tend to produce very low levels of carotenoids, thus extensive modification may be required in accordance with the present invention. Neurospora and Gibberella are considered relatively tractable from an experimental standpoint. Both are filamentous fungi, such that production at commercial scales can be a challenge necessary to overcome in utilization of such strains.
  • Mucor circinelloides is another available useful species. While its molecular genetics are generally less accessible than are those of some other organisms, it naturally produces ⁇ -carotene, thus may require less modification than other species available. [0051] Molecular genetics can be performed in Blakeslea, though significant effort may be required. Furthermore, cost-effective fermentation conditions can be challenging, as, for example, it may be required that the two mating types are mixed. Fungi of the genus Phycomyces are also possible sources which have the potential to pose fermentation process challenges, and these fungi are also may be less amenable to manipulate than several other potential host organisms.
  • targeting sequences of the host cell may be useful to include for directing heterologous proteins to subcellular localization.
  • useful targeting sequences can be added to heterologous sequence for proper intracellular localization of activity.
  • heterologous targeting sequences may be eliminated or altered in the selected heterologous sequence (e.g., alteration or removal of source organism plant chloroplast targeting sequences).
  • oleaginous organisms typically only accumulate lipid when grown under conditions of carbon excess and nitrogen or other nutrient limitation. Under these conditions, the organism readily depletes the limiting nutrient but continues to assimilate the carbon source. The "excess" carbon is channeled into lipid biosynthesis so that lipids (usually triacylglycerols) accumulate in the cytosol, typically in the form of bodies.
  • lipids usually triacylglycerols
  • Citric acid is generated in the mitochondria of all eukaryotic cells through the tricarboxylic acid (TCA) cycle, and can be moved into the cytosol (in exchange for malate) by citrate/malate translocase.
  • the enzyme isocitrate dehydrogenase which operates as part of the TCA cycle in the mitochondria, is strongly AMP-dependent. Thus, when AMP is depleted from the mitochondria, this enzyme is inactivated. When isocitrate dehydrogenase is inactive, isocitrate accumulates in the mitochondria. This accumulated isocitrate is then equilibrated with citric acid, presumably through the action of aconitase. Therefore, under conditions of low AMP, citrate accumulates in the mitochondria. As noted above, mitochondrial citrate is readily transported into the cytosol.
  • AMP depletion which in oleaginous organisms is believed to initiate the cascade leading to accumulation of citrate (and therefore acetyl-CoA) in the cytoplasm, occurs as a result of the nutrient depletion mentioned above.
  • citrate and therefore acetyl-CoA
  • AMP deaminase which catalyzes the reaction:
  • oleaginy requires both cytosolic acetyl-CoA and cytosolic
  • NADPH NADPH. It is believed that, in many oleaginous organisms, appropriate levels of cytosolic NADPH are provided through the action of malic enzyme (Enzyme 3 in Figure 2). Some oleaginous organisms (e.g., Lipomyces and some Candida) do not appear to have malic enzymes, however, so apparently other enzymes can provide comparable activity, although it is expected that a dedicated source of NADPH is probably required for fatty acid synthesis (see, for example, Wynn et al., Microbiol 145:1911, 1999; Ratledge Adv. Appl. Microbiol. 51 :1, 2002, each of which is incorporated herein by reference in its entirety).
  • malic enzyme Enzyme 3 in Figure 2
  • the oleaginy of a host organism may be enhanced by modifying the expression or activity of one or more polypeptides involved in generating cytosolic acetyl-CoA and/or NADPH.
  • modification of the expression or activity of one or more of acetyl-CoA carboxylase, pyruvate decarboxylase, ⁇ socitrate dehydrogenase, ATP-citrate lyase, malic enzyme, and AMP-deaminase can enhance oleaginy in accordance with the present invention.
  • Exemplary polypeptides which can be utilized or derived so as to enhance oleaginy in accordance with the present invention include, but are not limited to those acetyl-CoA carboxylase, pyruvate decarboxylase, isocitrate dehydrogenase, ATP-citrate lyase, malic enzyme, and AMP-deaminase polypeptides provided in Table 1, Table 2, Table 3, Table 4, Table 5, and Table 6, respectively.
  • enzymes and regulatory components relevant to oleaginy are already in place but could be modified, if desired, by for example altering expression or activity of one or more oleaginic polypeptides and/or by introducing one or more heterologous oleaginic polypeptides.
  • enzymes and regulatory components relevant to oleaginy are already in place but could be modified, if desired, by for example altering expression or activity of one or more oleaginic polypeptides and/or by introducing one or more heterologous oleaginic polypeptides.
  • a non-oleaginous host cell it is generally expected that at least one or more heterologous oleaginic polypeptides will be introduced.
  • the present invention contemplates not only introduction of heterologous oleaginous polypeptides, but also adjustment of expression or activity levels of heterologous or endogenous oleaginic polypeptides, including, for example, alteration of constitutive or inducible expression patterns.
  • expression patterns are adjusted such that growth in nutrient-limiting conditions is not required to induce oleaginy.
  • genetic modifications comprising alteration and/or addition of regulatory sequences (e.g., promoter elements, terminator elements) may be utilized to confer particular regulation of expression patterns.
  • Such genetic modifications may be utilized in conjunction with endogenous genes (e.g., for regulation of endogenous oleagenic polypeptide(s)); alternatively, such genetic modifications may be included so as to confer regulation of expression of at least one heterologous polypeptide (e.g., oleagenic polypeptide(s)).
  • promoters including, but not limited to Tefl, Gpdl promoters can be used in conjunction with endogenous genes and/or heterolous genes for modification of expression patterns of endogenous oleaginic polypeptides and/or heterolous oleagenic polypeptides.
  • exemplary terminator sequences include, but are not limited to, use of Y. lipolytica XPR2 terminator sequences.
  • At least one oleaginic polypeptide is introduced into a host cell.
  • a plurality e.g., two or more
  • the plurality of oleaginic polypeptides contains polypeptides from the same source organism; in other embodiments, the plurality includes polypeptides independently selected from different source organisms.
  • Representative examples of a variety of oleaginic polypeptides that may be introduced into or modified within host cells according to the present invention, include, but are not limited to, those provided in Tables 1-6.
  • these polypeptides e.g., malic enzyme and ATP-citrate lyase
  • source organisms for oleaginic polypeptides to be used in accordance with the present invention include, but are not limited to, Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Mucor, Phycomyces, Pythium, Rhodosporidium, Bliodotorula, Trichosporon, Yarrowia, Aspergillus, Botrytis, Cercospora, Fusarium (Gibberella), Kluyveromyces, Neurospora, Penicillium, Pichia (Hansenula), Puccinia, Saccharomyces, Sclerotium, Trichoderma, and Xanthophyllomyces (Phaffia).
  • the source species for acetyl CoA carboxylase, ATP-citrate lyase, malice enzyme and/or AMP deaminase polypeptides include, but are not limited to, Aspergillus nidulans, Cryptococcus neoformans, Fusarium fuj ⁇ kuroi, Kluyveromyces lactis, Neurospora crassa, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Ustilago maydis, and Yarrowia lipolytics
  • source species for pyruvate decarboxylase or isocitrate dehydrogenase polypeptides include, but are not limited to Neurospora crassa, Xanthophyllomyces dendrorhous (Phaffia rhodozyma), Aspergillus niger, Saccharomyces cerevisiae, Mu
  • Carotenoids are synthesized from isoprenoid precursors, some of which are also involved in the production of steroids and sterols.
  • the most common isoprenoid biosynthesis pathway is generally depicted in Figure 3.
  • acetyl-CoA is converted, via hydroxymethylglutaryl-CoA (HMG-CoA), into mevalonate.
  • Mevalonate is then phosphorylated and converted into the five-carbon compound isopentenyl pyrophosphate (IPP).
  • IPP isopentenyl pyrophosphate
  • DOXP 1 -deoxy-D- xyloglucose-5-phosphate
  • polypeptides corresponding to the acetoacetyl-CoA thiolase, HMG- CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, IPP isomerase, FPP synthase, and GGPP synthase shown in Figure 3 have been identified in and isolated from a wide variety of organisms and cells.
  • polypeptides are provided in Tables 7-15.
  • One or more of the polypeptides selected from those provided in any one of Tables 7- 15 may be utilized or derived for use in the methods and compositions in accordance with the present invention.
  • carotenoid production in a host organism may be adjusted by modifying the expression or activity of one or more proteins involved in isoprenoid biosynthesis.
  • modification involves introduction of one or more heterologous isoprenoid biosynthesis polypeptides into the host cell; alternatively or additionally, modifications may be made to the expression or activity of one or more endogenous or heterologous isoprenoid biosynthesis polypeptides.
  • heterologous isoprenoid biosynthesis polypeptides will often function even in significantly divergent organisms.
  • a plurality of different heterologous isoprenoid biosynthesis polypeptides is introduced into the same host cell.
  • this plurality contains only polypeptides from the same source organism (e.g., two or more sequences of, or sequences derived from, the same source organism); in other embodiments the plurality includes polypeptides independently selected from from different source organisms (e.g., two or more sequences of, or sequences derived from, at least two independent source organisms).
  • the source organisms include, but are not limited to, fungi of the genera Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Mucor, Phycomyces, Pythium, Bliodosporidium, Rhodotorula, Trichosporon, Yarrowia, Aspergillus, Botrytis, Cercospora, Fusarium (Gibberella), Kluyveromyces, Neurospora, Penicillium, Pichia (Hansenula), Puccinia, Saccharomyces, Schizosaccharomyces, Sclerotium, Trichoderms, Ustilago, and Xanthophyllomyces (Phaffia).
  • the source organisms are of a species including, but not limited to, Cryptococcus neoformans, Fusarium fujikuroi, Kluyverimyces lactis, Neurospora crassa, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Ustilago maydis, and Yarrowia lipolytica.
  • the isoprenoid biosynthesis pathway is also involved in the production of non-carotenoid compounds, such as sterols, steroids, and vitamins, such as vitamin E or vitamin K.
  • proteins that act on isoprenoid biosynthesis pathway intermediates, and divert them into biosynthesis of non-carotenoid compounds are therefore indirect inhibitors of carotenoid biosynthesis (see, for example, Figure 5, which illustrates points at which isoprenoid intermediates are channeled into other biosynthesis pathways).
  • Such proteins are therefore considered isoprenoid biosynthesis competitor polypeptides. Reductions of the level or activity of such isoprenoid biosynthesis competitor polypeptides are expected to increase carotenoid production in host cells according to the present invention.
  • production or activity of endogenous isoprenoid biosynthesis competitor polypeptides may be reduced or eliminated in host cells. In some embodiments, this reduction or elimination of the activity of an isoprenoid biosynthesis competitor polypeptide can be achieved by treatment of the host organism with small molecule inhibitors of enzymes of the ergosterol biosynthetic pathway.
  • Enzymes of the ergosterol biosynthetic pathway include, for example, squalene synthase, squalene epoxidase, 2,3-oxidosqualene-lanosterol cyclase, cytochrome P450 lanosterol 14 ⁇ -demethylase, C-14 sterol reductase, C-4 sterol methyl oxidase, SAM:C-24 sterol methyltransferase, C-8 sterol isomerase, C-5 sterol desaturase, C-22 sterol desaturase, and C-24 sterol reductase. Each of these enzymes is considered an isoprenoid biosynthesis competitor polypeptide.
  • Regulators of these enzymes may also be considered isoprenoid biosynthesis competitor polypeptides (e.g., the yeast proteins Sutl (Genbank Accession JC4374 GI:2133159) and Mot3 (Genbank Accession NP_013786 GL6323715), which may or may not have homologs in other organisms.
  • isoprenoid biosynthesis competitor polypeptides e.g., the yeast proteins Sutl (Genbank Accession JC4374 GI:2133159) and Mot3 (Genbank Accession NP_013786 GL6323715), which may or may not have homologs in other organisms.
  • reduction or elimination of the activity of an isoprenoid biosynthesis competitor polypeptide can be achieved by decreasing activity of the ubiquinone biosynthetic pathway.
  • the commitment step in ubiquinone biosynthesis is the formation ofp ⁇ r ⁇ -hydroxybenzoate (PHB) from tyrosine or phenylalanine in mammals or chorismate in bacteria, followed by condensation of PHB and isoprene precursor, resulting in addition of the prenyl group. This reaction is catalyzed by PHB-polyprenyltransferase.
  • PHB-polyprenyltransferase The isoprenoid side chain of ubiquinone is determined by the preny diphosphate synthase enzyme.
  • the 3-decaprenyl-4-hydroxybenzoic acid resulting from the condensation of PHB and decaprenyldiphosphate reaction undergoes further modifications, which include hydroxylation, methylation and decarboxylation, in order to form ubiquinone (CoQlO).
  • inhibition of prenyldiphosphate synthase leading from farnesyldiphosphate to extended isoprenoids, or inhibition of PHB polyprenyltransferase may be useful in increasing the amount of isoprenoid available for carotenoid biosynthesis.
  • Examples of prenyldiphosphate synthase and PHB-polyprenyltransferase enzymes are depicted in Tables 29 and 30, respectively).
  • Known small molecule inhibitors of isoprenoid biosynthesis competitor enzymes include, but are not limited to, zaragosic acid (including analogs thereof such as TAN1607A (Biochem Biophys Res Commun 1996 Feb 15;219(2):515-520)), RPR 107393 (3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-l-azabicyclo[2-2-2]octane dihydrochloride; J Pharmacol Exp Ther.
  • TAK-475 (l-[2-[(3R,5S)-l-(3-acetoxy-2,2- dimethylpropyl)-7-chloro- 1 ,2,3 ,5 -tetrahydro-2-oxo-5 -(2,3 -dimethoxyphenyl)-4, 1 - benzoxazepine-3-yl] acetyl] piperidin-4-acetic acid; Eur J Pharmacol.
  • heterologous isoprenoid biosynthesis competitor polypeptides may be utilized (whether functional or non-functional; in some embodiments, dominant negative mutants are employed).
  • One particular isoprenoid biosynthesis competitor polypeptide useful according to the present invention is squalene synthase which has been identified and characterized from a variety of organisms; representative examples of squalene synthase polypeptide sequences are included in Table 16.
  • the carotenoid biosynthesis pathway branches off from the isoprenoid biosynthesis pathway at the point where GGPP is formed.
  • the commitment step in carotenoid biosynthesis is the formation of phytoene by the head-to-head condensation of two molecules of GGPP, catalyzed by phytoene synthase (often called crtB; see Figure 6).
  • a series of dehydrogenation reactions each of which increases the number of conjugated double bonds by two, converts phytoene into lycopene via neurosporene.
  • the pathway branches at various points, both before and after lycopene production, so that a wide range of carotenoids can be generated. For example, action of a cyclase enzyme on lycopene generates ⁇ -carotene; action of a desaturase instead produces 3,4-didehydrolycopene.
  • ⁇ -carotene is converted to ⁇ - carotene through the action of a cyclase, ⁇ -carotene can be processed into any of a number of products (see, for example, Figure 6C), including astaxanthin (via echinone, hydroxyechinone, and phoenicoxanthin).
  • carotenoid production in a host organism may be adjusted by modifying the expression or activity of one or more proteins involved in carotenoid biosynthesis.
  • it will be desirable to utilize as host cells organisms that naturally produce one or more carotenoids.
  • the focus will be on increasing production of a naturally-produced carotenoid, for example by increasing the level and/or activity of one or more proteins involved in the synthesis of that carotenoid and/or by decreasing the level or activity of one or more proteins involved in a competing biosynthetic pathway.
  • heterologous carotenogenic polypeptides it will be desirable to introduce one or more heterologous carotenogenic polypeptides into a host cell.
  • any of a variety of heterologous polypeptides may be employed; selection will consider, for instance, the particular carotenoid whose production is to be enhanced.
  • the present invention contemplates not only introduction of heterologous carotenogenic polypeptides, but also adjustment of expression or activity levels of heterologous or endogenous carotenogenic polypeptides, including, for example, alteration of constitutive or inducible expression patterns.
  • expression patterns are adjusted such that growth in nutrient-limiting conditions is not required to induce oleaginy.
  • genetic modifications comprising alteration and/or addition of regulatory sequences (e.g., promoter elements, terminator elements) may be utilized to confer particular regulation of expression patterns.
  • Such genetic modifications may be utilized in conjunction with endogenous genes (e.g., for regulation of endogenous carotenogenic); alternatively, such genetic modifications may be included so as to confer regulation of expression of at least one heterologous polypeptide (e.g., carotenogenic polypeptide ⁇ )).
  • promoters including, but not limited to Tefl, Gpdl promoters can be used in conjunction with endogenous genes and/or heterolous genes for modification of expression patterns of endogenous carotenogenic polypeptide(s) and/or heterolous carotenogenic polypeptide(s).
  • exemplary terminator sequences include, but are not limited to, use of Y. lipolytica XPR2 terminator sequences.
  • proteins involved in carotenoid biosynthesis include, but are not limited to, phytoene synthase, phytoene dehydrogenase, lycopene cyclase, carotenoid ketolase, carotenoid hydroxylase, astaxanthin synthase (a single multifunctional enzyme found in some source organisms that typically has both ketolase and hydroxylase activities), carotenoid epsilon hydroxylase, lycopene cyclase (beta and epsilon subunits), carotenoid glucosyltransferase, and acyl CoA:diacyglycerol acyltransferase.
  • Representative example sequences for these carotenoid biosynthesis polypeptides are provided in Tables 17-25.
  • Xanthophylls can be distinguished from other carotenoids by the presence of oxygen containing functional groups on their cyclic end groups. For instance, lutein and zeaxanthin contain a single hydroxyl group on each of their terminal ring structures, while astaxanthin contains both a keto group and a hydroxyl on each terminal ring. This property makes xanthophylls more polar than carotenes such as beta-carotene and lycopene, and thus dramatically reduces their solubility in fats and lipids. Naturally occurring xanthophylls are often found as esters of the terminal hydroxyl groups, both mono- and diesters of fatty acids. They also occur as glucosides in certain species of bacteria.
  • solubility and dispersibility of xanthophylls can be greatly modified by the addition of ester moieties, and it is known that esterification can also affect the absorbability and/or bioavailability of a given carotenoid. It is an objective of this invention to maximize the amount of a particular xanthophyll accumulating within the intracellular triacylglyceride fraction of oleaginous yeasts, and one mechanism for achieving this goal is to increase the hydrophobic nature of the xanthophyll product that accumulates. One way of achieving this is to engineer the production of fatty- acyl mono- and/or diesters of the target xanthophyll compound.
  • a variety of enzymes can function to esterify carotenoids.
  • carotenoid glucosyltransferases have been identified in several bacterial species (see, e.g., Table 24).
  • acyl CoA:diacyglycerol acyltransferase (DGAT) and acyl CoA:monoacylglycerol acyltransferases (MGAT) which function in the final steps of triacylglycerol biosynthesis, are likely to serve an additional role in the esterification of xanthophylls.
  • Representative DGAT polypetides are shown in Table 25.
  • other enzymes may specifically modify carotenoids and molecules of similar structure (e.g.
  • potential source organisms for carotenoid biosynthesis polypeptides include, but are not limited to, genera of naturally oleaginous or non-oleaginous fungi that naturally produce carotenoids. These include, but are not limited to, Botrytis, Cercospora, Fusa ⁇ um (Gibberella), Mucor, Neurospora, Phycomyces, Puccina, Rhodotorula, Sclerotinm, Trichoderma, and Xanthophyllomyces.
  • Exemplary species include, but are not limited to, Neurospora crassa, Xanthophyllomyces dendrorhous (Phaffla rhodozyma), Mucor circinelloides, and Rhodotorula glutinis.
  • carotenoids are produced by a wide range of diverse organisms such as plants, algae, yeast, fungi, bacteria, cyanobacteria, etc. Any such organisms may be source organisms for carotenoid biosynthesis polypeptides according to the present invention.
  • the particular carotenogenic modification to be applied to a host cell in accordance with the present invention will be influenced by which carotenoid(s) is desired to be produced.
  • isoprenoid biosynthesis polypeptides are relevant to the production of most carotenoids.
  • Carotenoid biosynthesis polypeptides are also broadly relevant.
  • Ketolase is particularly relevant for production of canthaxanthin, as hydroxylase is for production of lutein and zeaxanthin, among others. Both hydroxylase and ketolase (or astaxanthin synthase) are particularly useful for production of astaxanthin.
  • inventive modified host cells in general, it will be desirable to cultivate inventive modified host cells under conditions that allow accumulation of at least about 20% of their dry cell weight as lipid.
  • inventive modified host cells are grown under conditions that permit accumulation of at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or even 80% or more of their dry cell weight as lipid.
  • the host cells utilized are cells which are naturally oleaginous, and induced to produce lipid to the desired levels.
  • the host cells are cells which naturally produce lipid, but have been engineered to increase production of lipid such that desired levels of lipid production and accumulation are achieved.
  • the host cells of the invention are not naturally oleaginous, but have been engineered to produce lipid such that desired levels of lipid production are obtained.
  • growth conditions that are effective for inducing lipid accumulation in a source organism may well also be useful for inducing lipid accumulation in a host cell into which the source organism's oleaginic polypeptides have been introduced.
  • modifications may be required in light of characteristics of the host cell, which modifications are within the skill of those of ordinary skill in the art.
  • the inventive modified host cell it will generally be desirable to ensure that production of the desired carotenoid by the inventive modified host cell occurs at an appropriate time in relation to the induction of oleaginy such that the carotenoid(s) accumulate(s) in the lipid bodies.
  • the host cells which do not naturally produce a certain carotenoid(s) are capable of production of other carotenoid(s) (e.g.
  • certain host cells may, for example, naturally produce ⁇ -carotene but may not naturally produce astaxanthin); in other aspects the host cells do not naturally produce any carotenoid(s). In other embodiments, it will be desirable to increase production levels of carotenoid(s) in a host cell which does naturally produce low levels of the carotenoid(s), such that increased detectable levels of the carotenoid(s) are produced.
  • the host cells which do naturally produce the carotenoid(s) also produce additional carotenoid(s) (e.g., astaxanthin, etc.); in still other aspects, the cells which naturally produce the carotenoid(s) (e.g., ⁇ -carotene) do not produce additional carotenoid(s).
  • the total carotenoid accumulation in the lipid bodies will be to a level at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20% or more of the total dry weight of the cells.
  • the total carotenoid accumulation in the lipid bodies will be to a level at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20% or more of the total dry weight of the cells.
  • Bacterial carotenogenic genes have already been demonstrated to be transferrable to other organisms, and are therefore particularly useful in accordance with the present invention (see, for example, Miura et al., Appl. Environ. Microbiol. 64:1226, 1998).
  • it may be desirable to utilize genes from other source organisms such as plant, alga, or microalgae; these organisms provide a variety of potential sources for ketolase and hydroxylase polypeptides.
  • Still additional useful source organisms include fungal, yeast, insect, protozoal, and mammalian sources of polypeptides.
  • the Mucor circinelloides multi-functional phytoene synthase/lycopene cyclase and the Neurospora crassa phytoene dehydrogenase genes can be expressed in Yarrowia lipolytica. Subsequent overexpression of the catalytic domain from N. crassa hydroxymethylglutaryl-CoA reductase and/or treatment of the modified Y. lipolytica strains with the squalene synthase inhibitor zaragozic acid further increases carotenoid production. Finally, Paracoccus marcusii genes encoding carotenoid hydroxylase and carotenoid ketolase enzymes are expressed in Y.
  • lipolytica ⁇ -carotene-producing strains and this modification results in the accumulation of astaxanthin.
  • Similar approaches to enhance carotenoid production could be employed in other oleaginous or non-oleaginous host organisms can be undertaken, using the same, homologous, or functionally similar carotogenic polypeptides.
  • cells are homogenized and then subjected to supercritical liquid extraction or solvent extraction (e.g., with solvents such as chloroform, hexane, methylene chloride, methanol, isopropanol, ethyl acetate, etc.), yielding a crude oil suspension.
  • This oil suspension may optionally be refined as known in the art. Refined oils may be used directly as feed or food additives. Alternatively or additionally, carotenoids can be isolated from the oil using conventional techniques.
  • oxidative stabilizers e.g., tocopherols, vitamin C; ethoxyquin; vitamin E, BHT, BHA, TBHQ, etc, or combinations thereof
  • microencapsulation for example with proteins, may be employed to add a physical barrier to oxidation and/or to improve handling (see, for example, U.S. Patent Application 2004/0191365).
  • Carotenoids produced according to the present invention can be utilized in any of a variety of applications, for example exploiting their biological or nutritional properties (e.g., anti-oxidant, anti-proliferative, etc.) and/or their pigment properties.
  • carotenoids may be used in pharmaceuticals (see, for example, Bertram, Nutr. Rev. 57:182, 1999; Singh et al., Oncology 12:1643, 1998; Rock, Pharmacol. Titer. 75:185, 1997; Edge et al, J. Photochem Photobiol 41 :189, 1997; U.S. Patent Application 2004/0116514; U.S.
  • Patent Application 2004/0259959 food supplements (see, for example, Koyama et al, J. Photochem Photobiol 9:265, 1991 ; Bauernfeind, Carotenoids as colorants and vitamin A precursors, Academic Press, NY, 1981 ; U.S. Patent Application 2004/0115309; U.S. Patent Application 2004/0234579), electro-optic applications, animal feed additives (see, for example, Krinski, Pure Appl. Chem. 66:1003, 1994; Polazza et al., Meth. Enzymol. 213 :403, 1992), cosmetics (as anti-oxidants and/or as cosmetics, including fragrances; see for example U.S. Patent Application 2004/0127554), etc.
  • Carotenoids produced in accordance with the present invention may also be used as intermediates in the production of other compounds (e.g., steroids, etc.).
  • astaxanthin and/or esters thereof may be useful in a variety of pharmaceutical applications and health foods including treatment of inflammatory diseases, asthma, atopic dermatitis, allergies, multiple myeloma, arteriosclerosis, cardiovascular disease, liver disease, cerebrovascular disease, thrombosis, neoangiogenesis-related diseases, including cancer, rheumatism, diabetic retinopathy; macular degeneration and brain disorder, hyperlipidemia, kidney ischemia, diabetes, hypertension, tumor proliferation and metastasis; and metabolic disorders.
  • carotenoids and astaxanthin may be useful in the prevention and treatment of fatigue, for improving kidney function in nephropathy from inflammatory diseases, as well as prevention and treatment of other life habit-related diseases.
  • astaxanthin has been found to play a role as inhibitors of various biological processes, including interleukin inhibitors, phosphodiesterase inhibitors inhibitors, phospholipase A2 inhibitors, cyclooxygenase-2 inhibitors, matrix metalloproteinase inhibitors, capillary endothelium cell proliferation inhibitors, lipoxygenase inhibitors. See, e.g., Japanese Publication No. 2006022121, published 20060126(JP Appl No. 2005-301156 filed 20051017); Japanese Publication No.
  • 2006016408 published 20060119(JP Appl No. 2005-301155 filed 20051017); Japanese Publication No. 2006016409, published 20060119(JP Appl No. 2005-301157 filed 20051017); Japanese Publication No. 2006016407, published 20060119(JP Appl No. 2005-301153 filed 20051017); Japanese Publication No. 2006008717, published 20060112(JP Appl No. 2005-301151 filed 20051017); Japanese Publication No. 2006008716, published 20060112(JP Appl No. 2005-301150 filed 20051017); Japanese Publication No. 2006008720, published 20060112(JP Appl No. 2005- 301158 filed 20051017); Japanese Publication No.
  • carotenoids produced by manipulated host cells as described herein are incorporated into a final product (e.g., food or feed supplement, pharmaceutical, cosmetic, dye-containing item, etc.) in the context of the host cell.
  • a final product e.g., food or feed supplement, pharmaceutical, cosmetic, dye-containing item, etc.
  • host cells may be lyophilized, freeze dried, frozen or otherwise inactivated, and then whole cells may be incorporated into or used as the final product.
  • the host cell may also be processed prior to incorporation in the product to increase bioavailability (e.g., via lysis).
  • a final product may incorporate only a portion of the host cell (e.g., fractionated by size, solubility), separated from the whole.
  • lipid droplets are isolated from the host cells and are incorporated into or used as the final product.
  • the carotenoids themselves, or individual carotenoid compounds are isolated and reformulated into the final product.
  • fatty acid and glucoside esters are the predominant carotenoid esters found in nature, whereas additional esters (e.g. with organic acids or inorganic phosphate) can be synthesized to generate useful product forms.
  • carotenoid esters can also be formulated as salts of the ester form (See, e.g., US Patent Publication No. 20050096477).
  • the amount of carotenoid incorporated into a given product may vary dramatically depending on the product, and the particular carotenoid(s) involved.
  • Amounts may range, for example, from less than 0.01% by weight of the product, to more than 1%, 10%, 20%, 30% or more; in some cases the carotenoid may comprise 100% of the product.
  • one or more produced carotenoids is incorporated into a component of food or feed (e.g., a food supplement).
  • Types of food products into which carotenoids can be incorporated according to the present invention are not particularly limited, and include beverages such as teas, juices, and liquors; confections such as jellies and biscuits; fat-containing foods and beverages such as dairy products; processed food products such as rice and soft rice (or porridge); infant formulas; or the like.
  • feedstuffs into which carotenoids produced in accordance with the present invention may be incorporated include, for instance, pet foods such as cat foods, dog foods and the like, feeds for aquarium fish, cultured fish or crustaceans, etc., feed for farm-raised animals (including livestock and further including fish or crustaceans raised in aquaculture).
  • Food or feed material into which the carotenoid(s) produced in accordance with the present invention is incorporated is preferably palatable to the organism which is the intended recipient. This food or feed material may have any physical properties currently known for a food material (e.g., solid, liquid, soft).
  • one or more produced carotenoids is incorporated into a cosmetic product.
  • cosmetics include, for instance, skin cosmetics (e.g., lotions, emulsions, creams and the like), lipsticks, anti-sunburn cosmetics, makeup cosmetics, fragrances, products for daily use (e.g., toothpastes, mouthwashes, bad breath preventive agents, solid soaps, liquid soaps, shampoos, conditioners), etc.
  • one or more produced carotenoids is incorporated into a pharmaceutical.
  • examples of such pharmaceuticals include, for instance, various types of tablets, capsules, drinkable agents, troches, gargles, etc.
  • the pharmaceutical is suitable for topical application.
  • Dosage forms are not particularly limited, and include capsules, oils, granula, granula subtilae, pulveres, tabellae, pilulae, trochisci, or the like. Oils and oil-filled capsules may provide additional advantages both because of their lack of ingredient decomposition during manufacturing, and because inventive carotenoid- containing lipid droplets may be readily incorporated into oil-based formulations. [00105] Pharmaceuticals according to the present invention may be prepared according to techniques established in the art including, for example, the common procedure as described in the United States Pharmacopoeia, for example.
  • Carotenoids produced according to the present invention may be incorporated into any pigment-containing product including, for example, fabric, paint, etc. They may also be incorporated into a product which is an environmental indicator, or an instrument such as a biosensor for use as a detection agent.
  • Example 1 Production ofylasmids for carotenoid strain construction.
  • Plasmids were generated for construction of carotenoid producing strains.
  • the GPDl and TEFl promoters are from Y. lipolytica as is the XPR2 terminator.
  • GGSl is the gene encoding the Y, lipolytica gene encoding geranylgeranylpyrophosphate synthase.
  • the nucleic acid coding sequence, and encoded Ggsl protein of pMB4591 and pMB4683 are as follows:
  • MO4568 5'- CACAAGGTACCAATGTGAAAGTGCGCGTGAT MO4571 5'-CACAAGGTACCAGAGACCGGGTTGGCGG
  • IA Production of pMB4628 Uefly-carRP LEW) encoding phvtoene synthase/lycopene cyclase: Intron-containing carRP was amplified from M. circinelloides
  • the resulting fragment was blunt-end ligated into pBluescriptSKII- cleaved with EcoRV, yielding pMB4599.
  • the 1.9 kb Xbal-Mlul fragment from pMB4599 was inserted into Nhel- and Mwl-cleaved pMB4603, yielding pMB4628.
  • the intron containing nucleic acid coding sequence, and encoded CarRP protein of pMB4628 are as follows:
  • pMB4599 was also used as a template for PCR amplification using MO4318, MO4643, MO4644, and MO4639 and
  • MO4644 5'- CACACGGTCTCTGGCATTTGGCGGTCCCTGGAAA producing fragments of 0.5 and 0.95 kb, that were subsequently cleaved with Acc65l and
  • Xbal-Mlul fragment from pMB4613 can be inserted into Nhel- and MM-cleaved pMB4603 to yield pCarRPdell.
  • IB Production of pMB4638 (teflp-carB ADEl), encoding phvtoene dehydrogenase: Intron-containing carB was amplified from M, circinelloides (ATCC 90680) genomic DNA using MO4530 and MO4542:
  • pMB4606 was then used as a template for PCR amplification using MO4318 and MO4648, and MO4646 and
  • MO4645 5 ' -CACACGGTCTCTTGCCCATATACATGGTCTGAAACG producing fragments of 0.4 and 0.85 and 0.7 kb, that were subsequently cleaved with ⁇ cc65I and Bs ⁇ l, and Bsal, and Bsal and BamRl, respectively. These fragments were ligated to pBS-
  • nucleic acid coding sequence and encoded CarB(i) protein of pMB4660 are as follows:
  • oligonucleotides For production of a truncated variant of the HMG-CoA reductase gene, which also encodes a 77 amino acid leader sequence derived from S. cerevisiae, the following oligonucleotides are synthesized:
  • Primers O and P are used to amplify a 0.23 kb fragment encoding Met- Ala followed by residues 530 to 604 of the Hmgl protein of S. cerevisiae, using genomic DNA as template.
  • Primers Q and MO4658 are used to amplify a 1.4 kb fragment encoding the C-terminal 448 residues of the Hmgl protein of Y. lipolytica, using genomic DNA as template. These fragments are ligated to the appropriate cloning vector, and the resultant plasmids, designated pOP and pQMO4658, are verified by sequencing. The OP fragment is liberated with-Y& ⁇ l and Asel, and the QMO4658 fragment is liberated with Mael and MuI. These fragments are then ligated to the ADEl TEFIp expression vector pMB4629 cut with Xbal and MMI to produce pTefHMG.
  • the native HMGl gene from Y. lipolytica may be modified without S. cerevisiae sequences as described in the table above using primers MO4658
  • nucleic acid coding sequence and encoded Hmgl mn ⁇ : protein of pMB4637 are as follows:
  • TEFl promoter fragment from pMB4629, to pMB4662 cut with Acc65 ⁇ and MMI to produce pMB4692 The nucleic acid coding sequence is depicted in bold underline above.
  • the resulting encoded crtZ protein of pMB4692 is as follows:
  • Example 2 Engineering Yarrowia lipolytica for increased carotenoid production.
  • 2A Production of Y. lipolytica expressing geranylgeranylpyrophosphate synthase and phytoene dehydrogenase: MF350 (MATB ura2-21 leu2-35 adel) was transformed with pMB4591 (teflp-GGSl) that had been cleaved upstream of URA5 with Ssp ⁇ ; a Ura + transformant carrying the plasmid at the ura2 locus was identified and named MF364.
  • MF447 was challenged with 1 g/L 5-fluoroorotic acid and Ura " segregants selected. Surprisingly, they were all found to retain the identical yellow appearance of their parent, implying that the loss of a functional URA3 gene did not coincide with the loss of a functional CarB enzyme. Southern analysis demonstrates that two fragments from a Kpnl- HindIII digest of MF447 DNA contain t/iL43p-hybridizing sequences, only one of which also hybridizes to carB. The other is absent in MF578, the Ura3 " segregant chosen for further manipulation.
  • MF578 Production of Y. lipolytica expressing phytoene synthase/lycopene cyclase, phytoene dehydrogenase and geranylgeranylpyrophosphate synthase: MF578 was transformed with pMB4683 (teflp-GGSl) that had been cleaved with SaH (upstream of URA3) or with Stul (within the GGSl ORF). Ura + Leu + colonies in both cases appeared bright orange on YNBglut+Lys and on YPD, and several produced greater than 4 mg carotene per gram of dry cell weight when grown as above.
  • MF633 contained a single copy of the plasmid at the GGSl locus, as inferred from Southern analysis. The others arose by nonhomologous or more complex integrations.
  • GBRPua strains Colonies meeting these criteria, as well as displaying resistance to 5-fluorootic acid, an indication that they harbor the ura3-302 allele, are chosen for further studies and hereafter referred to as GBRPua strains. Such a strain is selected for further analysis and modification.
  • Example 3 Extraction of carotenoids from Yarrowia liyolytica cells [00139] Shake-flask testing of generated strains was conducted using YPD medium
  • the mixture was then spun at maximum speed for 1 minute, and the supernatant was collected and deposited in a cold 16 ml glass vial.
  • the remaining cell debris was re-extracted at least three times, without the addition of zirconia beads; all supernatants were pooled in the 16 ml glass vial.
  • the glass vial was spun for 5 minutes at 2000 rpm at 4°C in a Sorvall tabletop centrifuge, and the supernatant was transferred to a new cold 16 ml glass vial.
  • a Speed Vac was used to concentrate the supernatant (room temperature in dark), and the samples were stored at -20 0 C or -80 0 C until immediately before HPLC analysis. Prior to HPLC analysis, the samples were resuspended in 1 ml ice-cold solvent and then transferred to a cold amber vial. Throughout the protocol, care was taken to avoid contact with oxygen, light, heat, and acids.
  • the injection volume was 10 ⁇ L.
  • the detector is a Waters 996 photodiode array detector.
  • the retention times for lipophilic molecules include astaxanthin (1.159 min), zeaxanthin (1.335), ⁇ -apo-8'-carotenal (2.86 min), ergosterol (3.11 min), lycopene (3.69 min), ⁇ -Carotene (4.02 min), and phytoene (4.13 min).
  • Astaxanthin, zeaxanthin, ⁇ -apo-8'-carotenal, lycopene and ⁇ -Carotene are detected at 475 nm, whereas ergosterol and phytoene were detected at 286 nm.
  • Example 5 Expression of a truncated form of EMG-CoA reductase results in increased carotenoid production
  • a truncated variant of the HMG-CoA reductase gene which also encodes a 77 amino acid leader sequence derived from S. cerevisiae Hmgl is introduced into a GRPBua strain (described in Example 2E above).
  • Plasmid pTefHMG can be cleaved with SnaBl, BbvCl, or Bsu36l to direct integration at the adel locus, or with BamHI to direct integration at the HMGl locus, or with EcoKV to promote random integration, in the GRPBua strains, restoring them to adenine prototrophy.
  • Resulting Ade + transformants are screened for increased carotenoid production.
  • the native HMGl gene from Y. lipolytica may be modified without S. cerevisiae sequences as described in Example ID above, to create pMB4637.
  • This plasmid can be digested as described for pTefHMG and transformed into GRPBua strains, and resulting transformants screened as described for increased carotenoid production.
  • a truncated variant of the N. crassa HMG-CoA reductase gene may be utilized and introduced into Y. lipolytica strains.
  • p641P (Yeast 2001 ; 18 (2001): 97-113) is modified by replacing the ICLl promoter with the GPD promoter, and by the addition of sequences conferring resistance to phleomycin.
  • Y. lipolytica genomic D ⁇ A is amplified with two primers.
  • GPDdist 5' CACACGGTacctgtaggttgggttgggtg
  • GPDprox 5' CACACGGATCCtgtttaattcaagaatgaatatagagaagagaag
  • the Ue gene under the control of the A.
  • nidulans GPD promoter is then excised from pBCphleo (Silar, Fungal Genetics Newsletter 42:73) as a 3.2 kb BcH-BamHl fragment and inserted into the unique BamEI site of "p641Pgpd", in the orientation that preserves the Ban ⁇ l site proximal to the GPD promoter, to create "p641Pgpdble” ,
  • cr asset genomic D ⁇ A is amplified with two primers:
  • ⁇ euhmg rev 5' CAC ACGG ATCcaagtgctgacgcggaacttg, and the resulting fragment is cleaved with BaniW. and inserted into U ⁇ roHI-digested "p641Pgpdble" in the correct orientation.
  • the resulting plasmid, "pZg” contains sequences encoding a truncated cytosolic catalytic domain of hydroxymethylglutaryl-CoA reductase from N. crassa (Genbank accession: XP_324892) under the control of the constitutive GPD promoter. This plasmid can be introduced into the Y.
  • Example 6 Introduction of heterologous carotene hydroxylase and carotene ketolase genes into Y. lipolvtica strains producing carotenoid for production of astaxanthin.
  • pMB4692 and pMB4698 described as in Example IE and IF above, can be sequentially introduced into the GRPBua strain (described in Example 2E).
  • the plasmid may be cleaved with SaR or BsrGl to direct integration at the uraS locus, or with Xbal to promote random integration, selecting for uracil prototrophy.
  • GRPBua Ura + transformants harboring pMB4692 are screened for zeaxanthin production in YPD.
  • Zeaxanthin-producing cells are transformed with pMB4698 (which can be cleaved with PpuMl, Sspl or BbvCl to direct integration at the adel locus, or with EcoRY to promote random integration) and prototrophic colonies are screened for astaxanthin production.
  • plasmid transformation may be reversed wherein pMB4698 is transformed first and transformants are selected for adenine prototrophy.
  • GRPBua Ade + transformants harboring ⁇ MB4698 are screened for canthaxanthin production.
  • Canthaxanthin-producing GRPBua[pMB4698] cells are transformed with pMB4692 and prototrophic colonies are screened for astaxanthin production.
  • carotenoid ketolase and carotenoid hydroxylase genes from P. marcusii can be introduced into the strains described in Example 2 above, in order to convert ⁇ -carotene into astaxanthin.
  • P. marcusii genomic D ⁇ A is amplified with two primers.
  • CrtZrev 5' CACACAGATCtcacgtgcgctcctgcgcc, and the resulting fragment is cleaved with BsmBl, modified with the Klenow fragment of DNA polymerase, and cleaved with BgIU.
  • This fragment is inserted into PmU- and BamHl- cleaved pINA1269 (J. MoI. Microbiol. Biotechnol. 2 (2000): 207-216), containing the hp4d promoter, the XPR2 terminator, the selectable LEU2 gene, and sequences necessary for selection and propagation in E. coli.
  • the resulting plasmid "pA" contains sequences encoding carotene hydroxylase from P. marcusii (crtZ gene)(Genbank accession: CAB56060.1) under the control of the hp4d promoter.
  • pYEGITEF is modified by substituting the LIP2 terminator for the XPR2 terminator as follows.
  • pINA1291 is digested with Avrll, modified with the Klenow fragment of DNA polymerase, and cleaved with EcoB ⁇ , and the small LIP2t containing fragment is ligated to "pYEGITEF” that has been digested with Sacll, modified with T4 DNA polymerase in the presence of dNTP, and cleaved with EcoKL.
  • the resulting plasmid is named " P YEGlTEF-LIP2t” .
  • P. marcusii genomic DNA is amplified with two primers.
  • CrtWrev 5' CACACAAGCTTtcatgcggtgtcccccttg
  • the resulting fragment is cleaved with Avrll and Hindlll, and inserted into ⁇ 4vrII- and .ffiwcflll-cleaved "pYEGlTEF-LIP2t”.
  • the resulting plasmid, "pBt” contains sequences encoding the carotene ketolase (crt W gene)(Genbank accession: CAB56059.1) under the control of the constitutive TEFl promoter.
  • pBt is cleaved with CM, modified with the Klenow fragment of DNA polymerase, and cleaved with JECORI, and the crt JF-containing fragment is isolated, mixed with the phosphorylated oligonucleotide adaptor pair:
  • pABt can be introduced into the Y. lipolytica strain described above in
  • Example 4 (TEF IpI al-l/XPR2t; hp4dlcarRPILIP2t ⁇ GPDplHMGR, nmc ), and transformants selected for leucine prototrophy.
  • Example 7 Partial inactivation of Y. lipolvtica ERG9 gene encoding saualene synthase results in increased carotenoid production: [00153] TA. In order to partially inactivate the ERG9 gene encoding squalene synthase, the neighboring FOL3 gene is disrupted, resulting in a folinic acid requirement.
  • This strain is then transformed with a mutagenized fragment of DNA partially spanning the two genes, and FoI + transformants are screened for decreased squalene synthase activity.
  • the resultant plasmid designated pBS-foB, is then cleaved with Acc65l and EcoRl, treated with T4pol as above, and ligated to the 3.4 kb EcoKV-Spel ADEl fragment (treated with T4pol) from pMB4529.
  • the resulting plasmid, pBSfol3 ⁇ ade can be cleaved with Bsi ⁇ I and Xbal to liberate a 5.5 kb fragment that is used to transform the GRBPua strains described above to adenine prototrophy.
  • Resulting Ade + transformants are screened for a folinic acid requirement, and for homologous integration by PCR analysis.
  • the resulting fragment containing the N- terminal three-quarters of the FOLS ORF and the C-terminal nine-tenths of the ERG9 ORF is used to transform strains.
  • the resulting FoI + Ade " transformants are screened for decreased squalene synthase activity by sensitivity to agents such as zaragozic acid, itraconazole, or fluconazole. Additionally, the resulting transformants are screened for increased carotenoid production.
  • RNA sequence [00157] TB.
  • the PCR fragment produced in 7A could be cloned and altered in such a way as to remove the 3 '-untranslated region of ERG9 gene. Replacement of the fol3 AADEl disruption by this fragment results in decreased expression of squalene synthase [Schuldiner et al. (2005), Cell 123:507-519][Muhlrad and Parker (1999), RNA
  • Ade strain, using the ADEl marker to disrupt the ERG93'-UTR.
  • ERG9 alleles can be identified in S. cerevisiae using plasmid shuffling techniques [Boeke et al. (1987), Methods Enzymol. 154:164-175], and using drug sensitivities as a phenotype. Defective genes can be transferred to Y. lipolytica using standard molecular genetic techniques.
  • Example 8 Treatment of Y. lipolvtica strains producing carotenoid with inhibitor of an isoprenoid biosynthesis competitor polypeptide results in increased carotenoid production
  • ⁇ Cultures produced in Example 2 are treated with the squalene synthase inhibitor, zaragozic acid (zaragozic acid at 0.5 ⁇ M) and monitored for ⁇ -carotene production, as described above.
  • Example 9 Constructing, an oleaginous strain ofSaccharomyces cerevisiae
  • AMP deaminase from Saccharomyces cerevisiae and the cytosolic malic enzyme from M. circinelloides are overexpressed in S. cereviseae strains in order to increase the total lipid content.
  • Similar approaches to enhance lipid production could be employed in other host organisms such as Xanthophyllomyces dendrorhous (Phqffia rhodozyma), using the same, homologous, or functionally similar oleaginic polypeptides.
  • RT-PCR is performed in two reactions containing the mR ⁇ A template and either of the following primer pairs.
  • acll lfwd: 5' CACACGGATCCTATAatgccttccgcaacgaccg lrev: 5' CACACACTAGttaaatttggacctcaacacgaccc acl2:
  • the bi-directional GALl-10 promoter is amplified from S. cerevisiae genomic D ⁇ A using the primers.
  • gall 0 5' CACACGGATCCaatmcaaaaattcttacttttttttggatggac gall : 5' CACACGGATCCtttttctccttgacgttaaagtatagagg, and the resulting 0.67 kb fragment is cleaved with BamUl and ligated in either orientation to S ⁇ mHI-digested "pl2" to create "plgal2" and "p2gall", containing GALl-acll/GALlO-acU and GALl 0-acll /GALl -acl2, respectively (Genbank accession: acll: CAB91740.2; acl2: CAB91741.2).
  • AMDlrev 5' CACACCCTAGGtcacttttcttcaatggttctcttgaaattg
  • GAL7p gal7prox: 5' CACACGAGCTCggaatattcaactgtttttttttatcatgttgatg gal7dist: 5' CACACGGAtccttcttgaaatatgcactctatatcttttag
  • the resulting fragment from the AMDl reaction (2.4 kb) is cleaved with Sad and Avrll
  • that from the GAL7 reaction (0.7 kb) is cleaved with Barri ⁇ l and Sphl, and both are ligated together into YEp 13 that has been digested with MeI and BamEI, creating the plasmid "pAMPD”.
  • RNA is prepared from lyophilized biomass of M. circinelloides, as described above, and the mRNA template is used in a RT-PCR reaction with two primers:
  • MAErev 5' CACACGTCGACttaatgatctcggtatacgagaggaac, and the resulting fragment is cleaved with Nhel and SaK, and ligated to Xbal- and Xhol- digested pRS413TEF (Mumberg, D. et al. (1995) Gene, 156:119-122), creating the plasmid "pTEFMAE", which contains sequences encoding the cytosolic NADP + -dependant malic enzyme from M. circinelloides (E.C. 1.1.1.40; mce gene; Genbank accession: AY209191) under the control of the constitutive TEFl promoter.
  • the plasmids "plgal2”, “pAMPD”, and “pTEFMAE” are sequentially transformed into a strain of S. cereviseae to restore prototrophy for uracil ("plgal2"), leucine (“pAMPD”), and histidine (“pTEFMAE”) (Guthrie and Fink Methods in Enzymology 194:1- 933, 1991).
  • the resulting transformants are tested for total lipid content following shake flask testing in either synthetic complete (SC) medium lacking uracil, leucine and histidine, as described in Example 3, or in a 2-step fermentation process.
  • SC synthetic complete
  • Intracellular lipid content of the modified and control S. cerevisiae strains is analyzed using the fluorescent probe, Nile Red (J Microbiol Meth (2004) 56:331-338).
  • Nile Red J Microbiol Meth (2004) 56:331-338.
  • cells diluted in buffer are stained with Nile Red, excited at 488 nm, and the fluorescent emission spectra in the wavelength region of 400-700 nm are acquired and compared to the corresponding spectra from cells not stained with Nile Red.
  • the total lipid content is determined by gas chromatographic analysis of the total fatty acids directly transmethylesterified from dried cells, as described (Appl
  • Non-transformed S. cerevisiae strains produce 6% and 10% total lipid (dry cell weight basis) after growth in YPD and lipid accumulation medium, respectively.
  • Yeast strains expressing the multiple oleaginic polypeptides produce 17% and 25% total lipid following growth in YPD and lipid accumulation medium, respectively.
  • Example 10 Introduction of heterologous carotene hydroxylase into Y. lipolytica strains producing carotenoid for production ofzeaxanthin
  • MF578 ⁇ tef-carRP tef-carB was transformed with pMB4692 that had been cleaved with SaR.
  • pMB4692 that had been cleaved with SaR.
  • Ura + colonies inferred to contain tef-crtZ by PCR analysis were able to produce zeaxanthin in YPD shake flasks, and in one case, all of the carotene was depleted.
  • Table 21 Examples of astaxanthin synthase polypeptides and putative astaxanthin s nthase polypeptides.
  • acyl CoA:diacyglyceroI acyltransferase (DGAT) polypeptides examples include acyl CoA:diacyglyceroI acyltransferase (DGAT) polypeptides.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)

Abstract

The present invention provides systems for producing engineered oleaginous yeast or fungi that express carotenoids.

Description

PRODUCTION OF CAROTENOIDS IN OLEAGINOUS YEAST AND FUNGI
Related Applications
[0001] This application claims the benefit of U.S. Provisional Application No. 60/663,621, filed March 18, 2005, the contents of which are hereby incorporated by reference in their entirety.
Background of the Invention
[0002] Carotenoids are organic pigments ranging in color from yellow to red that are naturally produced by certain organisms, including photosynthetic organisms (e.g., plants, algae, cyanobacteria), and some fungi. Carotenoids are responsible for the orange color of carrots, as well as the pink in flamingos and salmon, and the red in lobsters and shrimp. Animals, however, cannot produce carotenoids and must receive them through their diet. [0003] Carotenoid pigments (e.g., β-carotene and astaxanthin) are used industrially as ingredients for food and feed stocks, both serving a nutritional function and enhancing consumer acceptability. For example, astaxanthin is widely used in salmon aquaculture to provide the orange coloration characteristic of their wild counterparts. Some carotenoids are also precursors of vitamin A. Also, carotenoids have antioxidant properties, and may have various health benefits (see, for example, Jyonouchi et al., Nutr, Cancer 16:93, 1991; Giovannucci et al., /. Natl. Cancer Inst. 87:1767, 1995; Miki, Pure Appl. Chem 63:141, 1991; Chew et al., Anticancer Res. 19:1849, 1999; Wang et al., Antimicrob. Agents Chemother. 44:2452, 2000). Some carotenoids such as β-carotene, lycopene, and lutein are currently sold as nutritional supplements.
[0004] jn general, the biological systems that produce carotenoids are industrially intractable and/or produce the compounds at such low levels that commercial scale isolation is not practicable. Thus, most carotenoids used in industry are produced by chemical synthesis. There is a need for improved biological systems that produce carotenoids. Some efforts have previously been made to genetically engineer certain bacteria or fungi to produce higher levels of carotenoids (see, for example, Misawa et al., J. Biotechnol. 59:169, 1998; Visser et al., FEMS Yeast Research 4:221, 2003). However, improved systems, allowing higher levels of production and greater ease of isolation, are needed.
Summary of the Invention
[0005] The present invention provides improved systems for the biological production of carotenoids. In one aspect, the invention encompasses the discovery that it is desirable to produce carotenoids in oleaginous organisms. Without wishing to be bound by any particular theory, the present inventors propose that biological systems may be able to accumulate higher levels of carotenoids if the compounds are sequestered in lipid bodies. Regardless of whether absolute levels are higher, however, carotenoids that are accumulated within lipid bodies in oleaginous organisms are readily isolatable through isolation of the lipid bodies.
[0006] The present invention therefore provides oleaginous fungi (including, for example, yeast or other unicellular fungi) that produce one or more carotenoids. The present invention also provides methods of constructing such yeast and fungi, methods of using such yeast and fungi to produce carotenoids, and methods of preparing carotenoid-containing compositions, such as food or feed additives, or nutritional supplements, using carotenoids produced in such oleaginous yeast or fungi. In particular, the present invention provides systems and methods for generating yeast and fungi containing one or more oleaginic and/or carotenogenic modifications that increase the oleaginicity and/or alter their carotenoid- producing capabilities as compared with otherwise identical organisms that lack the modifϊcation(s).
[0007] The present invention further encompasses the general recognition that lipid- accumulating systems are useful for the production and/or isolation of lipophilic agents (such as, but not limited to isoprenoids, or isoprenoid-derived compounds). Thus, according to the present invention, it is desirable to engineer organisms to produce such lipophilic agents and/or to accumulate lipid.
[0008] Various other aspects of the present invention will be apparent to those of ordinary skill in the art from the present description, including the appended claims.
Brief Description of the Drawing
[0009] Figure IA-I D depicts certain common carotenoids.
[0010] Figure 2 depicts how sufficient levels of acetyl-CoA and NADPH may be accumulated in the cytosol of oleaginous organisms to allow for production of significant levels of cytosolic lipids. Enzymes: 1, pyruvate decarboxylase; 2, malate dehydrogenase; 3, malic enzyme; 4, pyruvate dehydrogenase; 5, citrate synthase; 6, ATP-citrate lyase; 7, citrate/malate translocase.
[0011] Figures 3 A and 3B depict the mevalonate isoprenoid biosynthesis pathway, which typically operates in eukaryotes, including fungi.
[0012] Figure 4 depicts the mevalonate-independent isoprenoid biosynthesis pathway, also known as the DXP pathway, which typically operates in bacteria and in the plastids of plants.
[0013] Figure 5 depicts intermediates in the isoprenoid biosynthesis pathway and how they feed into biosynthetic pathways of other biomolecules, including carotenoids as well as non-carotenoid compounds such as sterols, steroids, and vitamins, such as vitamin E or vitamin K.
[0014] Figures 6A-6D illustrate various carotenoid biosynthetic pathways. Figure
6A highlights branches leading to various cyclic and acyclic xanthophylls; Figure 6B shows certain X. dendrorhous pathways that generate dicyclic and monocyclic carotenoids, including astaxanthin; Figure 6C shows interconnecting pathways for converting β-carotene into any of a variety of other carotenoids, including astaxanthin; Figure 6D depicts possible routes of synthesis of cyclic carotenoids and common plant and algal xanthophylls from neurosporene. [0015] Figures 7A-7C show an alignment of certain representative fungal HMG-
CoA reductase polypeptides. As can be seen, these polypeptides show very high identity across the catalytic region, and also have complex membrane spanning domains. In some embodiments of the invention, these membrane-spanning domains are disrupted or are removed, so that, for example, a hyperactive version of the polypeptide may be produced. [0016] Figures 8A-8D depict schematic representations of plasmids generated and described in detail in the exemplification.
Definitions
[0017] Carotenogenic modification: The term "carotenogenic modification", as used herein, refers to a modification of a host organism that adjusts production of one or more carotenoids, as described herein. For example, a carotenogenic modification may increase the production level of one or more carotenoids, and/or may alter relative production levels of different carotenoids. In principle, an inventive carotenogenic modification may be any chemical, physiological, genetic, or other modification that appropriately alters production of one or more carotenoids in a host organism produced by that organism as compared with the level produced in an otherwise identical organism not subject to the same modification. In most embodiments, however, the carotenogenic modification will comprise a genetic modification, typically resulting in increased production of one or more selected carotenoids. In some embodiments, the selected carotenoid is one or more of astaxanthin, β-carotene, canthaxanthin, lutein, lycopene, phytoene, zeaxanthin, and/or modifications of zeaxanthin or astaxanthin (e.g., glucoside, esterifϊed zeaxanthin or astaxanthin). In some embodiments, the selected carotenoid is one or more xanthophylls, and/or a modification thereof (e.g., glucoside, esterifϊed xanthophylls). In certain embodiments, the selected xanthophyl is selected from the group consisting of astaxanthin, lutein, zeaxanthin, lycopene, and modifications thereof. In some embodiments, the selected carotenoid is one or more of astaxanthin, β-carotene, canthaxanthin, lutein, lycopene, and zeaxanthin and/or modifications of zeaxanthin or astaxanthin. In some embodiments, the carotenoid is β-carotene. In some embodiments, the selected carotenoid is astaxanthin. In some embodiments, the selected carotenoid is other than β-carotene.
[0018] Carotenogenic polypeptide: The term "carotenogenic polypeptide", as used herein, refers to any polypeptide that is involved in the process of producing carotenoids in a cell, and may include polypeptides that are involved in processes other than carotenoid production but whose activities affect the extent or level of production of one or more carotenoids, for example by scavenging a substrate or reactant utilized by a carotenoid polypeptide that is directly involved in carotenoid production. Carotenogenic polypeptides include isoprenoid biosynthesis polypeptides, carotenoid biosynthesis polypeptides, and isoprenoid biosynthesis competitor polypeptides, as those terms are defined herein. The term also encompasses polypeptides that may affect the extent to which carotenoids are accumulated in lipid bodies.
[0019] Carotenoid: The term "carotenoid" is understood in the art to refer to a structurally diverse class of pigments derived from isoprenoid pathway intermediates. The commitment step in carotenoid biosynthesis is the formation of phytoene from geranylgeranyl pyrophosphate. Carotenoids can be acyclic or cyclic, and may or may not contain oxygen, so that the term carotenoids include both carotenes and xanthophylls. In general, carotenoids are hydrocarbon compounds having a conjugated polyene carbon skeleton formally derived from the five-carbon compound IPP, including triterpenes (C30 diapocarotenoids) and tetraterpenes (C40 carotenoids) as well as their oxygenated derivatives and other compounds that are, for example, C35, C50, C6o, C70, C80 in length or other lengths. Many carotenoids have strong light absorbing properties and may range in length in excess of C2oo- C30 diapocarotenoids typically consist of six isoprenoid units joined in such a manner that the arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1 ,6-positional relationship and the remaining non-terminal methyl groups are in a 1,5- positional relationship. Such C30 carotenoids may be formally derived from the acyclic C30H42 structure, having a long central chain of conjugated double bonds, by: (i) hydrogenation (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v) esterification/glycosylation, or any combination of these processes. C40 carotenoids typically consist of eight isoprenoid units joined in such a manner that the arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1,6-positional relationship and the remaining non-terminal methyl groups are in a 1,5- positional relationship. Such C40 carotenoids may be formally derived from the acyclic C40H56 structure, having a long central chain of conjugated double bonds, by (i) hydrogenation, (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v) esterification/glycosylation, or any combination of these processes. The class of C40 carotenoids also includes certain compounds that arise from rearrangements of the carbon skeleton, or by the (formal) removal of part of this structure. More than 600 different carotenoids have been identified in nature; certain common carotenoids are depicted in Figure 1. Carotenoids include but are not limited to: antheraxanthin, adonirubin, adonixanthin, astaxanthin, canthaxanthin, capsorubrin, β-cryptoxanthin, α-carotene, β-carotene, β,ψ- carotene, δ-carotene, ε-carotene, echinenone, 3-hydroxyechinenone, 3'-hydroxyechinenone, γ- carotene, ψ-carotene, 4-keto- γ-carotene, ζ-carotene, α-cryptoxanthin, deoxyflexixanthin, diatoxanthin, 7,8-didehydroastaxanthin, didehydrolycopene, fucoxanthin, fucoxanthinol, isorenieratene, β-isorenieratene, lactucaxanthin, lutein, lycopene, myxobactone, neoxanthin, neurosporene, hydroxyneurosporene, peridinin, phytoene, rhodopin, rhodopin glucoside, 4- keto-rubixanthin, siphonaxanthin, spheroidene, spheroidenone, spirilloxanthin, torulene, 4- keto-torulene, 3-hydroxy-4-keto-torulene, uriolide, uriolide acetate, violaxanthin, zeaxanthin- β-diglucoside, zeaxanthin, and C30 carotenoids. Additionally, carotenoid compounds include derivatives of these molecules, which may include hydroxy-, methoxy-, oxo-, epoxy-, carboxy-, or aldehydic functional groups. Further, included carotenoid compounds include ester (e.g., glycoside ester, fatty acid ester) and sulfate derivatives (e.g., esterified xanthophylls).
[0020] Carotenoid biosynthesis polypeptide: The term "carotenoid biosynthesis polypeptide" refers to any polypeptide that is involved in the synthesis of one or more carotenoids. To mention but a few, these carotenoid biosynthesis polypeptides include, for example, polypeptides of phytoene synthase, phytoene dehydrogenase (or desaturase), lycopene cyclase, carotenoid ketolase, carotenoid hydroxylase, astaxanthin synthase, carotenoid epsilon hydroxylase, lycopene cyclase (beta and epsilon subunits), carotenoid glucosyltransferase, and acyl CoA:diacyglycerol acyltransferase. Representative examples of carotenoid biosynthesis polypeptide sequences are presented in Tables 17-25. [0021] Gene: The term "gene", as used herein, generally refers to a nucleic acid encoding a polypeptide, optionally including certain regulatory elements that may affect expression of one or more gene products (i.e., RNA or protein).
[0022] Heterologous: The term "heterologous", as used herein to refer to genes or polypeptides, refers to a gene or polypeptide that does not naturally occur in the organism in which it is being expressed. It will be understood that, in general, when a heterologous gene or polypeptide is selected for introduction into and/or expression by a host cell, the particular source organism from which the heterologous gene or polypeptide may be selected is not essential to the practice of the present invention. Relevant considerations may include, for example, how closely related the potential source and host organisms are in evolution, or how related the source organism is with other source organisms from which sequences of other relevant polypeptides have been selected.
[0023] Host cell: As used herein, the "host cell" is a yeast or fungal cell that is manipulated according to the present invention to accumulate lipid and/or to express one or more carotenoids as described herein. A "modified host cell", as that term is used herein, is a host cell that contains at least one oleaginic modification and/or at least one carotenogenic modification according to the present invention.
[0024] Isolated: The term "isolated", as used herein, means that the isolated entity has been separated from at least one component with which it was previously associated. When most other components have been removed, the isolated entity is "purified". Isolation and/or purification may be performed using any techniques known in the art including, for example, fractionation, extraction, precipitation, or other separation. [0025] Isoprenoid biosynthesis competitor polypeptide: The term "isoprenoid biosynthesis competitor polypeptide", as used herein, refers to a polypeptide whose expression in a cell reduces the level of geranylgeranyl diphosphate (GGPP) available to enter the carotenoid biosynthesis pathway. For example, isoprenoid biosynthesis competitor polypeptides include enzymes that act on isoprenoid intermediates prior to GGPP, such that less GGPP is generated (see, for example, Figure 5). Squalene synthase is but one isoprenoid biosynthesis competitor polypeptide according to the present invention; representative squalene synthase sequences are presented in Table 16. Prenyldiphosphate synthase enzymes and/?αrø-hydroxybenzoate (PHB) polypreny transferase are yet additional isoprenoid biosynthesis competitor polypeptides according to the present invention; representative prenyldiphosphate synthase enzymes and PHB polyprenyltransferase polypeptides are presented in Table 29 and 30 respectively.
[0026] Isoprenoid biosynthesis polypeptide: The term "isoprenoid biosynthesis polypeptide" refers to any polypeptide that is involved in the synthesis of isoprenoids. For example, as discussed herein, acetoacetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, IPP isomerase, FPP synthase, and GGPP synthase, are all involved in the mevalonate pathway for isoprenoid biosynthesis. Each of these proteins is also an isoprenoid biosynthesis polypeptide for purposes of the present invention, and sequences of representative examples of these enzymes are provided in Tables 7-15. [0027] Isoprenoid pathway: The "isoprenoid pathway" is understood in the art to refer to a metabolic pathway that either produces or utilizes the five-carbon metabolite isopentyl pyrophosphate (IPP). As discussed herein, two different pathways can produce the common isoprenoid precursor IPP — the "mevalonate pathway" and the "non-mevalonate pathway". The term "isoprenoid pathway" is sufficiently general to encompass both of these types of pathway. Biosynthesis of isoprenoids from IPP occurs by polymerization of several five-carbon isoprene subunits. Isoprenoid metabolites derived from IPP are of varying size and chemical structure, including both cyclic and acyclic molecules. Isoprenoid metabolites include, but are not limited to, monoterpenes, sesquiterpenes, diterpenes, sterols, and polyprenols such as carotenoids.
[0028] Oleaginic modification: The term "oleaginic modification", as used herein, refers to a modification of a host organism that adjusts the desirable oleaginy of that host organism, as described herein. In some cases, the host organism will already be oleaginous in that it will have the ability to accumulate lipid to at least about 20% of its dry cell weight. It may nonetheless be desirable to apply an oleaginic modification to such an organism, in accordance with the present invention, for example to increase (or, in some cases, possibly to decrease) its total lipid accumulation, or to adjust the types or amounts of one or more particular lipids it accumulates (e.g., to increase relative accumulation of triacylglycerol). In other cases, the host organism may be non-oleaginous (though may contain some enzymatic and regulatory components used in other organisms to accumulate lipid), and may require oleaginic modification in order to become oleaginous in accordance with the present invention. The present invention also contemplates application of oleaginic modification to non-oleaginous host strains such that their oleaginicity is increased even though, even after being modified, they may not be oleaginous as defined herein. In principle, the oleaginic modification may be any chemical, physiological, genetic, or other modification that appropriately alters oleaginy of a host organism as compared with an otherwise identical organism not subjected to the oleaginic modification. In most embodiments, however, the oleaginic modification will comprise a genetic modification, typically resulting in increased production and/or activity of one or more oleaginic polypeptides. In some embodiments, the oleaginic modification comprises at least one chemical, physiological, genetic, or other modification; in other embodiments, the oleaginic modification comprises more than one chemical, physiological, genetic, or other modification. In certain aspects where more than one modification is utilized, such modifications can comprise any combination of chemical, physiological, genetic, or other modification (e.g., one or more genetic modification and chemical or physiological modification).
[0029] Oleaginic polypeptide: The term "oleaginic polypeptide", as used herein, refers to any polypeptide that is involved in the process of lipid accumulation in a cell and may include polypeptides that are involved in processes other than lipid biosynthesis but whose activities affect the extent or level of accumulation of one or more lipids, for example by scavenging a substrate or reactant utilized by an oleaginic polypeptide that is directly involved in lipid accumulation. For example, as discussed herein, acetyl-CoA carboxylase, pyruvate decarboxylase, isocitrate dehydrogenase, ATP-citrate lyase, malic enzyme, and AMP deaminase, among other proteins, are all involved in lipid accumulation in cells. In general, reducing the activity of pyruvate decarboxylase or isocitrate dehydrogenase, and/or increasing the activity of acetyl CoA carboxylase, ATP-citrate lyase, malic enzyme and/or AMP deaminase is expected to promote oleaginy. Each of these proteins is an oleaginic polypeptide for purposes of the present invention, and sequences of representative examples of these enzymes are provided in Tables 1-6.
[0030] Oleaginous: The term "oleaginous", refers to the ability of an organism to accumulate lipid to at least about 20% of its dry cell weight. In certain embodiments of the invention, oleaginous yeast or fungi accumulate lipid to at least about 25% of their dry cell weight. In other embodiments, inventive oleaginous yeast or fungi accumulate lipid within the range of about 20-45% of their dry cell weight. In some embodiments, oleaginous organisms may accumulate lipid to as much as about 70% of their dry cell weight. In some embodiments of the invention, oleaginous organisms may accumulate a large fraction of total lipid accumulation in the form of triacylglycerol. In certain embodiments, the majority of the accumulated lipid is in the form of triacylglycerol. Alternatively or additionally, the lipid may accumulate in the form of intracellular lipid bodies, or oil bodies. In certain embodiments, the present invention utilizes yeast or fungi that are naturally oleaginous. In some aspects, naturally oleaginous organisms are manipulated (e.g., genetically, chemically, or otherwise) so as to futher increase the level of accumulated lipid in the organism. In other embodiments, yeast or fungi that are not naturally oleaginous are manipulated (e.g., genetically, chemically, or otherwise) to accumulate lipid as described herein. For the purposes of the present invention, Xanthophyllomyces dendrorhous (Phaffia rhodo∑ymά) and Candida utilis are not naturally oleaginous fungi.
[0031] Polypeptide: The term "polypeptide", as used herein, generally has its art- recognized meaning of a polymer of at least three amino acids. However, the term is also used to refer to specific functional classes of polypeptides, such as, for example, oleaginic polypeptides, carotenogenic polypeptides, isoprenoid biosynthesis polypeptides, carotenoid biosynthesis polypeptides, and isoprenoid biosynthesis competitor polypeptides. For each such class, the present specification provides several examples of known sequences of such polypeptides. Those of ordinary skill in the art will appreciate, however, that the term "polypeptide" is intended to be sufficiently general as to encompass not only polypeptides having the complete sequence recited herein (or in a reference or database specifically mentioned herein), but also to encompass polypeptides that represent functional fragments (i.e., fragments retaining at least one activity) of such complete polypeptides. Moreover, those of ordinary skill in the art understand that protein sequences generally tolerate some substitution without destroying activity. Thus, any polypeptide that retains activity and shares at least about 30-40% overall sequence identity, often greater than about 50%, 60%, 70%, or 80%, and further usually including at least one region of much higher identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99% in one or more highly conserved regions (e.g., isocitrate dehydrogenase polypeptides often share a conserved AMP-binding motif; HMG-CoA reductase polypeptides typically include a highly conserved catalytic domain (see, for example, Figure 7); acetyl coA carboxylase typically has a carboxyl transferase domain; see, for example, Downing et al., Chem. Abs. 93:484, 1980; Gil et al., Cell 41 :249, 1985; Jitrapakdee et al. Curr Protein Pept Sci. 4:217, 2003; U.S. Patent Number 5,349,126, each of which is incorporated herein by reference in its entirety), usually encompassing at least 3-4 and often up to 20 or more amino acids, with another polypeptide of the same class, is encompassed within the relevant term "polypeptide" as used herein.
[0032] Source organism: The term "source organism", as used herein, refers to the organism in which a particular polypeptide sequence can be found in nature. Thus, for example, if one or more heterologous polypeptides is/are being expressed in a host organism, the organism in which the polypeptides are expressed in nature (and/or from which their genes were originally cloned) is referred to as the "source organism". Where more than one heterologous polypeptides are being expressed in a host organism, one or more source organism(s) may be utilized for independent selection of each of the heterologous polypeptide(s). It will be appreciated that any and all organisms that naturally contain relevant polypeptide sequences may be used as source organisms in accordance with the present invention. Representative source organisms include, for example, animal, mammalian , insect, plant, fungal, yeast, algal, bacterial, cyanobacterial, archaebacterial and protozoal source organisms.
Detailed Description of Certain Preferred Embodiments of the Invention
[0033] As noted above, the present invention encompasses the discovery that carotenoids can desirably be produced in oleaginous yeast and fungi. According to the present invention, strains that both (i) accumulate lipid, often in the form of cytoplasmic oil bodies and typically to at least about 20% of their dry cell weight; and (ii) produce carotenoid(s) at a level at least about 1%, and in some embodiments at least about 3-20%, of their dry cell weight, are generated through manipulation of host cells (i.e., strains, including, e.g., naturally-occurring strains, strains which have been previously modified, etc.). These manipulated host cells are then used to produce carotenoids, so that carotenoids that partition into the lipid bodies can readily be isolated.
[0034] In general, it will be desirable to balance oleaginy and carotenoid production in inventive cells such that, as soon as a minimum desirable level of oleaginy is achieved, substantially all further carbon which is capable of being utilized and diverted into biosynthesis of products is diverted into a carotenoid production pathway. In some embodiments of the invention, this strategy involves engineering cells to be oleaginous; in other embodiments, it involves engineering cells to accumulate a higher level of lipid, particularly cytoplasmic lipid, than they would accumulate in the absence of such engineering even though the engineered cells may not become "oleaginous" as defined herein. In other embodiments, the extent to which an oleaginous host cell accumulates lipid is actually reduced so that remaining carbon can be utilized in carotenoid production. Host Cells
[0035] Those of ordinary skill in the art will readily appreciate that a variety of yeast and fungal strains exist that are naturally oleaginous or that naturally produce carotenoids. Any of such strains may be utilized as host strains according to the present invention, and may be engineered or otherwise manipulated to generate inventive oleaginous, carotenoid- producing strains. Alternatively, strains that naturally are neither oleaginous nor carotenoid- producing may be employed. Furthermore, even when a particular strain has a natural capacity for oleaginy or for carotenoid production, its natural capabilities may be adjusted as described herein, so as to change the production level of lipid and/or carotenoid. In certain embodiments engineering or manipulation of a strain results in modification of a type of lipid and/or carotenoid which is produced. For example, a strain may be naturally oleaginous and/or carotenogenic, however engineering or modification of the strain may be employed so as to change the type of lipid which is accumulated and or to change the type of carotenoid which is produced.
[0036] When selecting a particular yeast or fungal strain for use in accordance with the present invention, it will generally be desirable to select one whose cultivation characteristics are amenable to commercial scale production. For example, it will generally (though not necessarily always) be desirable to avoid filamentous organisms, or organisms with particularly unusual or stringent requirements for growth conditions. However, where conditions for commercial scale production can be applied which allow for utilization of filamentous organisms, these may be selected as host cells. In some embodiments of the invention, it will be desirable to utilize edible organisms as host cells, as they may optionally be formulated directly into food or feed additives, or into nutritional supplements, as desired. For ease of production, some embodiments of the invention utilize host cells that are genetically tractable, amenable to molecular genetics (e.g., can be efficiently transformed, especially with established or available vectors; optionally can incorporate and/or integrate multiple genes, for example sequentially; and/or have known genetic sequence; etc), devoid of complex growth requirements (e.g., a necessity for light), mesophilic (e.g., prefer growth temperatures with in the range of about 25-32 0C), able to assimilate a variety of carbon and nitrogen sources and/or capable of growing to high cell density. Alternatively or additionally, various embodiments of the invention utilize host cells that grow as single cells rather than multicellular organisms (e.g., as mycelia).
[0037] In general, when it is desirable to utilize a naturally oleaginous organism in accordance with the present invention, any modifiable and cultivatable oleaginous organism may be employed. In certain embodiments of the invention, yeast or fungi of genera including, but not limited to, Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Mucor, Phycomyces, Pythium, Rltodosporidium, Rliodotorula, Trichosporon, and Yarrow ia are employed. In certain particular embodiments, organisms of species that include, but are not limited to, Blakeslea frispora, Candida pulcherrima, C. revkauβ, C. tropicalis, Cryptococcus curvatus, Cunninghamella echinulata, C. elegans, C. japonica, Lipomyces starkeyi, L. lipoferus, Mortierella alpina, M. isabellina, M. ramanniana, M. vinacea, Mucor circinelloides, Phycomyces blakesleanus, Pythium irregulare, Rhodosporidium toruloides, Rhodotorula glutinis, R. gracilis, R. graminis, R. mucilaginosa, R pinicola, Trichosporon pullans, T. cutaneum, and Yarrowia lipolytica are used.
[0038] Of these naturally oleaginous strains, some also naturally produce carotenoids and some do not. In most cases, only low levels (less than about 0.05% dry cell weight) of carotenoids are produced by naturally-occurring carotenogenic, oleaginous yeast or fungi. Higher levels of β-carotene are sometimes produced, but high levels of other carotenoids are generally not observed.
[0039] In general, any organism that is naturally oleaginous and non-carotenoid- producing (e.g., produce less than about 0.05% dry cell weight, do not produce the carotenoid of interest) may be utilized as a host cell in accordance with the present invention. In some embodiments, the organism is a yeast or fungus from a genus such as, but not limited to, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Pythium, Trichosporon, and Yarrowia; in some embodiments, the organism is of a species including, but not limited to, Mortierella alpina and Yarrowia lipolytica.
[0040] Comparably, the present invention may utilize any naturally oleaginous, carotenoid-producing organism as a host cell. In general, the present invention may be utilized to increase carbon flow into the isoprenoid pathway in naturally carotenoid-producing organisms (particularly for organisms other than Blakeslea and Phycomyces), and/or to shift production from one carotenoid (e.g., β-carotene) to another (e.g., astaxanthin). Introduction of one or more carotenogenic modifications (e.g., increased expression of one or more endogenous or heterologous carotenogenic polypeptides), in accordance with the present invention, can achieve these goals.
[0041] In certain embodiments of the invention, the utilized oleaginous, carotenoid- producing organism is a yeast or fungus, for example of a genus such as, but not limited to, Blakeslea, Mucor, Phycomyces, Khodosporidium, and Rhodotorula; in some embodiments, the organism is of a species such as, Mucor circinelloides and PJjodotorula glutinis. [0042] When it is desirable to utilize strains that are naturally non-oleaginous as host cells in accordance with the present invention, genera of non-oleaginous yeast or fongi include, but are not limited to, Aspergillus, Botrytis, Cercospora, Fusarium (Gibberella), Kluyveromyces, Neurospora, Penicillium, Pichia (Hansenula), Puccinia, Saccharomyces, Sclerotium, Trichoderma, and Xanthophyllomyces (Phaffia); in some embodiments, the organism is of a species including, but not limited to, Aspergillus nidulans, A. niger, A. terreus, Botrytis cinerea, Cercospora nicotianae, Fusarium fujikuroi {Gibberella zeae), Kluyveromyces lactis, K. lactis, Neurospora crassa, Pichia pastoris, Puccinia distincta, Saccharomyces cerevisiae, Sclerotium rolfsii, Trichoderma reesei, and Xanthophyllomyces dendrorhous (Phaffia rhodozyma).
[0043] It will be appreciated that the term "non-oleaginous", as used herein, encompasses both strains that naturally have some ability to accumulate lipid, especially cytoplasmically, but do not do so to a level sufficient to qualify as "oleaginous" as defined herein, as well as strains that do not naturally have any ability to accumulate extra lipid, e.g., extra-membranous lipid. It will further be appreciated that, in some embodiments of the invention, it will be sufficient to increase the natural level of oleaginy of a particular host cell, even if the modified cell does not qualify as oleaginous as defined herein. [0044] As with the naturally oleaginous organisms, some of the naturally non- oleaginous fungi naturally produce carotenoids, whereas others do not. Genera of naturally non-oleaginous fungi that do not naturally produce carotenoids (e.g., produce less than about 0.05% dry cell weight, do not produce carotenoid of interest) may desirably be used as host cells in accordance with the present invention include, but are not limited to, Aspergillus, Kluyveromyces, Penicillium, Saccharomyces, and Pichia; species include, but are not limited to, Aspergillus niger and Saccharomyces cerevisiae. Genera of naturally non-oleaginous fungi that do naturally produce carotenoids and that may desirably be used as host cells in accordance with the present invention include, but are not limited to, Botrytis, Cercospora, Fusarium (Gibberella), Neurospora, Puccinia, Sclerotium, Trichoderma, and Xanthophyllomyces (Phaffia); species include, but are not limited to, Xanthophyllomyces dendrorhous (Phaffia rhodozyma).
[0045] As discussed above, any of a variety of organisms may be employed as host cells in accordance with the present invention. In certain embodiments of the invention, host cells will be Yarrowia lipolytica cells. Advantages of 7. lipolytica include, for example, tractable genetics and molecular biology, availability of genomic sequence (see, for example. Sherman et al. Nucleic Acids Res. 32(Database issue):D315-8, 2004), suitability to various cost-effective growth conditions, and ability to grow to high cell density. In addition, Y. lipolytica is naturally oleaginous, such that fewer manipulations may be required to generate an oleaginous, carotenoid-producing Y. lipolytica strain than might be required for other organisms. Furthermore, there is already extensive commercial experience with Y. lipolytica. [0046] Saccharomyces cerevisiae is also a useful host cell in accordance with the present invention, particularly due to its experimental tractability and the extensive experience that researchers have accumulated with the organism. Although cultivation of Saccharomyces under high carbon conditions may result in increased ethanol production, this can generally be managed by process and/or genetic alterations.
[0047] Additional useful hosts include Xanthophyllomyces dendrorhous (Phaffia rhodozyma), which is experimentally tractable and naturally carotenogenic. Xanthophyllomyces dendrorhous (Phaffia rhodozyma) strains can produce several carotenoids, including astaxanthin.
[0048] Aspergillus niger and Mortierella alpina accumulate large amounts of citric acid and fatty acid, respectively; Mortierella alpina is also oleaginous. [0049] Neurospora or Gibberella are also useful. They are not naturally oleaginous and tend to produce very low levels of carotenoids, thus extensive modification may be required in accordance with the present invention. Neurospora and Gibberella are considered relatively tractable from an experimental standpoint. Both are filamentous fungi, such that production at commercial scales can be a challenge necessary to overcome in utilization of such strains.
[0050] Mucor circinelloides is another available useful species. While its molecular genetics are generally less accessible than are those of some other organisms, it naturally produces β-carotene, thus may require less modification than other species available. [0051] Molecular genetics can be performed in Blakeslea, though significant effort may be required. Furthermore, cost-effective fermentation conditions can be challenging, as, for example, it may be required that the two mating types are mixed. Fungi of the genus Phycomyces are also possible sources which have the potential to pose fermentation process challenges, and these fungi are also may be less amenable to manipulate than several other potential host organisms.
[0052] Those of ordinary skill in the art will appreciate that the selection of a particular host cell for use in accordance with the present invention will also affect, for example, the selection of expression sequences utilized with any heterologous polypeptide to be introduced into the cell, and will also influence various aspects of culture conditions, etc. Much is known about the different gene regulatory requirements, protein targeting sequence requirements, and cultivation requirements, of different host cells to be utilized in accordance with the present invention (see, for example, with respect to Yarrowict, Barth et al. FEMS Microbiol Rev. 19:219, 1997; Madzak et al. J Biotechnol. 109:63, 2004; see, for example, with respect to Xanthophyllomyces, Verdoes et al. Appl Environ Microbiol 69: 3728-38, 2003 ; Visser et al. FEMS Yeast Res 4: 221-31, 2003; Martinez et al. Antonie Van Leeuwenhoek. 73(2):147-53, 1998; Kim et al. Appl Environ Microbiol. 64(5):1947-9, 1998; Wery et al. Gene. 184(l):89-97, 1997; see, for example, with respect to Saccharomyces, Guthrie and Fink Methods in Enzymology 194:1-933, 1991). In certain aspects, for example, targeting sequences of the host cell (or closely related analogs) may be useful to include for directing heterologous proteins to subcellular localization. Thus, such useful targeting sequences can be added to heterologous sequence for proper intracellular localization of activity. In other aspects (e.g., addition of mitochondrial targeting sequences), heterologous targeting sequences may be eliminated or altered in the selected heterologous sequence (e.g., alteration or removal of source organism plant chloroplast targeting sequences). Engineering Oleaginy
[0053] All living organisms synthesize lipids for use in their membranes and various other structures. However, most organisms do not accumulate in excess of about 10% of their dry cell weight as total lipid, and most of this lipid generally resides within cellular membranes.
[0054] Significant biochemical work has been done to define the metabolic enzymes necessary to confer oleaginy on microorganisms (primarily for the purpose of engineering single cell oils as commercial sources of arachidonic acid and docosahexaenoic acid; see for example Ratledge Biochimie 86:807, 2004, the entire contents of which are incorporated herein by reference). Although this biochemical work is compelling, prior to the present invention, there have been no reports of de novo oleaginy being established through genetic engineering with the genes encoding the key metabolic enzymes.
[0055] It should be noted that oleaginous organisms typically only accumulate lipid when grown under conditions of carbon excess and nitrogen or other nutrient limitation. Under these conditions, the organism readily depletes the limiting nutrient but continues to assimilate the carbon source. The "excess" carbon is channeled into lipid biosynthesis so that lipids (usually triacylglycerols) accumulate in the cytosol, typically in the form of bodies. [0056] In general, it is thought that, in order to be oleaginous, an organism must produce both acetyl-CoA and NADPH in the cytosol, which can then be utilized by the fatty acid synthase machinery to generate lipids. In at least some oleaginous organisms, acetyl- CoA is generated in the cytosol through the action of ATP-citrate lyase, which catalyzes the reaction:
(1) citrate + CoA + ATP → acetyl-CoA + oxaloacetate + ADP + P,. [UU57J Of course, in order for ATP-citrate lyase to generate appropriate levels of acetyl-CoA in the cytosol, it must first have an available pool of its substrate citric acid. Citric acid is generated in the mitochondria of all eukaryotic cells through the tricarboxylic acid (TCA) cycle, and can be moved into the cytosol (in exchange for malate) by citrate/malate translocase.
[0058] In most oleaginous organisms, and in some non-oleaginous organisms, the enzyme isocitrate dehydrogenase, which operates as part of the TCA cycle in the mitochondria, is strongly AMP-dependent. Thus, when AMP is depleted from the mitochondria, this enzyme is inactivated. When isocitrate dehydrogenase is inactive, isocitrate accumulates in the mitochondria. This accumulated isocitrate is then equilibrated with citric acid, presumably through the action of aconitase. Therefore, under conditions of low AMP, citrate accumulates in the mitochondria. As noted above, mitochondrial citrate is readily transported into the cytosol.
[0059] AMP depletion, which in oleaginous organisms is believed to initiate the cascade leading to accumulation of citrate (and therefore acetyl-CoA) in the cytoplasm, occurs as a result of the nutrient depletion mentioned above. When oleaginous cells are grown in the presence of excess carbon source but under conditions limiting for nitrogen or some other nutrient(s), the activity of AMP deaminase, which catalyzes the reaction:
(2) AMP → inosine 5'-monophosphate + NH3 is strongly induced. The increased activity of this enzyme depletes cellular AMP in both the cytosol and the mitochondria. Depletion of AMP from the mitochondria is thought to inactivate the AMP-dependent isocitrate dehydrogenase, resulting in accumulation of citrate in the mitochondria and, therefore, the cytosol. This series of events is depicted diagrammatically in Figure 2.
[0060] As noted above, oleaginy requires both cytosolic acetyl-CoA and cytosolic
NADPH. It is believed that, in many oleaginous organisms, appropriate levels of cytosolic NADPH are provided through the action of malic enzyme (Enzyme 3 in Figure 2). Some oleaginous organisms (e.g., Lipomyces and some Candida) do not appear to have malic enzymes, however, so apparently other enzymes can provide comparable activity, although it is expected that a dedicated source of NADPH is probably required for fatty acid synthesis (see, for example, Wynn et al., Microbiol 145:1911, 1999; Ratledge Adv. Appl. Microbiol. 51 :1, 2002, each of which is incorporated herein by reference in its entirety). [0061] Thus, according to the present invention, the oleaginy of a host organism may be enhanced by modifying the expression or activity of one or more polypeptides involved in generating cytosolic acetyl-CoA and/or NADPH. For example, modification of the expression or activity of one or more of acetyl-CoA carboxylase, pyruvate decarboxylase, ϊsocitrate dehydrogenase, ATP-citrate lyase, malic enzyme, and AMP-deaminase can enhance oleaginy in accordance with the present invention. Exemplary polypeptides which can be utilized or derived so as to enhance oleaginy in accordance with the present invention include, but are not limited to those acetyl-CoA carboxylase, pyruvate decarboxylase, isocitrate dehydrogenase, ATP-citrate lyase, malic enzyme, and AMP-deaminase polypeptides provided in Table 1, Table 2, Table 3, Table 4, Table 5, and Table 6, respectively. [0062] In some embodiments of the invention, where an oleaginous host cell is employed, enzymes and regulatory components relevant to oleaginy are already in place but could be modified, if desired, by for example altering expression or activity of one or more oleaginic polypeptides and/or by introducing one or more heterologous oleaginic polypeptides. In those embodiments of the invention where a non-oleaginous host cell is employed, it is generally expected that at least one or more heterologous oleaginic polypeptides will be introduced.
[0063] The present invention contemplates not only introduction of heterologous oleaginous polypeptides, but also adjustment of expression or activity levels of heterologous or endogenous oleaginic polypeptides, including, for example, alteration of constitutive or inducible expression patterns. In some embodiments of the invention, expression patterns are adjusted such that growth in nutrient-limiting conditions is not required to induce oleaginy. For example, genetic modifications comprising alteration and/or addition of regulatory sequences (e.g., promoter elements, terminator elements) may be utilized to confer particular regulation of expression patterns. Such genetic modifications may be utilized in conjunction with endogenous genes (e.g., for regulation of endogenous oleagenic polypeptide(s)); alternatively, such genetic modifications may be included so as to confer regulation of expression of at least one heterologous polypeptide (e.g., oleagenic polypeptide(s)). For example, promoters including, but not limited to Tefl, Gpdl promoters can be used in conjunction with endogenous genes and/or heterolous genes for modification of expression patterns of endogenous oleaginic polypeptides and/or heterolous oleagenic polypeptides. Similarly, exemplary terminator sequences include, but are not limited to, use of Y. lipolytica XPR2 terminator sequences.
[0064] In some embodiments, at least one oleaginic polypeptide is introduced into a host cell. In some embodiments of the invention, a plurality (e.g., two or more) of different oleaginic polypeptides is introduced into the same host cell. In some embodiments, the plurality of oleaginic polypeptides contains polypeptides from the same source organism; in other embodiments, the plurality includes polypeptides independently selected from different source organisms. 10065] Representative examples of a variety of oleaginic polypeptides that may be introduced into or modified within host cells according to the present invention, include, but are not limited to, those provided in Tables 1-6. As noted above, it is expected that at least some of these polypeptides (e.g., malic enzyme and ATP-citrate lyase) should desirably act in concert, and possibly together with one or more components of fatty acid synthase, such that, in some embodiments of the invention, it will be desirable to utilize two or more oleaginic polypeptides from the same source organism.
[0066] In general, source organisms for oleaginic polypeptides to be used in accordance with the present invention include, but are not limited to, Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Mucor, Phycomyces, Pythium, Rhodosporidium, Bliodotorula, Trichosporon, Yarrowia, Aspergillus, Botrytis, Cercospora, Fusarium (Gibberella), Kluyveromyces, Neurospora, Penicillium, Pichia (Hansenula), Puccinia, Saccharomyces, Sclerotium, Trichoderma, and Xanthophyllomyces (Phaffia). In some embodiments, the source species for acetyl CoA carboxylase, ATP-citrate lyase, malice enzyme and/or AMP deaminase polypeptides include, but are not limited to, Aspergillus nidulans, Cryptococcus neoformans, Fusarium fujϊkuroi, Kluyveromyces lactis, Neurospora crassa, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Ustilago maydis, and Yarrowia lipolytics, in some embodiments, source species for pyruvate decarboxylase or isocitrate dehydrogenase polypeptides include, but are not limited to Neurospora crassa, Xanthophyllomyces dendrorhous (Phaffia rhodozyma), Aspergillus niger, Saccharomyces cerevisiae, Mucor circinelloides, Khodotorula glutinis, Candida utilis, Mortierella alpina and Yarrowia lipolytica. Engineering Carotenoid Production
[0067] Carotenoids are synthesized from isoprenoid precursors, some of which are also involved in the production of steroids and sterols. The most common isoprenoid biosynthesis pathway, sometimes referred to as the "mevalonate pathway", is generally depicted in Figure 3. As shown, acetyl-CoA is converted, via hydroxymethylglutaryl-CoA (HMG-CoA), into mevalonate. Mevalonate is then phosphorylated and converted into the five-carbon compound isopentenyl pyrophosphate (IPP). Following isomerization of IPP into dimethylallyl pyrophosphate (DMAPP), three sequential condensation reactions with additional molecules of IPP generate the ten-carbon molecule geranyl pyrophosphate (GPP), followed by the fifteen-carbon molecule farnesyl pyrophosphate (FPP), and finally the twenty-carbon compound geranylgeranyl pyrophosphate (GGPP). [0068] An alternative isoprenoid biosynthesis pathway, that is utilized by some organisms (particularly bacteria) and is sometimes called the "mevalonate-independent pathway", is depicted in Figure 4. This pathway is initiated by the synthesis of 1 -deoxy-D- xyloglucose-5-phosphate (DOXP) from pyruvate and glyceraldehyde-3 -phosphate. DOXP is then converted, via a series of reactions shown in Figure 4, into IPP, which isomerizes into DMAPP and is then converted, via GPP and FPP, into GGPP as shown in Figure 3 and discussed above.
[0069] Various proteins involved in isoprenoid biosynthesis have been identified and characterized in a number of organisms. Moreover, various aspects of the isoprenoid biosynthesis pathway are conserved throughout the fungal, bacterial, plant and animal kingdoms. For example, polypeptides corresponding to the acetoacetyl-CoA thiolase, HMG- CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, IPP isomerase, FPP synthase, and GGPP synthase shown in Figure 3 have been identified in and isolated from a wide variety of organisms and cells. Representative examples of a wide variety of such polypeptides are provided in Tables 7-15. One or more of the polypeptides selected from those provided in any one of Tables 7- 15 may be utilized or derived for use in the methods and compositions in accordance with the present invention.
[0070] According to the present invention, carotenoid production in a host organism may be adjusted by modifying the expression or activity of one or more proteins involved in isoprenoid biosynthesis. In some embodiments, such modification involves introduction of one or more heterologous isoprenoid biosynthesis polypeptides into the host cell; alternatively or additionally, modifications may be made to the expression or activity of one or more endogenous or heterologous isoprenoid biosynthesis polypeptides. Given the considerable conservation of components of the isoprenoid biosynthesis polypeptides, it is expected that heterologous isoprenoid biosynthesis polypeptides will often function even in significantly divergent organisms. Furthermore, should it be desirable to introduce more than one heterologous isoprenoid biosynthesis polypeptide, in many cases polypeptides from different source organisms will function together. In some embodiments of the invention, a plurality of different heterologous isoprenoid biosynthesis polypeptides is introduced into the same host cell. In some embodiments, this plurality contains only polypeptides from the same source organism (e.g., two or more sequences of, or sequences derived from, the same source organism); in other embodiments the plurality includes polypeptides independently selected from from different source organisms (e.g., two or more sequences of, or sequences derived from, at least two independent source organisms).
[0071] In some embodiments of the present invention that utilize heterologous isoprenoid biosynthesis polypeptides, the source organisms include, but are not limited to, fungi of the genera Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Mucor, Phycomyces, Pythium, Bliodosporidium, Rhodotorula, Trichosporon, Yarrowia, Aspergillus, Botrytis, Cercospora, Fusarium (Gibberella), Kluyveromyces, Neurospora, Penicillium, Pichia (Hansenula), Puccinia, Saccharomyces, Schizosaccharomyces, Sclerotium, Trichoderms, Ustilago, and Xanthophyllomyces (Phaffia). In certain embodiments, the source organisms are of a species including, but not limited to, Cryptococcus neoformans, Fusarium fujikuroi, Kluyverimyces lactis, Neurospora crassa, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Ustilago maydis, and Yarrowia lipolytica.
[0072] As noted above, the isoprenoid biosynthesis pathway is also involved in the production of non-carotenoid compounds, such as sterols, steroids, and vitamins, such as vitamin E or vitamin K. Proteins that act on isoprenoid biosynthesis pathway intermediates, and divert them into biosynthesis of non-carotenoid compounds are therefore indirect inhibitors of carotenoid biosynthesis (see, for example, Figure 5, which illustrates points at which isoprenoid intermediates are channeled into other biosynthesis pathways). Such proteins are therefore considered isoprenoid biosynthesis competitor polypeptides. Reductions of the level or activity of such isoprenoid biosynthesis competitor polypeptides are expected to increase carotenoid production in host cells according to the present invention. [0073] In some embodiments of the present invention, production or activity of endogenous isoprenoid biosynthesis competitor polypeptides may be reduced or eliminated in host cells. In some embodiments, this reduction or elimination of the activity of an isoprenoid biosynthesis competitor polypeptide can be achieved by treatment of the host organism with small molecule inhibitors of enzymes of the ergosterol biosynthetic pathway. Enzymes of the ergosterol biosynthetic pathway include, for example, squalene synthase, squalene epoxidase, 2,3-oxidosqualene-lanosterol cyclase, cytochrome P450 lanosterol 14α-demethylase, C-14 sterol reductase, C-4 sterol methyl oxidase, SAM:C-24 sterol methyltransferase, C-8 sterol isomerase, C-5 sterol desaturase, C-22 sterol desaturase, and C-24 sterol reductase. Each of these enzymes is considered an isoprenoid biosynthesis competitor polypeptide. Regulators of these enzymes may also be considered isoprenoid biosynthesis competitor polypeptides (e.g., the yeast proteins Sutl (Genbank Accession JC4374 GI:2133159) and Mot3 (Genbank Accession NP_013786 GL6323715), which may or may not have homologs in other organisms.
[0074] In other embodiments, reduction or elimination of the activity of an isoprenoid biosynthesis competitor polypeptide can be achieved by decreasing activity of the ubiquinone biosynthetic pathway. The commitment step in ubiquinone biosynthesis is the formation ofpαrø-hydroxybenzoate (PHB) from tyrosine or phenylalanine in mammals or chorismate in bacteria, followed by condensation of PHB and isoprene precursor, resulting in addition of the prenyl group. This reaction is catalyzed by PHB-polyprenyltransferase. The isoprenoid side chain of ubiquinone is determined by the preny diphosphate synthase enzyme. The 3-decaprenyl-4-hydroxybenzoic acid resulting from the condensation of PHB and decaprenyldiphosphate reaction undergoes further modifications, which include hydroxylation, methylation and decarboxylation, in order to form ubiquinone (CoQlO). Thus, inhibition of prenyldiphosphate synthase leading from farnesyldiphosphate to extended isoprenoids, or inhibition of PHB polyprenyltransferase may be useful in increasing the amount of isoprenoid available for carotenoid biosynthesis. (Examples of prenyldiphosphate synthase and PHB-polyprenyltransferase enzymes are depicted in Tables 29 and 30, respectively).
[0075] Known small molecule inhibitors of isoprenoid biosynthesis competitor enzymes include, but are not limited to, zaragosic acid (including analogs thereof such as TAN1607A (Biochem Biophys Res Commun 1996 Feb 15;219(2):515-520)), RPR 107393 (3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-l-azabicyclo[2-2-2]octane dihydrochloride; J Pharmacol Exp Ther. 1997 May;281(2):746-52), ER-28448 (5-{N-[2-butenyl-3-(2- methoxyphenyl)]-N-methylamino}-l,l-ρenthylidenebis(phosphonic acid) trisodium salt; Journal of Lipid Research, Vol. 41, 1136-1144, July 2000), BMS-188494 (The Journal of Clinical Pharmacology, 1998; 38:1116-1121), TAK-475 (l-[2-[(3R,5S)-l-(3-acetoxy-2,2- dimethylpropyl)-7-chloro- 1 ,2,3 ,5 -tetrahydro-2-oxo-5 -(2,3 -dimethoxyphenyl)-4, 1 - benzoxazepine-3-yl] acetyl] piperidin-4-acetic acid; Eur J Pharmacol. 2003 Apr 11;466(1- 2):155-61), YM-53601 ((E)-2-[2-fluoro-2-(quinuclidin-3-ylidene) ethoxy]-9H-carbazole monohydrochloride; Br J Pharmacol. 2000 Sep;131(l):63-70), or squalestatin I that inhibit squalene synthase; terbinafme that inhibits squalene epoxidase; various azoles that inhibit cytochrome P450 lanosterol 14α-demethylase; and fenpropimorph that inhibits the C-14 sterol reductase and the C-8 sterol isomerase. In other embodiments, heterologous isoprenoid biosynthesis competitor polypeptides may be utilized (whether functional or non-functional; in some embodiments, dominant negative mutants are employed). [0076] One particular isoprenoid biosynthesis competitor polypeptide useful according to the present invention is squalene synthase which has been identified and characterized from a variety of organisms; representative examples of squalene synthase polypeptide sequences are included in Table 16. In some embodiments of the invention that utilize squalene synthase (or modifications of squalene synthase) source organisms include, but are not limited to, Neurospora crassa, Xanthophyllomyces dendrorhous (Phaffia rhodozyma), Aspergillus niger, Saccharomyces cerevisiae, Mucor circinelloides, Rhotorula glutinis, Candida utilis, Mortierella alpina, and Yarrowia lipolytica. [0077] The carotenoid biosynthesis pathway branches off from the isoprenoid biosynthesis pathway at the point where GGPP is formed. The commitment step in carotenoid biosynthesis is the formation of phytoene by the head-to-head condensation of two molecules of GGPP, catalyzed by phytoene synthase (often called crtB; see Figure 6). A series of dehydrogenation reactions, each of which increases the number of conjugated double bonds by two, converts phytoene into lycopene via neurosporene. The pathway branches at various points, both before and after lycopene production, so that a wide range of carotenoids can be generated. For example, action of a cyclase enzyme on lycopene generates γ-carotene; action of a desaturase instead produces 3,4-didehydrolycopene. γ-carotene is converted to β- carotene through the action of a cyclase, β-carotene can be processed into any of a number of products (see, for example, Figure 6C), including astaxanthin (via echinone, hydroxyechinone, and phoenicoxanthin).
[0078] According to the present invention, carotenoid production in a host organism may be adjusted by modifying the expression or activity of one or more proteins involved in carotenoid biosynthesis. As indicated, in some embodiments, it will be desirable to utilize as host cells organisms that naturally produce one or more carotenoids. In some such cases, the focus will be on increasing production of a naturally-produced carotenoid, for example by increasing the level and/or activity of one or more proteins involved in the synthesis of that carotenoid and/or by decreasing the level or activity of one or more proteins involved in a competing biosynthetic pathway. Alternatively or additionally, in some embodiments it will be desirable to generate production of one or more carotenoids not naturally produced by the host cell.
[0079] According to some embodiments of the invention, it will be desirable to introduce one or more heterologous carotenogenic polypeptides into a host cell. As will be apparent to those of ordinary skill in the art, any of a variety of heterologous polypeptides may be employed; selection will consider, for instance, the particular carotenoid whose production is to be enhanced. The present invention contemplates not only introduction of heterologous carotenogenic polypeptides, but also adjustment of expression or activity levels of heterologous or endogenous carotenogenic polypeptides, including, for example, alteration of constitutive or inducible expression patterns. In some embodiments of the invention, expression patterns are adjusted such that growth in nutrient-limiting conditions is not required to induce oleaginy. For example, genetic modifications comprising alteration and/or addition of regulatory sequences (e.g., promoter elements, terminator elements) may be utilized to confer particular regulation of expression patterns. Such genetic modifications may be utilized in conjunction with endogenous genes (e.g., for regulation of endogenous carotenogenic); alternatively, such genetic modifications may be included so as to confer regulation of expression of at least one heterologous polypeptide (e.g., carotenogenic polypeptide^ )). For example, promoters including, but not limited to Tefl, Gpdl promoters can be used in conjunction with endogenous genes and/or heterolous genes for modification of expression patterns of endogenous carotenogenic polypeptide(s) and/or heterolous carotenogenic polypeptide(s). Similarly, exemplary terminator sequences include, but are not limited to, use of Y. lipolytica XPR2 terminator sequences.
[0080] As indicated in Figure 6 and in the literature, proteins involved in carotenoid biosynthesis include, but are not limited to, phytoene synthase, phytoene dehydrogenase, lycopene cyclase, carotenoid ketolase, carotenoid hydroxylase, astaxanthin synthase (a single multifunctional enzyme found in some source organisms that typically has both ketolase and hydroxylase activities), carotenoid epsilon hydroxylase, lycopene cyclase (beta and epsilon subunits), carotenoid glucosyltransferase, and acyl CoA:diacyglycerol acyltransferase. Representative example sequences for these carotenoid biosynthesis polypeptides are provided in Tables 17-25.
[0081] Xanthophylls can be distinguished from other carotenoids by the presence of oxygen containing functional groups on their cyclic end groups. For instance, lutein and zeaxanthin contain a single hydroxyl group on each of their terminal ring structures, while astaxanthin contains both a keto group and a hydroxyl on each terminal ring. This property makes xanthophylls more polar than carotenes such as beta-carotene and lycopene, and thus dramatically reduces their solubility in fats and lipids. Naturally occurring xanthophylls are often found as esters of the terminal hydroxyl groups, both mono- and diesters of fatty acids. They also occur as glucosides in certain species of bacteria. The solubility and dispersibility of xanthophylls can be greatly modified by the addition of ester moieties, and it is known that esterification can also affect the absorbability and/or bioavailability of a given carotenoid. It is an objective of this invention to maximize the amount of a particular xanthophyll accumulating within the intracellular triacylglyceride fraction of oleaginous yeasts, and one mechanism for achieving this goal is to increase the hydrophobic nature of the xanthophyll product that accumulates. One way of achieving this is to engineer the production of fatty- acyl mono- and/or diesters of the target xanthophyll compound.
[0082] A variety of enzymes can function to esterify carotenoids. For example, carotenoid glucosyltransferases have been identified in several bacterial species (see, e.g., Table 24). In addition, acyl CoA:diacyglycerol acyltransferase (DGAT) and acyl CoA:monoacylglycerol acyltransferases (MGAT), which function in the final steps of triacylglycerol biosynthesis, are likely to serve an additional role in the esterification of xanthophylls. Representative DGAT polypetides are shown in Table 25. Furthermore, other enzymes may specifically modify carotenoids and molecules of similar structure (e.g. sterols) and be available for modification and ester production. [0083] In some embodiments of the invention, potential source organisms for carotenoid biosynthesis polypeptides include, but are not limited to, genera of naturally oleaginous or non-oleaginous fungi that naturally produce carotenoids. These include, but are not limited to, Botrytis, Cercospora, Fusaήum (Gibberella), Mucor, Neurospora, Phycomyces, Puccina, Rhodotorula, Sclerotinm, Trichoderma, and Xanthophyllomyces. Exemplary species include, but are not limited to, Neurospora crassa, Xanthophyllomyces dendrorhous (Phaffla rhodozyma), Mucor circinelloides, and Rhodotorula glutinis. Of course, carotenoids are produced by a wide range of diverse organisms such as plants, algae, yeast, fungi, bacteria, cyanobacteria, etc. Any such organisms may be source organisms for carotenoid biosynthesis polypeptides according to the present invention. [0084] It will be appreciated that the particular carotenogenic modification to be applied to a host cell in accordance with the present invention will be influenced by which carotenoid(s) is desired to be produced. For example, isoprenoid biosynthesis polypeptides are relevant to the production of most carotenoids. Carotenoid biosynthesis polypeptides are also broadly relevant. Ketolase is particularly relevant for production of canthaxanthin, as hydroxylase is for production of lutein and zeaxanthin, among others. Both hydroxylase and ketolase (or astaxanthin synthase) are particularly useful for production of astaxanthin. Production and Isolation of Carotenoids
[0085] As discussed above, accumulation of lipid bodies in oleaginous organisms is generally induced by growing the relevant organism in the presence of excess carbon source and limiting nitrogen. Specific conditions for inducing such accumulation have previously been established for a number of different oleaginous organisms (see, for example, Wolf (ed.) Nonconventional yeasts in biotechnology Vol. 1, Springer- Verlag, Berlin, Germany, pp. 313- 338; Lipids 18(9):623, 1983; Indian J. Exp. Biol. 35(3):313, 1997; J. Ind. Microbiol. Biotechnol. 30(l):75, 2003; Bioresour Technol. 95(3):287, 2004, each of which is incorporated herein by reference in its entirety).
[0086] In general, it will be desirable to cultivate inventive modified host cells under conditions that allow accumulation of at least about 20% of their dry cell weight as lipid. In other embodiments, the inventive modified host cells are grown under conditions that permit accumulation of at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or even 80% or more of their dry cell weight as lipid. In certain embodiments, the host cells utilized are cells which are naturally oleaginous, and induced to produce lipid to the desired levels. In other embodiments, the host cells are cells which naturally produce lipid, but have been engineered to increase production of lipid such that desired levels of lipid production and accumulation are achieved. [0087] In certain embodiments, the host cells of the invention are not naturally oleaginous, but have been engineered to produce lipid such that desired levels of lipid production are obtained. Those of ordinary skill in the art will appreciate that, in general, growth conditions that are effective for inducing lipid accumulation in a source organism, may well also be useful for inducing lipid accumulation in a host cell into which the source organism's oleaginic polypeptides have been introduced. Of course, modifications may be required in light of characteristics of the host cell, which modifications are within the skill of those of ordinary skill in the art.
[0088] It will also be appreciated by those of ordinary skill in the art that it will generally be desirable to ensure that production of the desired carotenoid by the inventive modified host cell occurs at an appropriate time in relation to the induction of oleaginy such that the carotenoid(s) accumulate(s) in the lipid bodies. In some embodiments, it will be desirable to induce production of the carotenoid(s) in a host cell which does not naturally produce the carotenoid(s), such that detectable levels of the carotenoid(s) is/are produced. In certain aspects the host cells which do not naturally produce a certain carotenoid(s) are capable of production of other carotenoid(s) (e.g. certain host cells may, for example, naturally produce β-carotene but may not naturally produce astaxanthin); in other aspects the host cells do not naturally produce any carotenoid(s). In other embodiments, it will be desirable to increase production levels of carotenoid(s) in a host cell which does naturally produce low levels of the carotenoid(s), such that increased detectable levels of the carotenoid(s) are produced. In certain aspects, the host cells which do naturally produce the carotenoid(s) (e.g., β-carotene) also produce additional carotenoid(s) (e.g., astaxanthin, etc.); in still other aspects, the cells which naturally produce the carotenoid(s) (e.g., β-carotene) do not produce additional carotenoid(s).
[0089] In certain embodiments of the invention, it will be desirable to accumulate carotenoids to levels (i.e., considering the total amount of all produced carotenoids together) that are greater than at least about 1% of the dry weight of the cells. In some embodiments, the total carotenoid accumulation in the lipid bodies will be to a level at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20% or more of the total dry weight of the cells. In certain embodiments of the invention, it will be desirable to achieve total levels of carotenoid accumulation in the lipid bodies (i.e., considering the total amount of all produced carotenoids together) that are greater than at least about 1% of the dry weight of the cells. In some embodiments, the total carotenoid accumulation in the lipid bodies will be to a level at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20% or more of the total dry weight of the cells.
[0090] Bacterial carotenogenic genes have already been demonstrated to be transferrable to other organisms, and are therefore particularly useful in accordance with the present invention (see, for example, Miura et al., Appl. Environ. Microbiol. 64:1226, 1998). In other embodiments, it may be desirable to utilize genes from other source organisms such as plant, alga, or microalgae; these organisms provide a variety of potential sources for ketolase and hydroxylase polypeptides. Still additional useful source organisms include fungal, yeast, insect, protozoal, and mammalian sources of polypeptides. [0091] In certain embodiments, the Mucor circinelloides multi-functional phytoene synthase/lycopene cyclase and the Neurospora crassa phytoene dehydrogenase genes can be expressed in Yarrowia lipolytica. Subsequent overexpression of the catalytic domain from N. crassa hydroxymethylglutaryl-CoA reductase and/or treatment of the modified Y. lipolytica strains with the squalene synthase inhibitor zaragozic acid further increases carotenoid production. Finally, Paracoccus marcusii genes encoding carotenoid hydroxylase and carotenoid ketolase enzymes are expressed in Y. lipolytica β-carotene-producing strains, and this modification results in the accumulation of astaxanthin. Similar approaches to enhance carotenoid production could be employed in other oleaginous or non-oleaginous host organisms can be undertaken, using the same, homologous, or functionally similar carotogenic polypeptides.
[0092] It should be noted that, for inventive organisms that produce more than one carotenoid, it will sometimes be possible to adjust the relative amounts of individual carotenoids produced by adjusting growth conditions. For example, it has been reported that controlling the concentration of dissolved oxygen in a culture during cultivation can regulate relative production levels of certain carotenoids such as β-carotene, echinenone, β- cryptoxanthin, 3-hydroxyechinenone, asteroidenone, canthaxanthin, zeaxanthin, adonirubin, adonixanthin and astaxanthin (see, for example, United States Patent Number 6,825,002 to Tsubokura et al., the entire contents of which are incorporated herein by reference). [0093] Particularly for embodiments of the present invention directed toward production of astaxanthin, it will often be desirable to utilize one or more genes from a natural astaxanthin-producing organism. Where multiple heterologous polypeptides are to be expressed, it may be desirable to utilize the same source organism for all, or to utilize closely related source organisms. [0094] One advantage provided by the present invention is that, in addition to allowing the production of high levels of carotenoids, the present invention allows those produced compounds to be readily isolated because they accumulate in the lipid bodies within oleaginous organisms. Methods and systems for isolating lipid bodies have been established for a wide variety of oleaginous organisms (see, for example, United States Patents 5,164,308; 5,374,657; 5,422,247; 5,550,156; 5,583,019; 6,166,231; 6,541,049; 6,727,373; 6,750,048; and 6,812,001, each of which is incorporated herein by reference in its entirety). In brief, cells are typically recovered from culture, often by spray drying, filtering or centrifugation. In some instances, cells are homogenized and then subjected to supercritical liquid extraction or solvent extraction (e.g., with solvents such as chloroform, hexane, methylene chloride, methanol, isopropanol, ethyl acetate, etc.), yielding a crude oil suspension. This oil suspension may optionally be refined as known in the art. Refined oils may be used directly as feed or food additives. Alternatively or additionally, carotenoids can be isolated from the oil using conventional techniques.
[0095] Given the sensitivity of carotenoids generally to oxidation, many embodiments of the invention employ oxidative stabilizers (e.g., tocopherols, vitamin C; ethoxyquin; vitamin E, BHT, BHA, TBHQ, etc, or combinations thereof) during and/or after carotenoid isolation. Alternatively or additionally, microencapsulation, for example with proteins, may be employed to add a physical barrier to oxidation and/or to improve handling (see, for example, U.S. Patent Application 2004/0191365). Uses
[0096] Carotenoids produced according to the present invention can be utilized in any of a variety of applications, for example exploiting their biological or nutritional properties (e.g., anti-oxidant, anti-proliferative, etc.) and/or their pigment properties. For example, according to the present invention, carotenoids may be used in pharmaceuticals (see, for example, Bertram, Nutr. Rev. 57:182, 1999; Singh et al., Oncology 12:1643, 1998; Rock, Pharmacol. Titer. 75:185, 1997; Edge et al, J. Photochem Photobiol 41 :189, 1997; U.S. Patent Application 2004/0116514; U.S. Patent Application 2004/0259959), food supplements (see, for example, Koyama et al, J. Photochem Photobiol 9:265, 1991 ; Bauernfeind, Carotenoids as colorants and vitamin A precursors, Academic Press, NY, 1981 ; U.S. Patent Application 2004/0115309; U.S. Patent Application 2004/0234579), electro-optic applications, animal feed additives (see, for example, Krinski, Pure Appl. Chem. 66:1003, 1994; Polazza et al., Meth. Enzymol. 213 :403, 1992), cosmetics (as anti-oxidants and/or as cosmetics, including fragrances; see for example U.S. Patent Application 2004/0127554), etc. Carotenoids produced in accordance with the present invention may also be used as intermediates in the production of other compounds (e.g., steroids, etc.). [0097] For example, astaxanthin and/or esters thereof may be useful in a variety of pharmaceutical applications and health foods including treatment of inflammatory diseases, asthma, atopic dermatitis, allergies, multiple myeloma, arteriosclerosis, cardiovascular disease, liver disease, cerebrovascular disease, thrombosis, neoangiogenesis-related diseases, including cancer, rheumatism, diabetic retinopathy; macular degeneration and brain disorder, hyperlipidemia, kidney ischemia, diabetes, hypertension, tumor proliferation and metastasis; and metabolic disorders. Additionally, carotenoids and astaxanthin may be useful in the prevention and treatment of fatigue, for improving kidney function in nephropathy from inflammatory diseases, as well as prevention and treatment of other life habit-related diseases. Still further, astaxanthin has been found to play a role as inhibitors of various biological processes, including interleukin inhibitors, phosphodiesterase inhibitors inhibitors, phospholipase A2 inhibitors, cyclooxygenase-2 inhibitors, matrix metalloproteinase inhibitors, capillary endothelium cell proliferation inhibitors, lipoxygenase inhibitors. See, e.g., Japanese Publication No. 2006022121, published 20060126(JP Appl No. 2005-301156 filed 20051017); Japanese Publication No. 2006016408, published 20060119(JP Appl No. 2005-301155 filed 20051017); Japanese Publication No. 2006016409, published 20060119(JP Appl No. 2005-301157 filed 20051017); Japanese Publication No. 2006016407, published 20060119(JP Appl No. 2005-301153 filed 20051017); Japanese Publication No. 2006008717, published 20060112(JP Appl No. 2005-301151 filed 20051017); Japanese Publication No. 2006008716, published 20060112(JP Appl No. 2005-301150 filed 20051017); Japanese Publication No. 2006008720, published 20060112(JP Appl No. 2005- 301158 filed 20051017); Japanese Publication No. 2006008719, published 20060112(JP Appl No. 2005-301154 filed 20051017); Japanese Publication No. 2006008718, published 20060112(JP Appl No. 2005-301152 filed 20051017); Japanese Publication No. 2006008713, published 20060112(JP Appl No. 2005-301147 filed 20051017); Japanese Publication No. 2006008715, published 20060112(JP Appl No. 2005-301149 filed 20051017); Japanese Publication No. 2006008714, published 20060112(JP Appl No. 2005-301148 filed 20051017); and Japanese Publication No. 2006008712, published 20060112 (JP Appl No. 2005-301146 filed 20051017).
[0098] It will be appreciated that, in some embodiments of the invention, carotenoids produced by manipulated host cells as described herein are incorporated into a final product (e.g., food or feed supplement, pharmaceutical, cosmetic, dye-containing item, etc.) in the context of the host cell. For example, host cells may be lyophilized, freeze dried, frozen or otherwise inactivated, and then whole cells may be incorporated into or used as the final product. The host cell may also be processed prior to incorporation in the product to increase bioavailability (e.g., via lysis). Alternatively or additionally, a final product may incorporate only a portion of the host cell (e.g., fractionated by size, solubility), separated from the whole. For example, in some embodiments of the invention, lipid droplets are isolated from the host cells and are incorporated into or used as the final product. In other embodiments, the carotenoids themselves, or individual carotenoid compounds are isolated and reformulated into the final product.
[0099] As stated above, fatty acid and glucoside esters are the predominant carotenoid esters found in nature, whereas additional esters (e.g. with organic acids or inorganic phosphate) can be synthesized to generate useful product forms. For delivery, carotenoid esters can also be formulated as salts of the ester form (See, e.g., US Patent Publication No. 20050096477). [00100] The amount of carotenoid incorporated into a given product may vary dramatically depending on the product, and the particular carotenoid(s) involved. Amounts may range, for example, from less than 0.01% by weight of the product, to more than 1%, 10%, 20%, 30% or more; in some cases the carotenoid may comprise 100% of the product. [00101] In some embodiments of the invention, one or more produced carotenoids is incorporated into a component of food or feed (e.g., a food supplement). Types of food products into which carotenoids can be incorporated according to the present invention are not particularly limited, and include beverages such as teas, juices, and liquors; confections such as jellies and biscuits; fat-containing foods and beverages such as dairy products; processed food products such as rice and soft rice (or porridge); infant formulas; or the like. In some embodiments of this aspect of the invention, it may be useful to incorporate the carotenoids within bodies of edible lipids as it may facilitate incorporation into certain fat- containing food products.
[00102] Examples of feedstuffs into which carotenoids produced in accordance with the present invention may be incorporated include, for instance, pet foods such as cat foods, dog foods and the like, feeds for aquarium fish, cultured fish or crustaceans, etc., feed for farm-raised animals (including livestock and further including fish or crustaceans raised in aquaculture). Food or feed material into which the carotenoid(s) produced in accordance with the present invention is incorporated is preferably palatable to the organism which is the intended recipient. This food or feed material may have any physical properties currently known for a food material (e.g., solid, liquid, soft).
[00103] In some embodiments of the invention, one or more produced carotenoids is incorporated into a cosmetic product. Examples of such cosmetics include, for instance, skin cosmetics (e.g., lotions, emulsions, creams and the like), lipsticks, anti-sunburn cosmetics, makeup cosmetics, fragrances, products for daily use (e.g., toothpastes, mouthwashes, bad breath preventive agents, solid soaps, liquid soaps, shampoos, conditioners), etc. [00104] In some embodiments, one or more produced carotenoids is incorporated into a pharmaceutical. Examples of such pharmaceuticals include, for instance, various types of tablets, capsules, drinkable agents, troches, gargles, etc. In some embodiments, the pharmaceutical is suitable for topical application. Dosage forms are not particularly limited, and include capsules, oils, granula, granula subtilae, pulveres, tabellae, pilulae, trochisci, or the like. Oils and oil-filled capsules may provide additional advantages both because of their lack of ingredient decomposition during manufacturing, and because inventive carotenoid- containing lipid droplets may be readily incorporated into oil-based formulations. [00105] Pharmaceuticals according to the present invention may be prepared according to techniques established in the art including, for example, the common procedure as described in the United States Pharmacopoeia, for example.
[00106] Carotenoids produced according to the present invention may be incorporated into any pigment-containing product including, for example, fabric, paint, etc. They may also be incorporated into a product which is an environmental indicator, or an instrument such as a biosensor for use as a detection agent.
EXEMPLIFICATION:
[00107] Table 26 below describes certain Yarrowia lipolytica strains used in the following exemplification:
TABLE 26: Yarrowia lipolytica strains.
Figure imgf000031_0001
[00108] (The genotypes at LYCl, LYSl, XPR2, and PEXl 7 were not determined in crosses nor verified for ATCC strains.)
[00109] All basic molecular biology and DNA manipulation procedures described herein are generally performed according to Sambrook et al. or Ausubel et al. (Sambrook J,
Fritsch EF, Maniatis T (eds). 1989. Molecular Cloning: A Laboratory Manual. Cold Spring
Harbor Laboratory Press: New York; Ausubel FM, Brent R, Kingston RE, Moore DD,
Seidman JG, Smith JA, Struhl K (eds). 1998. Current Protocols in Molecular Biology. Wiley:
New York).
Example 1: Production ofylasmids for carotenoid strain construction.
[00110] Plasmids were generated for construction of carotenoid producing strains.
The following subparts describe production of plasmids encoding carotenogenic polypeptides.
Plasmids used in these studies and details of their construction are described in Table 27. Additional plasmid construction details and descriptions of their use are found in the text of the relevant subsection. All PCR amplifications used NRRL Y- 1095 genomic DNA as template unless otherwise specified. The URA 5 gene described below is allelic with the ura2-
21 auxotrophy above. The GPDl and TEFl promoters are from Y. lipolytica as is the XPR2 terminator.
[00111] GGSl is the gene encoding the Y, lipolytica gene encoding geranylgeranylpyrophosphate synthase. The nucleic acid coding sequence, and encoded Ggsl protein of pMB4591 and pMB4683 are as follows:
[00112] atggattataacagcgcggatttcaaggagatatggggcaaggccgccgacaccgcgctgctgggaccgta caactacctcgccaacaaccggggccacaacatcagagaacacttgatcgcagcgttcggagcggttatcaaggtggacaagagcg atctcgagaccatttcgcacatcaccaagattttgcataactcgtcgctgcttgttgatgacgtggaagacaactcgatgctccgacgagg cctgccggcagcccattgtctgtttggagtcccccaaaccatcaactccgccaactacatgtactttgtggctctgcaggaggtgctcaa gctcaagtcttatgatgccgtctccattttcaccgaggaaatgatcaacttgcatagaggtcagggtatggatctctactggagagaaaca ctcacttgcccctcggaagacgagtatctggagatggtggtgcacaagaccggtggactgtttcggctggctctgagacttatgctgtcg gtggcatcgaaacaggaggaccatgaaaagatcaactttgatctcacacaccttaccgacacactgggagtcatttaccagattctggat gattacctcaacctgcagtccacggaattgaccgagaacaagggattctgcgaagatatcagcgaaggaaagttttcgtttccgctgatt cacagcatacgcaccaacccggataaccacgagattctcaacattctcaaacagcgaacaagcgacgcttcactcaaaaagtacgcc gtggactacatgagaacagaaaccaagagtttcgactactgcctcaagaggatacaggccatgtcactcaaggcaagttcgtacattga tgatctagcagcagctggccacgatgtctccaagctacgagccattttgcattattttgtgtccacctctgactgtgaggagagaaagtact ttgaggatgcgcagtga
[00113] mdynsadfkeiwgkaadtallgpynylanm-ghnirehliaafgavikvdksdletishitkilhnssllvdd vednsmlrrglpaahclfgvpqtinsanymyfvalqevlklksydavsifteeminlhrgqgmdlywretltcpsedeylemvv hktgglfrlalrlmlsvaskqedhekinfdlthltdtlgviyqilddylnlqsteltenkgfcedisegkfsfplihsirtnpdnheilnilk qrtsdaslkkyavdymrtetksfdyclkriqamslkassyiddlaaaghdvsklrailhyfvstsdceerkyfedaq
TABLE 27: Plasmids
Figure imgf000032_0001
Figure imgf000033_0001
[00114] Certain oligonucleotides referred to in Table 27 above are as follows:
MO4471 5'-CTGGGTGACCTGGAAGCCTT
MO4472 5'-AAGATCAATCCGTAGAAGTTCAG
MO4475 S'-AAGCGATTACAATCTTCCTTTGG
MO4476 5'-CCAGTCCATCAACTCAGTCTCA
MO4477 5'-GCATTGCTTATTACGAAGACTAC
MO4478 5'-CCACTGTCCTCCACTACAAACAC
MO4534 5'-CACAAACGCGTTCACTGCGCATCCTCAAAGT
MO4544 5'-CACAATCTAGACACAAATGGATTATAACAGCGCGGAT
MO4566 5'-CACAAACTAGTTTGCCACCTACAAGCCAGAT
MO4568 5'- CACAAGGTACCAATGTGAAAGTGCGCGTGAT MO4571 5'-CACAAGGTACCAGAGACCGGGTTGGCGG
MO4591 5'- CACAAGCGGCCGCGCTAGCATGGGGATCGATCTCTTATAT
MO4592 S'-CACAAGCGGCCGCGCTAGCGAATGATTCTTATACTCAGAAG
MO4593 5'-CACAAGCGGCCGCACGCGTGCAATTAACAGATAGTTTGCC
MO4659 5'- CACAAGCTAGCTGGGGATGCGATCTCTTATATC
[00115] IA: Production of pMB4628 Uefly-carRP LEW) encoding phvtoene synthase/lycopene cyclase: Intron-containing carRP was amplified from M. circinelloides
(ATCC 90680) genomic DNA using MO4525 and MO4541 :
MO4525 5'-CACAAACGCGTTTAAATGGTATTTAGATTTCTCATT
MO4541 5'-CACAATCTAGACACAAATGCTGCTCACCTACATGGA and the resulting 1.9 kb fragment was phosphorylated with T4 polynucleotide kinase. The resulting fragment was blunt-end ligated into pBluescriptSKII- cleaved with EcoRV, yielding pMB4599. The 1.9 kb Xbal-Mlul fragment from pMB4599 was inserted into Nhel- and Mwl-cleaved pMB4603, yielding pMB4628. The intron containing nucleic acid coding sequence, and encoded CarRP protein of pMB4628 are as follows:
[00116] atgctgctcacctacatggaagtccacctctactacacgctgcctgtgctgggcgtcctgtcctggctgtcgcg gccgtactacacagccaccgatgcgctcaaattcaaatttctgacactggttgccttcacgaccgcctccgcctgggacaactacattgt ctaccacaaggcgtggtcctactgccccacctgcgtcaccgctgtcattggctacgtgcccttggaggagtacatgttcttcatcatcatg actctgttgaccgtggcattcaccaatctggtgatgcgctggcacctgcacagcttctttatcaggcctgaaacgcccgtcatgcagtcc gtcctggtccgtcttgtccccataacagccttattaatcactgcatacaaggcttgggtaagcaaacaaacaaatgatgtgccgcatcgca ttttaatattaaccattgcatacacagcatttggcggtccctggaaagccactgttctacggatcatgcattttgtggtacgcctgtccggttt tggccttattgtggtttggtgctggcgagtacatgatgcgtcgtccgctggcggtgctcgtctccattgcgctgcccacgctgtttctctgct gggtcgatgtcgtcgctattggcgccggcacatgggacatttcgctggccacaagcaccggcaagttcgtcgtgccccacctgcccgt ggaggaattcatgttctttgcgctaattaataccgttttggtatttggtacgtgtgcgatcgatcgcacgatggcgatcctccacctgttcaa aaacaagagtccttatcagcgcccataccagcacagcaagtcgttcctccaccagatcctcgagatgacctgggccttctgtttacccga ccaagtgctgcattcagacacattccacgacctgtccgtcagctgggacatcctgcgcaaggcctccaagtccttttacacggcctctgc tgtctttcccggcgacgtgcgccaagagctcggtgtgctatacgccttttgcagagccacggacgatctctgcgacaacgagcaggtc cctgtgcagacgcgaaaggagcagctgatactgacacatcagttcgtcagcgatctgtttggccaaaagacaagcgcgccgactgcc attgactgggacttttacaacgaccaactgcctgcctcgtgcatctctgccttcaagtcgttcacccgtttgcgccatgtgctggaagctgg agccatcaaggaactgctcgacgggtacaagtgggatttggagcgtcgctccatcagggatcaggaggatctcagatattactcagctt gtgtcgccagcagtgttggtgaaatgtgcactcgcatcatactggcccacgccgacaagcccgcctcccgccagcaaacacagtgga tcattcagcgtgcgcgtgaaatgggtctggtactccaatatacaaacattgcaagagacattgtcaccgacagcgaggaactgggcag atgctacctgcctcaggattggcttaccgagaaggaggtggcgctgattcaaggcggccttgcccgagaaattggcgaggagcgatt gctctcactgtcgcatcgcctcatctaccaggcagacgagctcatggtggttgccaacaagggcatcgacaagctgcccagccattgtc aaggcggcgtgcgtgcggcctgcaacgtctatgcttccattggcaccaagctcaagtcttacaagcaccactatcccagcagagcaca tgtcggcaattcgaaacgagtggaaattgctcttcttagcgtatacaacctttacaccgcgccaattgcgactagtagtaccacacattgc agacagggaaaaatgagaaatctaaataccatttaa
[00117] mlliymevhlyytlpvlgvlswlsrpyytatdalkfkfltlvafttasawdnyivyhkawsycptcvtavig yvpleeymffiimtUiΛ'aftalvmrwhlhsffirpetpvmqsvlvrlvpitallitaykawhlavpgkplfygscilwyacpvlall wfgageymmixplavlvsialptlflcwvdvvaigagtwdislatstgkfvvphlpveefmffalintvlvfgtcaidrtmailhlfk nkspyqrpyqhsksflhqilemtwafclpdqvlhsdtfhdlsvswdilrkasksfytasavfpgdvrqelgvlyafcratddlcdne qvpvqtrkeqlilthqfvsdlfgqktsaptaidwdfyndqlpascisafksftrlrhvleagaikelldgykwdlerrsirdqedlryys acvassvgemctriilahadkpasrqqtqwiiqraremglvlqytniardivtdseelgrcylpqdwltekevaliqgglareigeerl lslshrliyqadelmvvankgidklpshcqggvraacnvyasigtklksykhhypsrahvgnskrveiallsvynlytapiatsstth crqgkmrnlnti
[00118] Alternatively, pMB4599 was also used as a template for PCR amplification using MO4318, MO4643, MO4644, and MO4639 and
MO4318 5'-GTAAAACGACGGCCAGT
MO4643 5 '-CACACGGTCTCATGCCAAGCCTTGTATGCAGTGATTAA
MO4639 5'-CCACTGTGTTTGCTGGCGG
MO4644 5'- CACACGGTCTCTGGCATTTGGCGGTCCCTGGAAA producing fragments of 0.5 and 0.95 kb, that were subsequently cleaved with Acc65l and
Bsal, and Bsal and PpwMI, respectively. These fragments were ligated to pMB4599 that had been digested withv4cc65I and PpuMl, yielding pMB4613, harboring intronless carRP. The
1.85 kb Xbal-Mlul fragment from pMB4613 can be inserted into Nhel- and MM-cleaved pMB4603 to yield pCarRPdell.
[00119] IB: Production of pMB4638 (teflp-carB ADEl), encoding phvtoene dehydrogenase: Intron-containing carB was amplified from M, circinelloides (ATCC 90680) genomic DNA using MO4530 and MO4542:
MO4530 5'-CACAAACGCGTTTAAATGACATTAGAGTTATGAAC
MO4542 5'-CACAATCTAGACACAAATGTCCAAGAAACACATTGTC and the resulting 1.9 kb fragment was phosphorylated with T4 polynucleotide kinase and blunt-end ligated into pBS-SKII- cleaved with EcoKV, yielding pMB4606. pMB4606 was then used as a template for PCR amplification using MO4318 and MO4648, and MO4646 and
MO4647, and MO4343 and MO4645:
MO4318 5 '-GTAAAACGACGGCCAGT
MO4648 5'-CACAAGGTCTCAAGCACGCATCCCGGAACTG
MO4646 5 '-CACACGGTCTCAGGCATGTCGCCCTACGATGC
MO4647 5'-CACACGGTCTCATGCTTGCACCCACAAAGAATAGG
MO4343 5'-CAGGAAACAGCTATGAC
MO4645 5 ' -CACACGGTCTCTTGCCCATATACATGGTCTGAAACG producing fragments of 0.4 and 0.85 and 0.7 kb, that were subsequently cleaved with Λcc65I and Bsάl, and Bsal, and Bsal and BamRl, respectively. These fragments were ligated to pBS-
SKII- that had been cut with Acc651 and BamRl, yielding pMB4619, harboring intronless carB. The 1.75 kb Xbal-Mlul fragment from pMB4619 was inserted into NAeI- and MMI- cleaved pMB4629, yielding pMB4638. The resulting nucleic acid coding sequence and encoded CarB protein of pMB4638 are as follows:
[00120] atgtccaagaaacacattgtcattatcggtgctggcgtgggtggcacggctacagctgctcgtttggcccgcga aggcttcaaggtcactgtggtggagaaaaacgactttggtggcggccgctgctccttgatccatcaccagggccatcgctttgatcagg gcccgtcgctctacctgatgcccaagtactttgaggacgcctttgccgatctggacgagcgcattcaagaccacctggagctgctgcga tgcgacaacaactacaaggtgcactttgacgacggtgagtcgatccagctgtcgtctgacttgacacgcatgaaggctgaattggaccg cgtggagggcccccttggttttggccgattcctggatttcatgaaagagacacacatccactacgaaagcggcaccctgattgcgctca agaagaatttcgaatccatctgggacctgattcgcatcaagtacgctccagagatctttcgcttgcacctgtttggcaagatctacgaccg cgcttccaagtacttcaagaccaagaagatgcgcatggcattcacgtttcagaccatgtatatgggcatgtcgccctacgatgcgcctgc tgtctacagcctgttgcagtacaccgagttcgctgaaggcatctggtatccccgtggcggcttcaacatggtggttcagaagctagagg cgattgcaaagcaaaagtacgatgccgagtttatctacaatgcgcctgttgccaagattaacaccgatgatgccaccaaacaagtgaca ggtgtaaccttggaaaatggccacatcatcgatgccgatgcggttgtgtgtaacgcagatctggtctatgcttatcacaatctgttgcctcc ctgccgatggacgcaaaacacactggcttccaagaaattgacgtcttcttccatttccttctactggtccatgtccaccaaggtgcctcaat tggacgtgcacaacatctttttggccgaggcttatcaggagagctttgacgaaatcttcaaggactttggcctgccttctgaagcctccttc tacgtcaatgtgccctctcgcatcgatccttctgctgctcccgacggcaaggactctgtcattgtcttggtgcctattggtcatatgaagag caagacgggcgatgcttccaccgagaactacccggccatggtggacaaggcacgcaagatggtgctggctgtgattgagcgtcgtct gggcatgtcgaatttcgccgacttgattgagcatgagcaagtcaatgatcccgctgtatggcagagcaagttcaatctgtggagaggct caattctgggtttgtctcatgatgtgcttcaggtgctgtggttccgtcccagcacaaaggattctaccggtcgttatgataacctattctttgt gggtgcaagcacgcatcccggaactggtgttcccattgtccttgcaggaagcaagctcacctctgaccaagttgtcaagagctttggaa agacgcccaagccaagaaagatcgagatggagaacacgcaagcacctttggaggagcctgatgctgaatcgacattccctgtgtggt tctggttgcgcgctgccttttgggtcatgtttatgttcttttacttcttccctcaatccaatggccaaacgcccgcatcttttatcaataatttgtta cctgaagtattccgcgttcataactctaatgtcatttaa
[00121] mskkhiviigagvggtataarlaregfkvtvvekndfgggrcslihhqghrfdqgpslylmpkyfedafad lderiqdhlellrcdnnykvhfddgesiqlssdltrmkaeldrvegplgfgrfidfmkethihyesgtlialkknfesiwdlirikyap eifrlhlfgkiydrasJcyflctkkrniTiiaftfqtmymgmspydapavysllqytefaegiwyprggfnmvvqkleaiakqkydae fϊynapvakintddatkqvtgvtlenghiidadawcnadlvyayhnllppcrwtqntlaskkltsssisfywsmstkvpqldvhni flaeayqesfdeifkdfglpseasfyvnvpsridpsaapdgkdsvivlvpighmksktgdastenypamvdkarkmvlavierrl gmsnfadlieheqvndpavwqskfnlwrgsilglshdvlqvlwfrpstkdstgrydnlffvgasthpgtgvpivlagskltsdqvv ksfglctpkprkiementqapleepdaestφvwfwlraafwvmfmffyffpqsngqtpasfinnllpevfrvhnsnvi
[00122] 1C. Production of pMB4660 (tefly-carB URA3) encoding encoding phytoene dehydrogenase: The 4.3 kb Xhol-Notl fragment and the 1.8 kb Notl-Spel fragment from pMB4638 were ligated to the 1.9 kb Bsal- and iSζpel-cleaved URA3 gene generated by PCR amplification of 7. lipolytica genomic DNA using MO4684 and MO4685 to create pMB4660:
MO4684 5'-CATTCACTAGTGGTGTGTTCTGTGGAGCATTC
MO4685 5'-CACACGGTCTCATCGAGGTGTAGTGGTAGTGCAGTG
The resulting nucleic acid coding sequence and encoded CarB(i) protein of pMB4660 are as follows:
[00123] atgtccaagaaacacattgtcattatcggtgctggcgtgggtggcacggctacagctgctcgtttggcccgcga aggcttcaaggtcactgtggtggagaaaaacgactttggtggcggccgctgctccttgatccatcaccagggccatcgctttgatcagg gcccgtcgctctacctgatgcccaagtactttgaggacgcctttgccgatctggacgagcgcattcaagaccacctggagctgctgcga tgcgacaacaactacaaggtgcactttgacgacggtgagtcgatccagctgtcgtctgacttgacacgcatgaaggctgaattggaccg cgtggagggcccccttggttttggccgattcctggatttcatgaaagagacacacatccactacgaaagcggcaccctgattgcgctca agaagaatttcgaatccatctgggacctgattcgcatcaagtacgctccagagatctttcgcttgcacctgtttggcaagatctacgaccg cgcttccaagtacttcaagaccaagaagatgcgcatggcattcacgtttcagaccatgtatatgggcatgtcgccctacgatgcgcctgc tgtctacagcctgttgcagtacaccgagttcgctgaaggcatctggtatccccgtggcggcttcaacatggtggttcagaagctagagg cgattgcaaagcaaaagtacgatgccgagtttatctacaatgcgcctgttgccaagattaacaccgatgatgccaccaaacaagtgaca ggtgtaaccttggaaaatggccacatcatcgatgccgatgcggttgtgtgtaacgcagatctggtctatgcttatcacaatctgttgcctcc ctgccgatggacgcaaaacacactggcttccaagaaattgacgtcttcttccatttccttctactggtccatgtccaccaaggtgcctcaat tggacgtgcacaacatctttttggccgaggcttatcaggagagctttgacgaaatcttcaaggactttggcctgccttctgaagcctccttc tacgtcaatgtgccctctcgcatcgatccttctgctgctcccgacggcaaggactctgtcattgtcttggtgcctattggtcatatgaagag caagacgggcgatgcttccaccgagaactacccggccatggtggacaaggcacgcaagatggtgctggctgtgattgagcgtcgtct gggcatgtcgaatttcgccgacttgattgagcatgagcaagtcaatgatcccgctgtatggcagagcaagttcaatctgtggagaggct caattctgggtttgtctcatgatgtgcttcaggtgctgtggttccgtcccagcacaaaggattctaccggtcgttatgataacctattctttgt gggtgcaagcacgcatcccggaactggtgttcccattgtccttgcaggaagcaagctcacctctgaccaagttgtcaagagctttggaa agacgcccaagccaagaaagatcgagatggagaacacgcaagcacctttggaggagcctgatgctgaatcgacattccctgtgtggt tctggttgcgcgctgcctfttgggtcatgtttatgttcttttacttcttccctcaatccaatggccaaacgcccgcatcttttatcaataatttgtta cctgaagtattccgcgttcataactctaatgtcatttaa
[00124] mskkhiviigagvggtataarlaregfkvtvvekndfgggrcslihhqghrfdqgpslylmpkyfedafad
Ideriqdhlellrcdnnykvhfddgesiqlssdltrmkaeldrvegplgfgrfldfmkethihyesgtlialkknfesiwdlirikyap eifrlhlfgkiydraskyfktJdrniirnaftfqtaymgmspydapavysllqytefaegiwyprggfnmvvqkleaiakqkydae fiynapvakintddatkqvtgvtlenghiidadavvcnadlvyayhnllppcrwtqntlaskkltsssisfywsmstkvpqldvhni flaeayqesfdeifkdfglpseasfyvnvpsridpsaapdgkdsvivlvpighmksktgdastenypamvdkarkmvlavierrl gmsnfadlieheqvndpavwqskfnlwrgsilglshdvlqvlwfipstkdstgrydnlffvgasthpgtgvpivlagskltsdqvv ksfgktpkprkiementqapleepdaestfpvwfwlraafwvmfrnffyffpqsngqtpasfinnllpevfrvhnsnvi
[00125] ID. Production of pMB4637 and pTef-HMG encoding a truncated HMGl .
For production of a truncated variant of the HMG-CoA reductase gene, which also encodes a 77 amino acid leader sequence derived from S. cerevisiae, the following oligonucleotides are synthesized:
PRIMER O 5'-TTCTAGACACAAAAATGGCTGCAGACCAATTGGTGA
PRIMER P 5'-CATTAATTCTTCTAAAGGACGTATTTTCTTATC
PRIMER Q 5'-GTTCTCTGGACGACCTAGAGG
MO4658 5'-CACACACGCGTACACCTATGACCGTATGCAAAT
Primers O and P are used to amplify a 0.23 kb fragment encoding Met- Ala followed by residues 530 to 604 of the Hmgl protein of S. cerevisiae, using genomic DNA as template.
Primers Q and MO4658 are used to amplify a 1.4 kb fragment encoding the C-terminal 448 residues of the Hmgl protein of Y. lipolytica, using genomic DNA as template. These fragments are ligated to the appropriate cloning vector, and the resultant plasmids, designated pOP and pQMO4658, are verified by sequencing. The OP fragment is liberated with-Y&αl and Asel, and the QMO4658 fragment is liberated with Mael and MuI. These fragments are then ligated to the ADEl TEFIp expression vector pMB4629 cut with Xbal and MMI to produce pTefHMG.
[00126] Alternatively, the native HMGl gene from Y. lipolytica may be modified without S. cerevisiae sequences as described in the table above using primers MO4658
(described above) and MO4657, to create pMB4637:
MO4657 5 '-CACACTCTAGACACAAAAATGACCCAGTCTGTGAAGGTGG
The resulting nucleic acid coding sequence and encoded Hmgl mn<: protein of pMB4637 are as follows:
[00127] atgacccagtctgtgaaggtggttgagaagcacgttcctatcgtcattgagaagcccagcgagaaggaggag gacacctcttctgaagactccattgagctgactgtcggaaagcagcccaagcccgtgaccgagacccgttctctggacgacctagagg ctatcatgaaggcaggtaagaccaagcttctggaggaccacgaggttgtcaagctctctctcgagggcaagcttcctttgtatgctcttga gaagcagcttggtgacaacacccgagctgttggcatccgacgatctatcatctcccagcagtctaataccaagactttagagacctcaa agcttccttacctgcactacgactacgaccgtgtttttggagcctgttgcgagaacgttattggttacatgcctctccccgttggtgttgctg gccccatgaacattgatggcaagaactaccacattcctatggccaccactgagggttgtcttgttgcctcaaccatgcgaggttgcaagg ccatcaacgccggtggcggtgttaccactgtgcttactcaggacggtatgacacgaggtccttgtgtttccttcccctctctcaagcgggc tggagccgctaagatctggcttgattccgaggagggtctcaagtccatgcgaaaggccttcaactccacctctcgatttgctcgtctcca gtctcttcactctacccttgctggtaacctgctgtttattcgattccgaaccaccactggtgatgccatgggcatgaacatgatctccaagg gcgtcgaacactctctggccgtcatggtcaaggagtacggcttccctgatatggacattgtgtctgtctcgggtaactactgcactgacaa gaagcccgcagcgatcaactggatcgaaggccgaggcaagagtgttgttgccgaagccaccatccctgctcacattgtcaagtctgtt ctcaaaagtgaggttgacgctcttgttgagctcaacatcagcaagaatctgatcggtagtgccatggctggctctgtgggaggtttcaatg cacacgccgcaaacctggtgaccgccatctaccttgccactggccaggatcctgctcagaatgtcgagtcttccaactgcatcacgctg atgagcaacgtcgacggtaacctgctcatctccgtttccatgccttctatcgaggtcggtaccattggtggaggtactattttggagcccc agggggctatgctggagatgcttggcgtgcgaggtcctcacatcgagacccccggtgccaacgcccaacagcttgctcgcatcattgc ttctggagttcttgcagcggagctttcgctgtgttctgctcttgctgccggccatcttgtgcaaagtcatatgacccacaaccggtcccagg ctcctactccggccaagcagtctcaggccgatctgcagcgtctacaaaacggttcgaatatttgcatacggtcatag
[00128] mtqsvkvvekhvpiviekpsekeedtssedsieltvgkqpkpvtetrslddleaimkaglctklledhevvk lslegklplyalekqlgdntravgirrsiisqqsntktletsklpylhydydrvfgaccenvigymplpvgvagpmnidgknyhip mattegclvastmrgckainagggvttvltqdgmtrgpcvsfpslkragaakiwldseeglksmrkafiistsrfarlqslhstlagnl lfirfrtttgdamgmnmiskgvehslavmvkeygfpdmdivsvsgnyctdkkpaainwiegrgksvvaeatipahivksvlks evdalvelnisknligsamagsvggmahaanlvtaiylatgqdpaqnvessncitlmsnvdgnllisvsmpsievgtigggtilep qgamlemlgvrgphietpganaqqlariiasgvlaaelslcsalaaghlvqshmthnrsqaptpakqsqadlqrlqngsnicirs
[00129] IE. Production of pMB4692 (URA3 tefly-crtZ) encoding carotene hydroxylase. The following carotene hydroxylase (CrtZ) ORP sequence was synthesized; based on protein sequence of ' Novosphmgobium aromaticivorans, using Y. lipolytica codon bias:
5J- tMagacacaaaaatgggtggagccatgcagaccctcgctgctatcctgatcgtcctcggtacagtgctegctatggagtttgtc gcttggtcttctcataagtatatcatgcatggcttcggatggggatggcatagagaccatcacgagccccatgagggatttcttg agaagaatgacttatacgccatcgttggcgctgccctctcgatactcatgtttgccctcggctctcccatgatcatgggcgctgac gcctggtggcccggaacctggatcggactcggtgtcctcttctatggtgtcatctataccctcgtgcacgacggtctggtgcacc aacgatggtttagatgggtgcctaaacgaggttacgccaaacgactcgtgcaggcccataagctgcaccacgccaccattggc aaggaaggaggcgtctcattcggtttcgtgttcgcccgagatcccgccgttctgaagcaggagcttcgagctcaacgagaagc aggtatcgccgtgctgcgagaggctgtggaeggctagacgcgt
This sequence was cleaved using Xbal and Mlu\ and ligated, along with an Acc65l-Nhel
TEFl promoter fragment from pMB4629, to pMB4662 cut with Acc65\ and MMI to produce pMB4692, The nucleic acid coding sequence is depicted in bold underline above. The resulting encoded crtZ protein of pMB4692 is as follows:
[00130] mggamqtlaailivlgtvlamefvawsshkyimhgfgwgwhrdhhephegflekndlyaivgaalsil mfalgspmimgadawwpgtwiglgvlfygviytlvhdglvhqrwfrwvpkrgyakrlvqahklhhatigkeggvsfgfvfar dpavlkqelraqreagiavlreavdg
[00131] IF. Production of pMB4698 (ADEl teflp-crtW), encoding carotene ketolase.
The following carotene ketolase (CrtW) ORP sequence was synthesized, based on protein sequence of an environmental sequence isolated from the Sargasso Sea (Genbank accession
AACY01034193.1):
5'- ttctagacacaaaaatgactcgatctatttcctggccttccacctactggcacctccagccctcctgttcttcttgggtcgcaaacga attctctcctcaagcccgaaaaggtctcgtcctcgctggtctcattggttccgcttggctgcttactctcggacttggcttttcccttc ccctccatcaaacgagctggcttctcatcggttgtctcgttctccttagatctttcctgcacaccggactttttatcgttgcccatga cgctatgcacgcttctcttgttcctgaccaccctggccttaaccgttggattggacgtgtctgtcttctcatgtatgctggactctcct acaaaagatgctgccgaaatcaccgtcgacaccaccaagcccctgaaacagttgaagaccctgactaccaacgatgcactaa caacaatatcctcgactggtacgttcactttatgggaaattacctcggatggcaacaattgcttaatctctcttgcgtttggctcgc tctcaccttccgtgtttctgactactctgctcaattcttccacctgctccttttctctgtccttcctctcatcgtctcctcctgtcaactct tcctcgtgggaacctggctgccacaccgacgaggcgctactactcgacccggcgttaccactcgatccctgaacttccaccctg ctctttccttcgctgcttgctaccacttcggttaccaccgtgaacaccatgaatctccctctactccttggttccaacttcctaaactc cgagaaggttctctcatctaaacgcgt
This sequence was cleaved using Xbal and Mlul and ligated to pMB4629 cut with Nhel and Mlul to produce pMB4698. The nucleic acid coding sequence is depicted in bold underline above. The resulting encoded crtW protein of pMB4698 is as follows: [00132] mtrsiswpstywhlqpscsswvanefspqarkglvlagligsawlltlglgfslplhqtswlligclvllrsflh tglfivahdamhaslvpdhpglrmvigrvcllmyaglsykrccmhn'hhqapetvedpdyqrctnnnildwyvhfmgnylgw qqllnlscvwlaltfrvsdysaqffhlllfsvlplivsscqlflvgtwlphrrgattrpgvttrslnfhpalsfaacyhfgyhrehhespst pwfqlpklregsli
Example 2: Engineering Yarrowia lipolytica for increased carotenoid production. [00133] 2A. Production of Y. lipolytica expressing geranylgeranylpyrophosphate synthase and phytoene dehydrogenase: MF350 (MATB ura2-21 leu2-35 adel) was transformed with pMB4591 (teflp-GGSl) that had been cleaved upstream of URA5 with Sspϊ; a Ura+ transformant carrying the plasmid at the ura2 locus was identified and named MF364. It was subsequently transformed with pMB4638 (teflp-carB) that had been cleaved at ADEl with Sspl and a prototrophic transformant was chosen that harbored the plasmid at the αdel locus. This strain was named MF502.
[00134] 2B. Production of Y. lipolyticα expressing geranylgeranylpyrophosphate synthase, phytoene dehydrogenase and phytoene synthase/lvcopene cyclase MF502 was transformed with pMB4628 (teflp-cαrRP) that had been treated with Sspl. Nine prototrophic colonies were chosen that were uncolored, orange, or very orange on the transformation plate (YNB agar with 1% glucose and 0.1% glutamate [YNBglut]) after two to three days of growth. Two, MF597 and MF600 (the very orange ones), produced greater than 4 mg carotene per g dry cell weight (DCW) after four days of growth in YPD at 3O0C. Southern analysis reveals a different single Kpril-Hindlll band in genomic DNA from MF597 and MF600, neither of which suggested that homologous integration occurred at leu2-270. [00135] 2C. Production of Y. lipolyticα expressing phytoene synthase/lvcopene cyclase and phytoene dehydrogenase: ATCC201249 (MATA urα3~302 leu2-270 lys8-ll) was transformed with Sspl-cleaved pMB4628. Hundreds of Leu+ colonies were pooled, re- grown, and transformed with pMB4660 (teflp-cαrB) that had been cleaved upstream of URA3 with SaR. One colony that was noticeably yellow after 5 days at 300C on YNBglut plus 0.6 mM lysine was selected, named MF447, and found to produce 0.2 mg carotene per gram dry cell weight after 4 days of growth in YPD.
[00136] MF447 was challenged with 1 g/L 5-fluoroorotic acid and Ura" segregants selected. Surprisingly, they were all found to retain the identical yellow appearance of their parent, implying that the loss of a functional URA3 gene did not coincide with the loss of a functional CarB enzyme. Southern analysis demonstrates that two fragments from a Kpnl- HindIII digest of MF447 DNA contain t/iL43p-hybridizing sequences, only one of which also hybridizes to carB. The other is absent in MF578, the Ura3" segregant chosen for further manipulation. Plasmid rescue and analysis of the DNA sequence encompassing the carRP intron in strains MF447, MF597 (example 2c), and MF600 (example 2c) revealed that exons 1 and 2 were contiguous and were each separated by an intron sequence that lacked the original internal Sspl site (present in pMB4628).
[00137] 2D. Production of Y. lipolytica expressing phytoene synthase/lycopene cyclase, phytoene dehydrogenase and geranylgeranylpyrophosphate synthase: MF578 was transformed with pMB4683 (teflp-GGSl) that had been cleaved with SaH (upstream of URA3) or with Stul (within the GGSl ORF). Ura+ Leu+ colonies in both cases appeared bright orange on YNBglut+Lys and on YPD, and several produced greater than 4 mg carotene per gram of dry cell weight when grown as above. One, MF633, contained a single copy of the plasmid at the GGSl locus, as inferred from Southern analysis. The others arose by nonhomologous or more complex integrations.
[00138] 2E. Production of Y. lipolytica expressing phytoene synthase/lycopene cyclase, phytoene dehydrogenase and geranylgeranylpyrophosphate synthase: MF364 is crossed with MF578, and spores from the resulting diploid are plated on YPD for two to three days at 3O0C. Orange Leu+ Ade" Ura" colonies are screened for the presence of tefp-carB, tefp-carRP, and tefp-GGSl by PCR, and for high carotenoid (>4 mg/g dry cell weight) production after growth in YPD liquid medium. Colonies meeting these criteria, as well as displaying resistance to 5-fluorootic acid, an indication that they harbor the ura3-302 allele, are chosen for further studies and hereafter referred to as GBRPua strains. Such a strain is selected for further analysis and modification. Example 3: Extraction of carotenoids from Yarrowia liyolytica cells [00139] Shake-flask testing of generated strains was conducted using YPD medium
(1% yeast extract, 2% peptone, 2% glucose). 20 ml cultures in 125 ml flasks were grown at 300C. Y, lipolytica cells were harvested from 72-96 hour cultures, and extractions were performed to determine carotenoid form and quantity. 1.8 ml of culture was placed into an Eppendorf tube. Cells were pelleted and washed twice with 1 ml H2O. After the second wash, the resuspended cells were transferred to a pre-weighed snap-cap tube with a hole poked in the top, and the cells were lyophilized overnight. After drying to completion, the tube was weighed in order to calculate dry cell weight. 0.25 ml from the same shake flask culture was placed into a 2 ml screw-cap tube for carotenoid extraction. Cells were pelleted and the supernatant was aspirated. Pelleted cells may be frozen at -800C and stored. An equal volume of cubic zirconia beads was added to cell pellets, along with 1 ml ice-cold extraction solvent (a 50/50 v/v mix of hexane and ethyl acetate containing 0.01% butylhydroxytoluene (BHT)). The mixture was then agitated (Mini-BeadBeater-8, BioSpec Products, Inc.) at maximum speed for 5 minutes at 40C. The mixture was then spun at maximum speed for 1 minute, and the supernatant was collected and deposited in a cold 16 ml glass vial. The remaining cell debris was re-extracted at least three times, without the addition of zirconia beads; all supernatants were pooled in the 16 ml glass vial. Following extraction, the glass vial was spun for 5 minutes at 2000 rpm at 4°C in a Sorvall tabletop centrifuge, and the supernatant was transferred to a new cold 16 ml glass vial. A Speed Vac was used to concentrate the supernatant (room temperature in dark), and the samples were stored at -200C or -800C until immediately before HPLC analysis. Prior to HPLC analysis, the samples were resuspended in 1 ml ice-cold solvent and then transferred to a cold amber vial. Throughout the protocol, care was taken to avoid contact with oxygen, light, heat, and acids.
Example 4: Quantification of carotenoid production by HPLC
[00140] For carotenoid analysis, samples were resuspended in ice-cold extraction solvent (a 50/50 v/v mix of hexane and ethyl acetate containing 0.01% butylhydroxytoluene (BHT)). An Alliance 2795 HPLC (Waters) equipped with a Waters XBridge Cl 8 column (3.5 μm, 2.1 x 50 mm) and Thermo Basic 8 guard column (2.1 x 10 mm) was used to resolve carotenoid at 25°C; authentic carotenoid samples were used as standards. The mobile phases and flow rates are shown below (Solvent A= Ethyl Acetate; Solvent B= Water; Solvent C= Methanol; Solvent D= Acetonitrile). The injection volume was 10 μL. The detector is a Waters 996 photodiode array detector. The retention times for lipophilic molecules include astaxanthin (1.159 min), zeaxanthin (1.335), β-apo-8'-carotenal (2.86 min), ergosterol (3.11 min), lycopene (3.69 min), β-Carotene (4.02 min), and phytoene (4.13 min). Astaxanthin, zeaxanthin, β-apo-8'-carotenal, lycopene and β-Carotene are detected at 475 nm, whereas ergosterol and phytoene were detected at 286 nm.
TABLE 28 Retention Times for Lipophilic Molecules
Figure imgf000042_0001
Figure imgf000043_0001
Example 5: Expression of a truncated form of EMG-CoA reductase results in increased carotenoid production
[00141] In order to increase carotenoid production, carbon flow through the isoprenoid pathway is enhanced by introducing a truncated variant of the HMG-CoA reductase gene.
[00142] In one approach, a truncated variant of the HMG-CoA reductase gene which also encodes a 77 amino acid leader sequence derived from S. cerevisiae Hmgl is introduced into a GRPBua strain (described in Example 2E above). Plasmid pTefHMG can be cleaved with SnaBl, BbvCl, or Bsu36l to direct integration at the adel locus, or with BamHI to direct integration at the HMGl locus, or with EcoKV to promote random integration, in the GRPBua strains, restoring them to adenine prototrophy. Resulting Ade+ transformants are screened for increased carotenoid production.
[00143] Alternatively, the native HMGl gene from Y. lipolytica may be modified without S. cerevisiae sequences as described in Example ID above, to create pMB4637. This plasmid can be digested as described for pTefHMG and transformed into GRPBua strains, and resulting transformants screened as described for increased carotenoid production. [00144] In still another approach, a truncated variant of the N. crassa HMG-CoA reductase gene may be utilized and introduced into Y. lipolytica strains. In order to generate a plasmid suitable for expression of the heterologous HMG-CoA reductase, p641P (Yeast 2001 ; 18 (2001): 97-113) is modified by replacing the ICLl promoter with the GPD promoter, and by the addition of sequences conferring resistance to phleomycin. Y. lipolytica genomic DΝA is amplified with two primers.
GPDdist: 5' CACACGGTacctgtaggttgggttgggtg GPDprox: 5' CACACGGATCCtgtttaattcaagaatgaatatagagaagagaag, and the resulting fragment (0.7 kb) is cleaved with BamΑl and Kpήl, and ligated to BamΑl- and iφrcl-cleaved p641P, creating the plasmid "p641Pgpd". The Ue gene under the control of the A. nidulans GPD promoter is then excised from pBCphleo (Silar, Fungal Genetics Newsletter 42:73) as a 3.2 kb BcH-BamHl fragment and inserted into the unique BamEI site of "p641Pgpd", in the orientation that preserves the BanϊΑl site proximal to the GPD promoter, to create "p641Pgpdble" ,
[00145] N. cr asset genomic DΝA is amplified with two primers:
Νeuhmg fwd: 5' CACACGGATCCACATCAACAatggcatctgccacccttcccc
Νeuhmg rev: 5' CAC ACGG ATCcaagtgctgacgcggaacttg, and the resulting fragment is cleaved with BaniW. and inserted into UαroHI-digested "p641Pgpdble" in the correct orientation. The resulting plasmid, "pZg", contains sequences encoding a truncated cytosolic catalytic domain of hydroxymethylglutaryl-CoA reductase from N. crassa (Genbank accession: XP_324892) under the control of the constitutive GPD promoter. This plasmid can be introduced into the Y. lipolytica strain created in Example 2E above, and transformants are selected by their resistance to phleomycin (100 μg/ml). Resulting transformants are tested for β-carotene production, as described above. Example 6: Introduction of heterologous carotene hydroxylase and carotene ketolase genes into Y. lipolvtica strains producing carotenoid for production of astaxanthin. [00146] For introduction of carotene hydroxylase and carotene ketolase into carotenoid producting Y. lipolytica, pMB4692 and pMB4698, described as in Example IE and IF above, can be sequentially introduced into the GRPBua strain (described in Example 2E). For the introduction of pMB4692, the plasmid may be cleaved with SaR or BsrGl to direct integration at the uraS locus, or with Xbal to promote random integration, selecting for uracil prototrophy. GRPBua Ura+ transformants harboring pMB4692 are screened for zeaxanthin production in YPD. Zeaxanthin-producing cells are transformed with pMB4698 (which can be cleaved with PpuMl, Sspl or BbvCl to direct integration at the adel locus, or with EcoRY to promote random integration) and prototrophic colonies are screened for astaxanthin production.
[00147] Alternatively, the order of plasmid transformation may be reversed wherein pMB4698 is transformed first and transformants are selected for adenine prototrophy. GRPBua Ade+ transformants harboring ρMB4698 are screened for canthaxanthin production. Canthaxanthin-producing GRPBua[pMB4698] cells are transformed with pMB4692 and prototrophic colonies are screened for astaxanthin production.
[00148] In another approach, the carotenoid ketolase and carotenoid hydroxylase genes from P. marcusii can be introduced into the strains described in Example 2 above, in order to convert β-carotene into astaxanthin. P. marcusii genomic DΝA is amplified with two primers.
CrtZfwd: 5' CACACCGTCTCAAatgaccaatttcctgatcgtcgtc
CrtZrev: 5' CACACAGATCtcacgtgcgctcctgcgcc, and the resulting fragment is cleaved with BsmBl, modified with the Klenow fragment of DNA polymerase, and cleaved with BgIU. This fragment is inserted into PmU- and BamHl- cleaved pINA1269 (J. MoI. Microbiol. Biotechnol. 2 (2000): 207-216), containing the hp4d promoter, the XPR2 terminator, the selectable LEU2 gene, and sequences necessary for selection and propagation in E. coli. The resulting plasmid "pA" contains sequences encoding carotene hydroxylase from P. marcusii (crtZ gene)(Genbank accession: CAB56060.1) under the control of the hp4d promoter.
[00149] "pYEGITEF" is modified by substituting the LIP2 terminator for the XPR2 terminator as follows. pINA1291 is digested with Avrll, modified with the Klenow fragment of DNA polymerase, and cleaved with EcoBΛ, and the small LIP2t containing fragment is ligated to "pYEGITEF" that has been digested with Sacll, modified with T4 DNA polymerase in the presence of dNTP, and cleaved with EcoKL. The resulting plasmid is named "PYEGlTEF-LIP2t" .
[00150] In order to amplify the carotenoid ketolase gene, P. marcusii genomic DNA is amplified with two primers.
CrtWfwd: 5' CACACCCTAGGCCatgagcgcacatgccctgc
CrtWrev: 5' CACACAAGCTTtcatgcggtgtcccccttg, and the resulting fragment is cleaved with Avrll and Hindlll, and inserted into ^4vrII- and .ffiwcflll-cleaved "pYEGlTEF-LIP2t". The resulting plasmid, "pBt", contains sequences encoding the carotene ketolase (crt W gene)(Genbank accession: CAB56059.1) under the control of the constitutive TEFl promoter.
[00151] In order to combine the two expression cassettes into a single plasmid, "pBt" is cleaved with CM, modified with the Klenow fragment of DNA polymerase, and cleaved with JECORI, and the crt JF-containing fragment is isolated, mixed with the phosphorylated oligonucleotide adaptor pair:
5 ' AATTCGCGGCCGCT and
5' AGCGGCCGCG, cleaved with Notl, and ligated to VVctfl-digested "pA". The resulting plasmid, "pABt", contains both the TEFlplcrtWILIP2t cassette and the hp4dlcrtZIXPR2t cassette as well as the selectable LEU2 gene.
[00152] "pABt" can be introduced into the Y. lipolytica strain described above in
Example 4 (TEF IpI al-l/XPR2t; hp4dlcarRPILIP2t\ GPDplHMGR,nmc), and transformants selected for leucine prototrophy.
Example 7: Partial inactivation of Y. lipolvtica ERG9 gene encoding saualene synthase results in increased carotenoid production: [00153] TA. In order to partially inactivate the ERG9 gene encoding squalene synthase, the neighboring FOL3 gene is disrupted, resulting in a folinic acid requirement.
This strain is then transformed with a mutagenized fragment of DNA partially spanning the two genes, and FoI+ transformants are screened for decreased squalene synthase activity.
[00154] The following oligonucleotides are synthesized:
PRIMER K 5'-CCTTCTAGTCGTACGTAGTCAGC;
PRIMER L 5'-CCACTGATCTAGAATCTCTTTCTGG and used to amplify a 2.3 kb fragment from Y, lipolytica genomic DNA spanning most of the
FOL3 gene, using Pfu polymerase. The resulting fragment is cleaved with Xbal and phosphorylated, then ligated into pBluescriptSK' that has been cleaved with Kpnl, treated with T4 DNA polymerase (T4pol) in the presence of dNTPs, and subsequently cleaved with
Xbal. The resultant plasmid, designated pBS-foB, is then cleaved with Acc65l and EcoRl, treated with T4pol as above, and ligated to the 3.4 kb EcoKV-Spel ADEl fragment (treated with T4pol) from pMB4529.
[00155] The resulting plasmid, pBSfol3Δade, can be cleaved with BsiΨI and Xbal to liberate a 5.5 kb fragment that is used to transform the GRBPua strains described above to adenine prototrophy. Resulting Ade+ transformants are screened for a folinic acid requirement, and for homologous integration by PCR analysis.
[00156] Strains that harbor the resultant/o/3Δ/iDi?i allele can be transformed with a
3.5 kb DNA fragment generated by mutagenic PCR amplification using the primers:
PRIMERM 5'-GGCTCATTGCGCATGCTAACATCG;
PRIMERN 5'-CGACGATGCTATGAGCTTCTAGACG, and Y. lipolytica genomic DNA as template. The resulting fragment containing the N- terminal three-quarters of the FOLS ORF and the C-terminal nine-tenths of the ERG9 ORF is used to transform strains. The resulting FoI+ Ade" transformants are screened for decreased squalene synthase activity by sensitivity to agents such as zaragozic acid, itraconazole, or fluconazole. Additionally, the resulting transformants are screened for increased carotenoid production.
[00157] TB. Alternatively, the PCR fragment produced in 7A could be cloned and altered in such a way as to remove the 3 '-untranslated region of ERG9 gene. Replacement of the fol3 AADEl disruption by this fragment results in decreased expression of squalene synthase [Schuldiner et al. (2005), Cell 123:507-519][Muhlrad and Parker (1999), RNA
5: 1299-1307], which can be confirmed as in 7A. This approach may also be used in a FoI+
Ade" strain, using the ADEl marker to disrupt the ERG93'-UTR.
[00158] 7C. In still another approach, partially defective ERG9 alleles can be identified in S. cerevisiae using plasmid shuffling techniques [Boeke et al. (1987), Methods Enzymol. 154:164-175], and using drug sensitivities as a phenotype. Defective genes can be transferred to Y. lipolytica using standard molecular genetic techniques.
Example 8: Treatment of Y. lipolvtica strains producing carotenoid with inhibitor of an isoprenoid biosynthesis competitor polypeptide results in increased carotenoid production
[00159] ^Cultures produced in Example 2 are treated with the squalene synthase inhibitor, zaragozic acid (zaragozic acid at 0.5 μM) and monitored for β-carotene production, as described above.
Example 9: Constructing, an oleaginous strain ofSaccharomyces cerevisiae
[00160] The genes encoding the two subunits of ATP-citrate lyase from N. crassa, the
AMP deaminase from Saccharomyces cerevisiae, and the cytosolic malic enzyme from M. circinelloides are overexpressed in S. cereviseae strains in order to increase the total lipid content. Similar approaches to enhance lipid production could be employed in other host organisms such as Xanthophyllomyces dendrorhous (Phqffia rhodozyma), using the same, homologous, or functionally similar oleaginic polypeptides.
[00161] Qiagen RΝAEasy kits (Qiagen, Valencia, CA.) are used to prepare messenger
RΝA from lyophilized biomass prepared from cultures of N. crassa. Subsequently, RT-PCR is performed in two reactions containing the mRΝA template and either of the following primer pairs. acll : lfwd: 5' CACACGGATCCTATAatgccttccgcaacgaccg lrev: 5' CACACACTAGttaaatttggacctcaacacgaccc acl2:
2fwd: 5' CACACGGATCCAATATAAatgtctgcgaagagcatcctcg
2rev: 5' CACACGCATGCttaagcttggaactccaccgcac
[00162] The resulting fragment from the acll reaction is cleaved with Spel and
BamBl, and that from the acl2 reaction is cleaved with BamRl and Sphl, and both are ligated together into YEp24 that has been digested with Nhel and Sphl, creating the plasmid "pl2". The bi-directional GALl-10 promoter is amplified from S. cerevisiae genomic DΝA using the primers. gall 0: 5' CACACGGATCCaatmcaaaaattcttactttttttttggatggac gall : 5' CACACGGATCCttttttctccttgacgttaaagtatagagg, and the resulting 0.67 kb fragment is cleaved with BamUl and ligated in either orientation to SαmHI-digested "pl2" to create "plgal2" and "p2gall", containing GALl-acll/GALlO-acU and GALl 0-acll /GALl -acl2, respectively (Genbank accession: acll: CAB91740.2; acl2: CAB91741.2). [00163] In order to amplify the S. cereviseae gene encoding AMP deaminase and a promoter suitable for expressing this gene, S. cerevisiae genomic DNA is amplified using two primer pairs in separate reactions: AMDl ORF:
AMDlFWD: 5' CACACGAGCTCAAAAatggacaatcaggctacacagag
AMDlrev: 5' CACACCCTAGGtcacttttcttcaatggttctcttgaaattg GAL7p: gal7prox: 5' CACACGAGCTCggaatattcaactgtttttttttatcatgttgatg gal7dist: 5' CACACGGAtccttcttgaaaatatgcactctatatcttttag, and the resulting fragment from the AMDl reaction (2.4 kb) is cleaved with Sad and Avrll, and that from the GAL7 reaction (0.7 kb) is cleaved with BarriΑl and Sphl, and both are ligated together into YEp 13 that has been digested with MeI and BamEI, creating the plasmid "pAMPD". This plasmid carries the S. cerevisiae gene, AMDl, encoding AMP deaminase, under the control of the galactose-inducible GAL7 promoter. [00164] Messenger RNA is prepared from lyophilized biomass of M. circinelloides, as described above, and the mRNA template is used in a RT-PCR reaction with two primers:
MAEfwd: 5' CACACGCTAGCTACAAAatgttgtcactcaaacgcatagcaac
MAErev: 5' CACACGTCGACttaatgatctcggtatacgagaggaac, and the resulting fragment is cleaved with Nhel and SaK, and ligated to Xbal- and Xhol- digested pRS413TEF (Mumberg, D. et al. (1995) Gene, 156:119-122), creating the plasmid "pTEFMAE", which contains sequences encoding the cytosolic NADP+-dependant malic enzyme from M. circinelloides (E.C. 1.1.1.40; mce gene; Genbank accession: AY209191) under the control of the constitutive TEFl promoter.
[00165] The plasmids "plgal2", "pAMPD", and "pTEFMAE" are sequentially transformed into a strain of S. cereviseae to restore prototrophy for uracil ("plgal2"), leucine ("pAMPD"), and histidine ("pTEFMAE") (Guthrie and Fink Methods in Enzymology 194:1- 933, 1991). The resulting transformants are tested for total lipid content following shake flask testing in either synthetic complete (SC) medium lacking uracil, leucine and histidine, as described in Example 3, or in a 2-step fermentation process. In the 2-step process, 1.5 ml of cells from an overnight 2 ml roll tube culture containing SC medium lacking uracil, leucine and histidine are centrifuged, washed in distilled water, and resuspended in 20 ml of a nitrogen-limiting medium suitable for lipid accumulation (30 g/L glucose, 1.5 g/L yeast extract, 0.5 g/L NH4Cl, 7 g/L KH2PO4, 5 g/L Na2HPO4- 12H2O, 1.5 g/L MgSO4-7H2O, 0.08 g/L FeCl3-6H2O, 0.01 g/L ZnSO4-7H2O, 0.1 g/L CaCl2-2H2O, 0.1 mg/L MnSO4-5H2O, 0.1 mg/L CuSO4-5H2O, 0.1 mg/L Co(NO3)2-6H2O; pH 5.5 (J Am Oil Chem Soc 70:891-894 (1993)) . [00166] Intracellular lipid content of the modified and control S. cerevisiae strains is analyzed using the fluorescent probe, Nile Red (J Microbiol Meth (2004) 56:331-338). In brief, cells diluted in buffer are stained with Nile Red, excited at 488 nm, and the fluorescent emission spectra in the wavelength region of 400-700 nm are acquired and compared to the corresponding spectra from cells not stained with Nile Red. To confirm results from the rapid estimation method, the total lipid content is determined by gas chromatographic analysis of the total fatty acids directly transmethylesterified from dried cells, as described (Appl
Microbiol Biotechnol. 2002 Nov;60(3):275-80). Non-transformed S. cerevisiae strains produce 6% and 10% total lipid (dry cell weight basis) after growth in YPD and lipid accumulation medium, respectively. Yeast strains expressing the multiple oleaginic polypeptides produce 17% and 25% total lipid following growth in YPD and lipid accumulation medium, respectively.
Example 10: Introduction of heterologous carotene hydroxylase into Y. lipolytica strains producing carotenoid for production ofzeaxanthin
[00167] MF578 {tef-carRP tef-carB) was transformed with pMB4692 that had been cleaved with SaR. Several Ura+ colonies inferred to contain tef-crtZ by PCR analysis were able to produce zeaxanthin in YPD shake flasks, and in one case, all of the carotene was depleted.
[00168] The following tables are referenced throughout the description:
pol e tides.
Figure imgf000050_0002
Figure imgf000050_0001
Table 2. Exam les of ruvate decarboxylase ol e tides.
Figure imgf000051_0002
Figure imgf000051_0001
Table 3. Examples of isocitrate deh dro enase
Figure imgf000052_0002
Figure imgf000052_0001
Table 4. Exam les of ATP-citrate l ase polype tides.
Figure imgf000053_0002
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000054_0002
Figure imgf000055_0001
Figure imgf000055_0002
Figure imgf000056_0001
Table 6. Exam les of AMP deaminase olype tides.
Figure imgf000057_0002
Figure imgf000057_0001
olypeptides.
Figure imgf000058_0001
Figure imgf000059_0002
Figure imgf000059_0001
Table 9. Exam les of HMG-CoA reductase poly eptides
Figure imgf000060_0002
Figure imgf000060_0001
Table 10. Exam les of mevalonate kinase pol e tides.
Figure imgf000061_0001
Figure imgf000061_0002
Figure imgf000062_0001
Table 11. Exam les of hos homevalonate kinase polypeptides.
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000064_0002
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000066_0002
Figure imgf000067_0002
Figure imgf000067_0001
peptides
Figure imgf000068_0001
Figure imgf000068_0002
Figure imgf000069_0001
lype tides
Figure imgf000070_0001
Figure imgf000070_0002
Figure imgf000071_0001
Figure imgf000071_0002
Figure imgf000072_0001
Figure imgf000072_0002
Figure imgf000073_0001
Figure imgf000074_0001
Table 17. Exam les of h toene deh dro enase ol e tides,
Figure imgf000075_0001
Figure imgf000075_0002
Figure imgf000076_0001
Figure imgf000076_0002
Figure imgf000077_0001
Figure imgf000077_0002
Genbank ow ACCESSION
273 NP 441167
274 NP 441254
275 NP 442491
276 NP 442727
277 NP 562475
278 NP 568712
279 NP 601630
280 NP 601630
281 NP 616426
282 NP 624522
283 NP 626360
284 NP 630834
285 NP 643053
286 NP 647302
287 NP 659552
288 NP 661086
289 NP 661546
290 NP 661701
291 NP 662300
292 NP 681023
293 NP 681127
294 NP 682351
295 NP 693380
296 NP 693382
297 NP 737250
298 NP 763380
299 NP 786524
300 NP 822198
301 NP 822828
302 NP 827278
303 NP 851528
304 NP 857496
305 NP 868798
306 NP 869339
307 NP 870237
308 NP 874530
309 NP 874561
310 NP 874977
311 NP 892236
312 NP 892265
313 NP 892458
314 NP 893232
315 NP 894882
316 NP 895385
317 NP 895793
318 NP 895829
Figure imgf000078_0001
Genbank Genbank ow ACCESSION Row ACCESSION
365 T50745 411 ZP 001116
366 T50749 412 ZP 001117
367 T50893 413 ZP 001119
368 T50910 414 ZP 001124
369 T51119 415 ZP 001510
370 T51 123 416 ZP 001591
371 XP 324732 417 ZP 001593
372 XP 383241 418 ZP 001602
373 XP 401825 419 ZP 001614
374 XP 470568 420 ZP 001645
375 XP 473486 421 ZP 001650
376 XP 477063 422 ZP 001722
377 XP 525801 423 ZP 001746
378 XP 540198 424 ZP 001752
379 YP 006049 425 ZP 001770
380 YP 013621 426 ZP 001777
381 YP 024310 427 ZP 001787
382 YP 041986 428 ZP 001837
383 YP 041988 429 ZP 001867
384 YP 044561 430 ZP 002073
385 YP 044564 431 ZP 002077
386 YP 062471 432 ZP 002339
387 YP 117947 433 ZP 002680
388 YP 120612 434 ZP 002705
389 YP 135077 435 ZP 002771
390 YP 136483 436 ZP 002892
391 YP 145331 437 ZP 002916
392 YP 145348 438 ZP 002963
393 YP 171014 439 ZP 003022
394 YP 172823 440 ZP 003036
395 YP 173078 441 ZP 003107
396 YP 173207 442 ZP 003202
397 YP 184572 443 ZP 003258
398 YP 187368 444 ZP 003268
399 YP 187371 445 ZP 003269
400 YP 187371 446 ZP 003276
401 YP 187371 447 ZP 003283
402 ZP 000490 448 ZP 003557
403 ZP 000509 449 ZP 003559
404 ZP 000518 450 ZP 003565
405 ZP 000566 451 ZP 003577
406 ZP 000627 452 ZP 003593
407 ZP 000627 453 ZP 003595
408 ZP 001073 441 ZP 003685
409 ZP 001081
410 ZP 001091 Table 18. Exam les of h toene
Figure imgf000080_0001
Figure imgf000080_0002
Figure imgf000081_0001
Figure imgf000081_0002
Figure imgf000082_0001
Figure imgf000082_0002
Figure imgf000083_0001
Table 19. Exam les of carotenoid ketolase ol e tides.
Figure imgf000084_0001
Figure imgf000084_0002
Figure imgf000085_0001
Table 20. Exam les of carotenoid hydroxylase ol e tides.
Figure imgf000086_0002
Figure imgf000086_0001
Table 21. Examples of astaxanthin synthase polypeptides and putative astaxanthin s nthase polypeptides.
Figure imgf000087_0001
Table 22. Exam les of carotenoid e silon h drox lase ol e tides.
Figure imgf000087_0002
Table 23. Exam les of l co ene c clase ol e tides beta and e silon subunits.
Figure imgf000087_0003
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0002
Table 24. Examples of carotenoid glucosyltransferase polypeptides.
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Table 25. Examples of acyl CoA:diacyglyceroI acyltransferase (DGAT) polypeptides.
Figure imgf000092_0002
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Table 30: Exam les of PHB-Pol ren ltransferase ol e tides
Figure imgf000098_0002
58385249 ENSANGP00000012220 [Anopheles gambiae str. PEST]
50746583 PREDICTED: similar to hypothetical protein CL640 [Gallus gallus]
54638587 GA21912-PA [Drosophila pseudoobscurai
21355567 CG9613 -PA [Drosophila melanogaster]
71005862 hypothetical protein UMO 1450. 1 [Ustilago maydis 521]
[00169] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above Description, but rather is as set forth in the following claims:

Claims

What is claimed is:
1. A recombinant fungus characterized by: a. the fungus is oleaginous in that it can accumulate lipid to at least about 20% of its dry cell weight; and b. the fungus produces at least one carotenoid, and can accumulate the produced carotenoid to at least about 1 % of its dry cell weight; wherein the fungus comprises at least one modification selected from the group consisting of carotenogenic modifications, oleaginic modifications, and combinations thereof, and wherein the at least one modification alters oleaginicity of the fungus, confers to the fungus oleaginy, confers to the fungus the ability to produce the at least one carotenoid to a level at least about 1% of its dry cell weight, or confers to the fungus the ability to produce at least one carotenoid which the fungus does not naturally produce.
2. The fungus of claim 1 wherein the fungus is naturally oleaginous.
3. The fungus of claim 1 wherein the fungus is not naturally oleaginous.
4. The fungus of any one of claims 1 -3 wherein the fungus does not naturally produce the at least one carotenoid.
5. The fungus of any one of claims 1 -3 wherein the fungus naturally produces the at least one carotenoid.
6. The fungus of any one of claims 1-3 wherein the fungus does not naturally produce at least one carotenoid.
7. The fungus of any one of claims 1-3 wherein the fungus naturally produces at least one carotenoid.
8. The fungus of claim 1 wherein the fungus grows as a single cell.
9. The fungus of claim 1 wherein the fungus is a yeast.
10. The fungus of any one of claims 1-9 wherein the fungus contains at least one oleaginic modification.
11. The fungus of claim 10 wherein the at least one oleaginic modification confers oleaginy upon the fungus.
12. The fungus of claim 10 wherein the at least one oleaginic modification alters oleaginicity of the fungus.
13. The fungus of claim 10 wherein the fungus further comprises at least one carotenogenic modification wherein the carotenogenic modification confers to the fungus the ability to produce the at least one carotenoid to a level at least about 1% of its dry cell weight or confers to the fungus the ability to produce at least one carotenoid which the fungus does not naturally produce.
14. The fungus of any one of claims 10-13 wherein the at least one oleaginic modification increases expression or activity of at least one oleaginic polypeptide.
15. The fungus of any one of claims 10-13, wherein the at least one oleaginic modification decreases expression or activity of at least one oleaginic polypeptide.
16. The fungus of any one of claims 10-13, wherein the at least one oleaginic modification increases expression or activity of at least one oleaginic polypeptide and decreases expression or activity of at least one other oleaginic polypeptide.
17. The fungus of claim 11 wherein the fungus is of the species Xanthophyllomyces dendrorhous (Phaffla rhodozyma).
18. The fungus of claim 11 wherein the fungus is of the species Saccharomyces cerevisae.
19. The fungus of claim 14 or 15, wherein the at least one oleaginic polypeptide is selected from the group consisting of acetyl-CoA carboxylase polypeptide, pyruvate decarboxylase polypeptide, isocitrate dehydrogenase polypeptide, ATP-citrate lyase polypeptide, malic enzyme polypeptide, AMP deaminase polypeptide, and combinations thereof.
20. The fungus of claim 14 or 15 wherein the least one oleaginic polypeptide is at least one polypeptide selected from the group consisting of a polypeptide in any one of Tables 1 through 6.
21. The fungus of any one of claims 14-16, wherein the at least one oleaginic modification comprises expression of at least one heterologous oleaginic polypeptide in the fungus.
22. The fungus of claim 21 , wherein the at least one oleaginic modification comprises expression of at least one heterologous gene encoding the at least one heterologous oleaginic polypeptide.
23. The fungus of claim 21 , wherein the at least one heterologous oleaginic polypeptide comprises an animal polypeptide, a mammalian polypeptide, an insect polypeptide, a plant polypeptide, a fungal polypeptide, a yeast polypeptide, an algal polypeptide, a bacterial polypeptide, a cyanobacterial polypeptide, an archaebacterial polypeptide, or a protozoal polypeptide.
24. The fungus of claim 21, wherein the at least one heterologous oleaginic polypeptide comprises at least two heterologous oleaginic polypeptides.
25. The fungus of claim 24, wherein the at least two heterologous oleaginic polypeptides are from a single source organism.
26. The fungus of claim 24, wherein the at least two heterologous oleaginic polypeptides are from at least two different source organisms.
27. The fungus of any one of claims 1-9 wherein the fungus contains at least one carotenogenic modification.
28. The fungus of claim 27 wherein the at least one carotenogenic modification confers to the fungus the ability to produce the at least one carotenoid to a level at least about 1% of its dry cell weight.
29. The fungus of claim 27 wherein the at least one carotenogenic modification confers to the fungus the ability to produce at least one carotenoid which the fungus does not naturally produce.
30. The fungus of claim 27 wherein the fungus further comprises at least one oleaginic modification wherein the oleaginic modification alters oleaginicity of the fungus or confers to the fungus oleaginy.
31. The fungus of any one of claims 27-30, wherein the at least one carotenogenic modification confers the ability to the fungus to produce the at least one carotenoid to a level selected from the group consisting of at least about 2%, at least about 3%, at least about 5%, and at least about 10% of the fungus' dry cell weight.
32. The fungus of any one of claims 27-31 , wherein the at least one carotenoid is selected from the group consisting of astaxanthin, β-carotene, canthaxanthin, zeaxanthin, lutein, lycopene, and combinations thereof.
33. The fungus of any one of claims 27-31 wherein the at least one carotenoid is predominantly astaxanthin.
34. The fungus of any one of claims 27-31 , wherein the at least one carotenogenic modification increases expression or activity of a carotenogenic polypeptide.
35. The fungus of any one of claims claims 27-31 , wherein the at least one carotenogenic modification decreases expression or activity of a carotenogenic polypeptide.
36. The fungus of any one of claims 27-31 , wherein the at least one carotenogenic modification increases expression or activity of at least one carotenogenic polypeptide and decreases expression or activity of at least one other carotenogenic polypeptide.
37. The fungus of any one of claims 34-36, wherein the at least one carotenogenic modification comprises expression of at least one heterologous carotenogenic polypeptide.
38. The fungus of claim 37 wherein the at least one carotenogenic modification comprises expression of at least one heterologous gene encoding the at least one heterologous carotenogenic polypeptide.
39. The fungus of claim 34 or 35, wherein the carotenogenic polypeptide is selected from the group consisting of: isoprenoid biosynthesis polypeptides, carotenoid biosynthesis polypeptides, isoprenoid biosynthesis competitor polypeptides, and combinations thereof.
40. The fungus of claim 39 wherein the isoprenoid biosynthesis polypeptides are selected from the group consisting of: acetoacetyl-CoA thiolase polypeptide, HMG-CoA synthase polypeptide, HMG-CoA reductase polypeptide, mevalonate kinase polypeptide, phosphomevalonate kinase polypeptide, mevalonate pyrophosphate decarboxylase polypeptide, IPP isomerase polypeptide, FPP synthase polypeptide, and GGPP synthase polypeptide.
41. The fungus of claim 39, wherein the carotenoid biosynthesis polypeptides are selected from the group consisting of: phytoene synthase polypeptide, phytoene dehydrogenase polypeptide, lycopene cyclase polypeptide, carotenoid ketolase polypeptide, carotenoid hydroxylase polypeptide, astaxanthin synthase polypeptide, carotenoid epsilon hydroxylase polypeptide, carotenoid glucosyltransferase polypeptide, lycopene cyclase (beta and epsilon subunits) polypeptides, and acyl CoA:diacyglycerol acyltransferase polypeptide.
42. The fungus of claim 39, wherein the isoprenoid biosynthesis competitor polypeptides are selected from the group consisting of squalene synthase polypeptide, prenyldiphosphate synthase and PHB polyprenyltransferase.
43. The fungus of claim 39, wherein the carotenogenic polypeptide is selected from the group consisting of any of the polypeptides of any one of Tables 7-25, Table 29, and Table 30, and combinations thereof.
44. The fungus of claim 37, wherein the at least one heterologous carotenogenic polypeptide comprises an animal polypeptide, a mammalian polypeptide, an insect polypeptide, a plant polypeptide, a fungal polypeptide, a yeast polypeptide, an algal polypeptide, a bacterial polypeptide, cyanobacterial polypeptide, an archaebacterial polypeptide, or a protozoal polypeptide.
45. The fungus of claim 37, wherein the at least one heterologous carotenogenic polypeptide comprises at least two heterologous carotenogenic polypeptides.
46. The fungus of claim 45, wherein the at least two heterologous carotenogenic polypeptides are from a single source organism.
47. The fungus of claim 45, wherein the at least two heterologous carotenogenic polypeptides are from at least two different source organisms.
48. A fungus according to any of the preceding claims wherein the fungus accumulates the produced at least one carotenoid to a level selected from the group consisting of: above about 1%, above about 2%, above about 3%, above about 5%, and above about 10% of the fungus' dry cell weight.
49. A fungus according to any of the preceding claims characterized in that the fungus accumulates lipid in the foπn of cytoplasmic bodies.
50. The fungus of claim 49 wherein the at least one carotenoid accumulates in the cytoplasmic oil bodies.
51. A strain of Yarrowia lipolytica comprising one or more modifications selected from the group consisting of an oleaginic modification, a carotenogenic modification, and combinations thereof, such that the strain accumulates from 1% to 10% of its dry cell weight as at least one carotenoid.
52. The strain of claim 51 further characterized in that it accumulates from 20% to 50% of its dry cell weight as lipid.
53. The strain of claim 52, wherein the strain accumulates from 20% to 50% of its dry cell weight as lipid in the form of cytoplasmic oil bodies.
54. The strain of claim 51 , wherein the strain comprises a carotenogenic modification selected from the group consisting of: a. expression of a polypeptide selected from a group consisting of a truncated endogenous HMG CoA reductase polypeptide that lacks the N-terminal membrane spanning domain, acetoacetyl-CoA thiolase, HMG-CoA synthase, FPP synthase, and GGPP synthase; b. expression of a heterologous polypeptide selected from the group consisting of phytoene synthase, phytoene desaturase, lycopene cyclase, carotenoid ketolase, carotenoid hydroxylase, and combinations thereof; c. decreased expression or activity of an endogenous polypeptide selected from the group consisting of squalene synthase polypeptide prenyldiphosphate synthase polypeptide and PHB polyprenyltransferase polypeptide; and combinations thereof.
55. The strain of any one of claims 51-54, wherein the strain accumulates 1-10% of its dry cell weight as β-carotene.
56. The strain of claim 51, wherein the strain comprises a carotenogenic modification selected from the group consisting of: a. expression of a polypeptide selected from a group consisting of a truncated endogenous HMG CoA reductase polypeptide that lacks the N-terminal membrane spanning domain, acetoacetyl-CoA thiolase, HMG-CoA synthase, FPP synthase, and GGPP synthase; b. expression of a heterologous polypeptide selected from the group consisting of phytoene synthase, phytoene desaturase, lycopene cyclase, carotenoid ketolase, carotenoid hydroxylase, astaxanthin synthase, carotenoid epsilon hydroxylase, lycopene cyclase (beta and epsilon subunits), carotenoid glucosyltransferase, acyl CoA:diacyglycerol acyltransferase, and combinations thereof; c. decreased expression or activity of an endogenous squalene synthase polypeptide; and combinations thereof.
57. The strain of any one of claims 51-53 or 56, wherein the strain accumulates 1 - 10% of its dry cell weight as astaxanthin or lutein.
58. A method of producing a carotenoid, the method comprising steps of: a. cultivating the fungus of any one of the preceding claims under conditions that allow production of the carotenoid; b. and isolating the produced carotenoid.
59. The method of claim 58, wherein the step of isolating comprises fractionating the cultivation medium to obtain at least one carotenoid-enriched fraction.
60. The method of claim 58, wherein: the step of cultivating comprises cultivating the fungus under conditions that allow accumulation of the carotenoid in cytoplasmic oil bodies; and the step of isolating comprises isolating oil derived from the cytoplasmic oil bodies.
61. The method of claim 58, wherein the carotenoid is selected from the group consisting of astaxanthin, β-carotene, canthaxanthin, zeaxanthin, lutein, lycopene, and combinations thereof.
62. The method of claim 58, wherein the carotenoid comprises astaxanthin.
63. A method of preparing a food or feed additive containing a carotenoid, the method comprising steps of: a. cultivating the fungus of any one of claims 1-57 under conditions that allow production of the carotenoid; b. isolating the carotenoid; and c. combining the isolated carotenoid with one or more other food or feed additive components.
PCT/US2006/010271 2005-03-18 2006-03-20 Production of carotenoids in oleaginous yeast and fungi WO2006102342A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2006227165A AU2006227165B2 (en) 2005-03-18 2006-03-20 Production of carotenoids in oleaginous yeast and fungi
JP2008502155A JP2008537878A (en) 2005-03-18 2006-03-20 Production of carotenoids in oleaginous yeasts and fungi
CA2602183A CA2602183C (en) 2005-03-18 2006-03-20 Production of carotenoids in oleaginous yeast and fungi
KR1020077021286A KR101482081B1 (en) 2005-03-18 2006-03-20 Production of carotenoids in oleaginous yeast and fungi
EA200701974A EA016258B1 (en) 2005-03-18 2006-03-20 Recombinant fungus producing carotenoids and methods of use thereof
EP06748522A EP1866428A2 (en) 2005-03-18 2006-03-20 Production of carotenoids in oleaginous yeast and fungi
CN2006800088162A CN101218352B (en) 2005-03-18 2006-03-20 Production of carotenoids in oleaginous yeast and fungi
BRPI0609040-0A BRPI0609040B1 (en) 2005-03-18 2006-03-20 YARROWIA RECOMBINATING FUNGUS, METHOD FOR CAROTENOID PRODUCTION AND METHOD FOR PREPARING A FOOD OR FOOD CONTAINING A CAROTENOID
IL185713A IL185713A0 (en) 2005-03-18 2007-09-04 A recombinant fungus that produces a carotenoid and a method for producing carotenoids utilizing the same
ZA2007/07651A ZA200707651B (en) 2005-03-18 2007-09-05 Production of cartonoids in oleaginous yeast and fungi
NO20075200A NO20075200L (en) 2005-03-18 2007-10-11 Preparation of carotenoids in oily yeasts and fungi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66362105P 2005-03-18 2005-03-18
US60/663,621 2005-03-18

Publications (2)

Publication Number Publication Date
WO2006102342A2 true WO2006102342A2 (en) 2006-09-28
WO2006102342A3 WO2006102342A3 (en) 2007-10-11

Family

ID=37024534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/010271 WO2006102342A2 (en) 2005-03-18 2006-03-20 Production of carotenoids in oleaginous yeast and fungi

Country Status (15)

Country Link
US (3) US7851199B2 (en)
EP (2) EP2371967B1 (en)
JP (4) JP2008537878A (en)
KR (1) KR101482081B1 (en)
CN (2) CN103589650A (en)
AU (1) AU2006227165B2 (en)
BR (1) BRPI0609040B1 (en)
CA (1) CA2602183C (en)
EA (1) EA016258B1 (en)
ES (1) ES2546484T3 (en)
IL (1) IL185713A0 (en)
NO (1) NO20075200L (en)
UA (1) UA94038C2 (en)
WO (1) WO2006102342A2 (en)
ZA (1) ZA200707651B (en)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120423A2 (en) * 2006-03-20 2007-10-25 Microbia Precision Engineering Production of quinone derived compounds in oleaginous yeast and fungi
WO2008073367A1 (en) * 2006-12-12 2008-06-19 E. I. Du Pont De Nemours And Company Carotenoid production in a recombinant oleaginous yeast
WO2008042338A3 (en) * 2006-09-28 2008-10-02 Microbia Prec Engineering Production of carotenoids in oleaginous yeast and fungi
WO2009126890A3 (en) * 2008-04-10 2010-03-04 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi
JP2011520471A (en) * 2008-05-23 2011-07-21 サイバス オイルズ，エルエルシー Production of squalene using yeast
US8017375B2 (en) 2007-12-23 2011-09-13 Gevo, Inc. Yeast organism producing isobutanol at a high yield
WO2011133610A1 (en) 2010-04-22 2011-10-27 E. I. Du Pont De Nemours And Company Method for obtaining polyunsaturated fatty acid-containing compositions from microbial biomass
WO2012027689A1 (en) 2010-08-26 2012-03-01 E. I. Du Pont De Nemours And Company Recombinant microbial host cells for high eicosapentaenoic acid production
WO2012027676A1 (en) 2010-08-26 2012-03-01 E. I. Du Pont De Nemours And Company Mutant delta-9 elongases and their use in making polyunsaturated fatty acids
WO2012027698A1 (en) 2010-08-26 2012-03-01 E.I. Du Pont De Nemours And Company Mutant hpgg motif and hdash motif delta-5 desaturases and their use in making polyunsaturated fatty acids
WO2012134978A2 (en) 2011-04-01 2012-10-04 Ice House America, Llc Ice bagging apparatus and methods
WO2012135773A1 (en) 2011-03-31 2012-10-04 E. I. Du Pont De Nemours And Company Yarrowia diacylglycerol acyltransferase promoter regions for gene expression in yeast
WO2012135777A1 (en) 2011-04-01 2012-10-04 E. I. Du Pont De Nemours And Company Yarrowia esterase/lipase promoter regions for gene expression in yeast
WO2012138613A1 (en) 2011-04-05 2012-10-11 E. I. Du Pont De Nemours And Company Yarrowia n-alkane-hydroxylating cytochrome p450 promoter regions for gene expression in yeast
WO2012138612A1 (en) 2011-04-07 2012-10-11 E. I. Du Pont De Nemours And Company Yarrowia peroxisomal 2,4-dienoyl-coa reductase promoter regions for gene expression in yeast
US8431381B2 (en) 2007-10-26 2013-04-30 Suntory Holdings Limited ATP:citrate lyase genes
US8455239B2 (en) 2007-12-23 2013-06-04 Gevo, Inc. Yeast organism producing isobutanol at a high yield
US8481286B2 (en) 2008-08-12 2013-07-09 Allylix, Inc. Method for production of isoprenoid compounds
US8614077B2 (en) 2007-12-23 2013-12-24 Gevo, Inc. Recovery of higher alcohols from dilute aqueous solutions
CN104152473A (en) * 2014-08-18 2014-11-19 中国烟草总公司郑州烟草研究院 Tobacco carotenoid isomerase gene and is application
WO2014191205A1 (en) * 2013-05-28 2014-12-04 Wacker Chemie Ag Yeast strain and method for producing lycopene
US20150024009A1 (en) * 2009-08-26 2015-01-22 Organobalance Gmbh Genetically modified organism for the production of lipids
WO2015082688A1 (en) 2013-12-06 2015-06-11 Dsm Ip Assets B.V. Biomass formulation
WO2015116781A3 (en) * 2014-01-31 2015-11-19 Dsm Ip Assets B.V. Promoters suitable for heterologous gene expression in yeast
EP3219815A3 (en) * 2009-11-23 2017-11-22 Nucelis Inc. Methods and compositions for producing squalene using yeast
EP3286303A1 (en) * 2015-04-21 2018-02-28 DSM IP Assets B.V. Microbial production of terpenoids
US9909130B2 (en) 2005-03-18 2018-03-06 Dsm Ip Assets B.V. Production of carotenoids in oleaginous yeast and fungi
EP3234105A4 (en) * 2014-12-15 2018-05-16 Temasek Life Sciences Laboratory Limited Methods for tuning carotenoid production levels and compositions in rhodosporidium and rhodotorula genera
EP3460044A1 (en) * 2014-05-16 2019-03-27 Academia Sinica Recombinant polynucleotide sequence for producing astaxanthin and uses thereof
WO2019058000A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Biosynthesis of retinoids
WO2019057999A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Production of trans-retinal
WO2019058001A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Production of retinyl esters
WO2019057998A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Production of retinol
WO2019057996A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Production of retinyl esters
EP3400295A4 (en) * 2016-01-08 2019-09-04 DSM IP Assets B.V. Mating type switch in yarrowia lipolytica
WO2020141168A1 (en) 2018-12-31 2020-07-09 Dsm Ip Assets B.V. Novel acetyl-transferases
WO2021009194A1 (en) 2019-07-16 2021-01-21 Dsm Ip Assets B.V. Novel beta-carotene oxidases
WO2021019101A1 (en) 2019-08-01 2021-02-04 Dsm Ip Assets B.V. Beta-carotene fermentation method
WO2021136689A1 (en) 2019-12-30 2021-07-08 Dsm Ip Assets B.V. Lipase-modified strain
WO2022003130A2 (en) 2020-07-01 2022-01-06 Dsm Ip Assets B.V. Yeast expression system
WO2022023173A1 (en) 2020-07-27 2022-02-03 Dsm Ip Assets B.V. Reduction of fatty acid retinyl ester formation
WO2022090547A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Production of carotenoids by fermentation
WO2022090549A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. In situ two-phase extraction system
WO2022090548A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Fermentative production of isoprenoids
WO2023006851A1 (en) 2021-07-27 2023-02-02 Dsm Ip Assets B.V. Fermentative production of retinyl acetate in the presence of ethanol
WO2023006179A1 (en) 2020-07-27 2023-02-02 Dsm Ip Assets B.V. Method to produce retinyl acetate
WO2023067030A1 (en) 2021-10-19 2023-04-27 Dsm Ip Assets B.V. Retinoid production
WO2023148187A1 (en) 2022-02-02 2023-08-10 Dsm Ip Assets B.V. Yarrowia production process
WO2024160711A1 (en) 2023-01-30 2024-08-08 Dsm Ip Assets B.V. Carrp enzyme variants and their use in producing carotenoid and apocarotenoid
WO2024160712A1 (en) 2023-01-30 2024-08-08 Dsm Ip Assets B.V. Novel acetyl-transferases
WO2024160658A1 (en) 2023-01-30 2024-08-08 Dsm Ip Assets B.V. Novel mutants of acetyl-transferase sb-atf

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8577205B2 (en) * 1998-07-30 2013-11-05 Tivo Inc. Digital video recording system
EP1813111A2 (en) * 2004-11-19 2007-08-01 Tivo, Inc. Method and apparatus for secure transfer of previously broadcasted content
WO2007050607A2 (en) 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
MY154965A (en) 2007-06-01 2015-08-28 Solazyme Inc Production of oil in microorganisms
JP2009000046A (en) * 2007-06-21 2009-01-08 Hitachi Zosen Corp Gene encoding enzyme involved in mevalonic acid pathway of eucommia ulmoides oliver
WO2009006386A2 (en) * 2007-06-29 2009-01-08 The Regents Of The University Of California Host cells and methods for producing isoprenyl alkanoates
WO2009010826A2 (en) * 2007-07-13 2009-01-22 Ocean Nutrition Canada Ltd. Novel genes and methods of producing carotenoids
MX2010011065A (en) 2008-04-09 2010-12-06 Solazyme Inc Direct chemical modification of microbial biomass and microbial oils.
WO2010062707A1 (en) * 2008-10-30 2010-06-03 Joule Unlimited, Inc. Methods and compositions for producing carbon-based products of interest in micro-organisms
WO2010053636A1 (en) * 2008-11-06 2010-05-14 Tate & Lyle Technology Ltd Enhanced production and purification of a natural high intensity sweetener
SG171428A1 (en) * 2008-11-28 2011-07-28 Solazyme Inc Manufacturing of tailored oils in recombinant heterotrophic microorganisms
US20120034548A1 (en) 2009-05-01 2012-02-09 W. L. Gore & Associates, Co., Ltd. Gas diffusion layer for fuel cell
DK2443248T3 (en) 2009-06-16 2018-03-12 Du Pont IMPROVEMENT OF LONG-CHAIN POLYUM Saturated OMEGA-3 AND OMEGA-6 FATTY ACID BIOS SYNTHESIS BY EXPRESSION OF ACYL-CoA LYSOPHOSPHOLIPID ACYL TRANSFERASES
EP2575486B1 (en) 2010-05-28 2021-09-01 Corbion Biotech, Inc. Food compositions comprising tailored oils
KR101283149B1 (en) 2010-08-06 2013-07-05 문기혁 Development of medium and culture condition for mixed culture Lyophyllum cinerascens, Pleurotus ostreatus, Flammulina velutipes, Pleurotus eryngii etc with phaffia rhodozyma and Method for production of feed additive with astaxanthin having antioxidant effect.
US20120040076A1 (en) * 2010-08-11 2012-02-16 E. I. Du Pont De Nemours And Company Aquaculture feed compositions
EP3521408B1 (en) 2010-11-03 2021-12-22 Corbion Biotech, Inc. Genetically-engineered chlorella or prototheca microbe and oil produced therefrom
CN102071154B (en) * 2010-12-08 2013-05-22 江南大学 Alpha-ketoglutarate producing yeast engineering strain and construction method thereof
JP2014505472A (en) * 2010-12-30 2014-03-06 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Oil content increased by increasing YAP1 transcription factor activity in oleaginous yeast
JP2014508516A (en) * 2011-01-28 2014-04-10 アミリス， インコーポレイテッド Screening of microcolonies encapsulated in gel
KR101964965B1 (en) 2011-02-02 2019-04-03 테라비아 홀딩스 인코포레이티드 Tailored oils produced from recombinant oleaginous microorganisms
JP2014510524A (en) * 2011-02-28 2014-05-01 オルガノバランス ゲーエムベーハー Yeast cells and their use for the production of terpenes
WO2012154626A1 (en) 2011-05-06 2012-11-15 Solazyme, Inc. Genetically engineered microorganisms that metabolize xylose
CN102286593B (en) * 2011-07-08 2013-03-13 山东大学 Method for increasing phytoene dehydrogenase in vitro reaction rate
CN102250958B (en) * 2011-07-08 2013-01-02 山东大学 Method for quickly extracting carotenoid generated by in-vitro enzyme reaction
EA201400836A8 (en) 2012-01-23 2016-03-31 ДСМ АйПи АССЕТС Б.В. OBTAINING Diterpen
US10059974B2 (en) * 2012-02-06 2018-08-28 The Research Foundation Of The City University Of New York Cells and methods for producing lutein
EP2831628A2 (en) * 2012-03-30 2015-02-04 Koninklijke Philips N.V. Portable medical imager with gui interface comprising a motion sensor
US8916365B2 (en) 2012-04-03 2014-12-23 E I Du Pont De Nemours And Company Expression of cytosolic malic enzyme in transgenic Yarrowia to increase lipid production
SG10201702442RA (en) 2012-04-18 2017-05-30 Terravia Holdings Inc Tailored oils
EP2861728B1 (en) 2012-06-19 2017-12-27 E. I. du Pont de Nemours and Company Improved production of polyunsaturated fatty acids by coexpression of acyl-coa: lysophosphatidylcholine acyltransferases and phospholipid: diacylglycerol acyltransferases
AU2013289943B2 (en) * 2012-07-13 2017-06-08 Calysta Inc. Biorefinery system, methods and compositions thereof
US10738328B1 (en) 2012-11-27 2020-08-11 University Of Kentucky Research Foundation Method and system for terpene production platforms in yeast
CA2895298A1 (en) 2012-12-20 2014-06-26 Christopher Farrell Carotene hydroxylase and its use for producing carotenoids
CN105339490A (en) 2012-12-20 2016-02-17 帝斯曼知识产权资产管理有限公司 Acetyl transferases and their use for producing carotenoids
US9828609B2 (en) 2013-03-12 2017-11-28 International Park Of Creativity Biological devices and methods for increasing the production of lycopene from plants
BR112015022160A2 (en) 2013-03-15 2017-11-21 Dsm Ip Assets Bv genetically modified host cell, process for degrading the nucleic acids of a host cell in vivo and / or in situ, process for producing a biomass product that is free of active nucleic acid molecules, as well as use of a thermophilic nuclease
EP2993993A2 (en) 2013-04-26 2016-03-16 Solazyme, Inc. Low polyunsaturated fatty acid oils and uses thereof
JP2015027288A (en) * 2013-06-05 2015-02-12 ヴァーレ、ソシエダージ、アノニマＶａｌｅ Ｓ．Ａ． Method for obtaining copper nanoparticles from rhodotorula mucilaginosa, bioremediation of waste water, and usage of rhodotorula mucilaginosa in production of copper nanoparticles
CA2925527A1 (en) 2013-10-04 2015-04-09 Solazyme, Inc. Tailored oils
CN105316246B (en) * 2014-06-03 2019-10-01 上海来益生物药物研究开发中心有限责任公司 Beta carotene high-yield strains and its application
ES2764273T3 (en) 2014-07-10 2020-06-02 Corbion Biotech Inc Novel Ketoacyl ACP Synthase Genes and Their Use
CN104293874B (en) * 2014-09-23 2017-12-01 中国海洋大学 A kind of method for preparing free astaxanthin
JP6436417B2 (en) * 2014-12-01 2018-12-12 住友ゴム工業株式会社 Amorpha-4,11-diene production increase method and natural rubber production increase method
CN107109393B (en) 2014-12-09 2021-08-03 帝斯曼知识产权资产管理有限公司 Method for producing abienol
US10619170B2 (en) 2015-01-06 2020-04-14 Dsm Ip Assets B.V. CRISPR-CAS system for a yeast host cell
CN104673813B (en) * 2015-03-24 2017-07-28 武汉大学 A kind of ophiobolin class compound parent nucleus synthetic gene AuOS and its application
CN104962488B (en) * 2015-07-22 2019-03-05 天津大学 A kind of restructuring yeast strains and its construction method and application
CN105087406B (en) * 2015-07-22 2019-03-05 天津大学 A kind of restructuring yeast strains and its construction method and application
JP2019165635A (en) * 2016-08-10 2019-10-03 味の素株式会社 Method for producing L-amino acid
WO2018078014A1 (en) 2016-10-27 2018-05-03 Dsm Ip Assets B.V. Geranylgeranyl pyrophosphate synthases
CN106676019B (en) * 2016-11-28 2019-09-17 无锡新和源发酵技术研究院有限公司 A method of utilizing Production of Astaxanthin from Fermentation by Microorganisms
CN108118007A (en) * 2016-11-30 2018-06-05 上海医药工业研究院 A kind of method and its genetic engineering bacterium of genetic engineering bacterium production beta carotene
CN106858552B (en) * 2017-01-21 2020-07-31 湖北工业大学 Preparation method of olive paste rich in carotenoid
PT3574105T (en) 2017-01-25 2021-05-31 Amyris Bio Products Portugal Unipessoal Lda Co-production of a sesquiterpene and a carotenoid
CN107058526B (en) * 2017-03-21 2020-12-29 济南大学 Method for analyzing corn kernel carotenoid metabolic regulation and control mechanism based on dynamic association of gene pair co-expression mode
CN109234216B (en) * 2017-07-10 2022-05-20 上海医药工业研究院 Genetically engineered bacterium for producing squalene and method thereof
US11603549B2 (en) 2017-09-12 2023-03-14 Bio Capital Holdings, LLC Biological devices and methods of use thereof to produce carotenoids
WO2020060948A1 (en) 2018-09-17 2020-03-26 Levadura Biotechnology, Inc. Production of cannabinoids in yeast using a fatty acid feedstock
CN109536518A (en) * 2018-10-31 2019-03-29 昆明理工大学 A kind of Phytoene dehydrogenase gene RKcrtI and its application
CN111321156B (en) * 2018-12-14 2021-05-25 华中农业大学 Application of OsLUT1 gene in regulation and control of rice photoprotection
WO2020141206A1 (en) * 2019-01-03 2020-07-09 Corbion Biotech Inc. Process for manufacturing lysed cell suspension
CN109666683B (en) * 2019-02-27 2021-10-29 昆明理工大学 Acetyl coenzyme A acetyltransferase gene RKAcaT2 and application thereof
CN109777815B (en) * 2019-03-28 2021-10-29 昆明理工大学 HMG-CoA synthetase gene RKHMGCS and application thereof
CN110499259B (en) * 2019-07-22 2021-07-27 浙江工业大学 Yarrowia lipolytica YW100-1 and application thereof
CN110540952B (en) * 2019-09-09 2021-05-11 北京科技大学 Prokaryotic microorganism for producing lutein and application thereof in production of lutein
CN110747206B (en) * 2019-11-05 2021-11-23 昆明理工大学 3-hydroxy-3-methylglutaryl coenzyme A reductase gene RKHMGR and application thereof
CN111171129B (en) * 2020-03-09 2022-02-01 山东省农业科学院作物研究所 Lce mutant of key gene in wheat carotenoid synthetic pathway and application thereof
CN111454854B (en) * 2020-05-02 2022-05-06 昆明理工大学 Rhodosporidium toruloides gene engineering strain for producing astaxanthin
JP2023533969A (en) * 2020-07-08 2023-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Modified Yeast Host Cells Useful for Isoprenol Production
CN113151340B (en) * 2020-11-25 2023-03-24 广州智特奇生物科技股份有限公司 Genetic engineering bacterium for increasing yield of beta-carotene and application thereof
CN113308387B (en) * 2021-03-31 2023-01-03 南京工业大学 Bacterial strain for co-production of unsaturated fatty acid and carotenoid and application thereof
MX2023012090A (en) 2021-04-16 2024-02-07 Capra Biosciences Inc Methods of isoprenoid synthesis using a genetically engineered hydrocarbonoclastic organism in a biofilm bioreactor.
KR102600520B1 (en) * 2021-06-09 2023-11-09 씨제이제일제당 주식회사 Geranylgeranyl pyrophosphate synthase variant and method of producing tetraterpene, precursor thereof and compounds in which the precursor is tetraterpene using the variant
CN113621631A (en) * 2021-08-11 2021-11-09 昆明理工大学 Mevalonate kinase gene RKMK and application thereof
CN114540403B (en) * 2021-11-12 2024-04-05 嘉必优生物技术（武汉）股份有限公司 Method for producing esterified astaxanthin and use of esterified gene
IL314069A (en) * 2022-01-28 2024-09-01 Massachusetts Inst Technology Methods of producing carotenoids from acid whey
CN115029257B (en) * 2022-05-05 2023-09-26 南京工业大学 Recombinant yarrowia lipolytica for producing beta-carotene and construction method and application thereof
CN114806914B (en) * 2022-05-20 2024-01-30 南京工业大学 Yarrowia lipolytica capable of producing beta-carotene at high yield and application thereof
US20240216321A1 (en) 2022-12-02 2024-07-04 Dsm Ip Assets B.V. Fermentatively-produced retinoid containing compositions, and the methdos of making and using the same
CN118064533A (en) * 2023-07-04 2024-05-24 广东筑美生物医疗科技有限公司 Method for producing beta-carotene by enhancing yarrowia lipolytica

Family Cites Families (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ190194A (en) 1978-05-08 1982-02-23 Cpc International Inc Production of oil by fermenting yeast in fatty acids
US4318987A (en) * 1979-11-16 1982-03-09 Murillo Araujo Francisco J β-Carotene producing strains of the fungus phycomyces blakesleenus
EP0052777A1 (en) * 1980-11-20 1982-06-02 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Process for the extraction of beta-carotene from algae
US5071764A (en) * 1983-10-06 1991-12-10 Pfizer Inc. Process for integrative transformation of yarrowia lipolytica
IN163393B (en) 1983-10-06 1988-09-17 Pfizer
US4880741A (en) * 1983-10-06 1989-11-14 Pfizer Inc. Process for transformation of Yarrowia lipolytica
EP0166659B1 (en) 1984-06-26 1989-08-30 Institut National De La Recherche Agronomique (Inra) Transformation vector for yeast yarrowia lipolytica, transformation process and transformed yeast
EP0246324B1 (en) 1985-01-22 1993-01-27 Japan as represented by Director-General, Agency of Industrial Science and Technology Method for obtaining lipids from fungus bodies
US4680314A (en) * 1985-08-30 1987-07-14 Microbio Resources, Inc. Process for producing a naturally-derived carotene/oil composition by direct extraction from algae
US4937189A (en) * 1985-10-18 1990-06-26 Pfizer Inc. Expression and secretion of heterologous proteins by Yarrowia lipolytica transformants
US4851339A (en) * 1986-04-01 1989-07-25 Hills Christopher B Extraction of anti-mutagenic pigments from algae and vegetables
DK199887D0 (en) 1987-04-15 1987-04-15 Danisco Bioteknologi As yeast strain
US5356810A (en) * 1987-04-15 1994-10-18 Gist-Brocades N.V. Astaxanthin-producing yeast cells, methods for their preparation and their use
US5360730A (en) * 1987-06-05 1994-11-01 Universal Foods Corporation Zeaxanthin producing strains of Neospongiococcum Excentricum
US5182208A (en) 1988-08-08 1993-01-26 Igene Biotechnology, Inc. Processes for in vivo production of astaxanthin and phaffia rhodozyma yeast of enhanced astaxanthin content
JP2880545B2 (en) 1988-08-08 1999-04-12 アイジーン・バイオテクノロジイ・インコーポレイテッド Method for in vivo production of astaxanthin and Phaffia rhodozyma yeast increasing astaxanthin content
US5356809A (en) 1988-08-08 1994-10-18 Igene Biotechnology, Inc. Processes for in vivo production of astaxanthin and phaffia rhodozyma yeast of enhanced astaxanthin content
US6849434B2 (en) 1988-08-31 2005-02-01 University Of Florida Research Foundation, Inc. Ethanol production in recombinant hosts
JP2950888B2 (en) * 1989-04-21 1999-09-20 麒麟麦酒株式会社 DNA strands useful for carotenoid synthesis
US5429939A (en) * 1989-04-21 1995-07-04 Kirin Beer Kabushiki Kaisha DNA sequences useful for the synthesis of carotenoids
NZ232366A (en) 1989-07-28 1991-08-27 Igene Biotechnology Inc Production of astaxanthin and the enhancement of its content in yeast
EP0427405A1 (en) 1989-10-27 1991-05-15 Enzymatix Ltd. Yeasts and their use in astaxanthin production
US5164308A (en) * 1990-05-21 1992-11-17 Martek Corporation Preparation of labelled triglyceride oils by cultivation of microorganisms
US5306862A (en) 1990-10-12 1994-04-26 Amoco Corporation Method and composition for increasing sterol accumulation in higher plants
US5212088A (en) 1990-10-23 1993-05-18 Phillips Petroleum Company Spheroplast fusions of phaffia rhodozyma cells
US5460949A (en) * 1990-11-15 1995-10-24 Amoco Corporation Method and composition for increasing the accumulation of squalene and specific sterols in yeast
WO1992012711A1 (en) 1991-01-24 1992-08-06 Martek Corporation Microbial oil mixtures and uses thereof
WO1992021764A1 (en) 1991-06-06 1992-12-10 Kyowa Hakko Kogyo Co., Ltd. Process for producing astaxanthin by fermentation
JP3202018B2 (en) 1991-12-17 2001-08-27 ギスト ブロカデス ナムローゼ フェンノートシャップ Novel strain of Paffia rhodozima containing high concentration of astaxanthin and low concentration of 3-hydroxy-3 ', 4'-didehydro-β, Ψ-carotene-4-one (HDCO)
IL104736A0 (en) 1992-03-27 1993-06-10 Zeagen Inc Method for producing beta-carotene using a fungal mated culture
US5328845A (en) * 1992-03-27 1994-07-12 Universal Foods Corporation Fungal negative microorganism capable of producing high levels of beta-carotene
CN1079001A (en) * 1992-04-03 1993-12-01 吉斯特·布罗卡迪斯公司 The phycomyces of intersexuality heterozygosis (phycomyces)
EP0587872B1 (en) 1992-04-03 2000-05-31 Dsm N.V. Intersexual heterozygous phycomyces
NZ248628A (en) 1992-09-11 1996-02-27 Gist Brocades Nv Transformed phaffia (yeast) strains and methods and vectors used
US5310554A (en) * 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
FR2700552B1 (en) * 1993-01-19 1995-04-21 Pernod Ricard Mutants of Phaffia rhodozyma, process for producing beta-carotene and use of biomass rich in beta-carotene.
ZA94614B (en) * 1993-02-11 1994-08-12 Sasol Chem Ind Pty Solvent extraction
US5466599A (en) 1993-04-19 1995-11-14 Universal Foods Corporation Astaxanthin over-producing strains of phaffia rhodozyma
US5607839A (en) 1993-07-22 1997-03-04 Nippon Oil Company, Ltd. Bacteria belonging to new genus process for production of carotenoids using same
JPH08508892A (en) * 1993-09-02 1996-09-24 ファイザー・インク． Multiple integration vector and Yarrowia lipolytica transformant
US5792903A (en) * 1993-10-25 1998-08-11 Yissum Research Development Company Of Hebrew University Of Jerusalem Lycopene cyclase gene
CA2180024C (en) 1993-12-27 2002-03-19 Norihiko Misawa Dna chain useful for xanthophyll synthesis and process for producing xanthophylls
JPH07242621A (en) 1994-03-02 1995-09-19 Nippon Oil Co Ltd Method for extracting carotenoid compound
JP3198842B2 (en) * 1994-03-24 2001-08-13 トヨタ自動車株式会社 Geranylgeranyl diphosphate synthase and DNA encoding the same
JPH08173170A (en) 1994-05-25 1996-07-09 Kirin Brewery Co Ltd Transformation system of candida utilis yeast and expression of heterologous gene therewith
JP3087575B2 (en) 1994-07-29 2000-09-11 トヨタ自動車株式会社 Heptaprenyl diphosphate synthase and DNA encoding the same
CA2197187C (en) 1994-08-16 2007-03-27 Bernd Best Process for extracting native products which are not water-soluble from native substance mixtures by means of centrifugal force
WO1996006172A1 (en) 1994-08-23 1996-02-29 Kirin Beer Kabushiki Kaisha Keto group introducing enzyme, dna coding for the same, and process for producing ketocarotenoid
US5910433A (en) * 1994-08-23 1999-06-08 Kirin Beer Kabushiki Kaisha Keto group-introducing enzyme, DNA coding therefor and method for producing ketocarotenoids
JP3727077B2 (en) 1994-09-27 2005-12-14 新日本石油株式会社 Extraction method of carotenoid compounds from bacterial cells
WO1996012013A1 (en) 1994-10-14 1996-04-25 Novo Nordisk A/S A NOVEL ENZYME WITH β-1,3-GLUCANASE ACTIVITY
EP0812360A4 (en) 1995-01-11 2000-08-09 Human Genome Sciences Inc Human geranylgeranyl pyrophosphate synthetase
US5786193A (en) * 1995-01-11 1998-07-28 Human Genome Sciences, Inc. Human geranylgeranyl pyrophosphate synthethase
US5583019A (en) 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
JP3120684B2 (en) * 1995-02-14 2000-12-25 トヨタ自動車株式会社 Mutant farnesyl diphosphate synthase that synthesizes geranylgeranyl diphosphate and DNA encoding the same
JP3151371B2 (en) 1995-03-10 2001-04-03 麒麟麦酒株式会社 DNA strands useful for increasing carotenoid production
CA2218741A1 (en) 1995-04-21 1996-10-24 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
EP0747484A1 (en) 1995-06-08 1996-12-11 Institut National De La Recherche Agronomique (Inra) Upstream activator sequences and recombinant promoter sequences functional in yarrowia and vectors containing them
DE69631924T2 (en) 1995-06-09 2004-08-12 Dsm Ip Assets B.V. Fermentative production of carotenoids
JPH11512927A (en) 1995-08-17 1999-11-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Genes and proteins that regulate cholesterol synthesis
JP3538998B2 (en) * 1995-09-01 2004-06-14 トヨタ自動車株式会社 Long-chain prenyl diphosphate synthase
JPH09107974A (en) 1995-10-19 1997-04-28 Toyota Motor Corp Thermostable geranylgeranyl diphosphate synthetase
US5916791A (en) 1995-11-24 1999-06-29 Hirschberg; Joseph Polynucleotide molecule from Haematococcus pluvialis encoding a polypeptide having a β--C--4--oxygenase activity for biotechnological production of (3S,3S)astaxanthin
US6329141B1 (en) 1995-12-22 2001-12-11 Dsm N.V. Methods for transforming Phaffia strains, transformed Phaffia strains so obtained and recombinant DNA in said methods
IL116995A (en) 1996-02-01 2000-08-31 Univ Ben Gurion Procedure for large-scale production of astaxanthin from haematococcus
WO1997029114A1 (en) 1996-02-08 1997-08-14 Board Of Regents Of The University Of Washington Biotin-containing compounds, biotinylation reagents and methods
US6255505B1 (en) 1996-03-28 2001-07-03 Gist-Brocades, B.V. Microbial polyunsaturated fatty acid containing oil from pasteurised biomass
WO1997039114A1 (en) 1996-04-12 1997-10-23 Novo Nordisk A/S AN ENZYME WITH β-1,3-GLUCANASE ACTIVITY
EP0922109A1 (en) * 1996-05-21 1999-06-16 Novo Nordisk A/S Novel yeast promoters suitable for expression cloning in yeast and heterologous expression of proteins in yeast
US6174715B1 (en) 1996-06-14 2001-01-16 Toyota Jidosha Kabushiki Kaisha Prenyl diphosphate synthetase genes
JP3209103B2 (en) 1996-07-03 2001-09-17 トヨタ自動車株式会社 Mutant prenyl diphosphate synthase
JP3379344B2 (en) 1996-07-24 2003-02-24 トヨタ自動車株式会社 Farnesyl diphosphate synthase
US6503729B1 (en) 1996-08-22 2003-01-07 The Board Of Trustees Of The University Of Illinois Selected polynucleotide and polypeptide sequences of the methanogenic archaeon, methanococcus jannashii
DE69739981D1 (en) 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae antigens and vaccines
JP3376838B2 (en) 1996-11-05 2003-02-10 トヨタ自動車株式会社 Prenyl diphosphate synthase
DK0872554T3 (en) 1996-12-02 2003-08-25 Hoffmann La Roche Improved carotenoid production by fermentation
ATE327340T1 (en) 1997-02-20 2006-06-15 Dsm Ip Assets Bv FERMENTATIVE PRODUCTION OF RECYCLABLE MATERIALS ON AN INDUSTRIAL SCALE BY USING CHEMICALLY DEFINED MEDIA
WO1998039468A1 (en) 1997-03-04 1998-09-11 Suntory Limited Process for preparing highly unsaturated fatty acid and lipid containing highly unsaturated fatty acid
US6131086A (en) 1997-04-02 2000-10-10 Walker Digital, Llc Method and system for allowing viewers to purchase program products
US5858700A (en) 1997-04-03 1999-01-12 Kemin Foods, Lc Process for the isolation and purification of lycopene crystals
US5968809A (en) 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
ES2337530T3 (en) 1997-05-02 2010-04-26 Dsm Ip Assets B.V. INSULATION OF CAROTENOID CRYSTALS FROM MICROBIAL BIOMASS.
CN1268178A (en) 1997-05-06 2000-09-27 人体基因组科学有限公司 Enterococcus faecalis polynucleotides and polypeptides
DE69834246T2 (en) 1997-06-05 2007-02-01 Calgene Llc, Davis FAT ACYL-COA: FAT ALCOHOL O-ACYL TRANSFERASES
EP1009859A1 (en) 1997-06-20 2000-06-21 Human Genome Sciences Lyme disease vaccines
US5935808A (en) 1997-07-29 1999-08-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Carotenoid-producing bacterial species and process for production of carotenoids using same
WO1999006585A1 (en) 1997-08-01 1999-02-11 Martek Biosciences Corporation Dha-containing nutritional compositions and methods for their production
AU3749199A (en) 1998-04-24 1999-11-16 E.I. Du Pont De Nemours And Company Carotenoid biosynthesis enzymes
US6600089B1 (en) 1998-04-24 2003-07-29 E. I. Du Pont De Nemours And Company Carotenoid biosynthesis enzymes
TWI250210B (en) 1998-05-06 2006-03-01 Dsm Ip Assets Bv An isolated DNA sequence coding for an enzyme involved in the mevalonate pathway or the pathway from isopentenyl pyrophosphate to farnesyl pyrophosphate
DE19821009A1 (en) 1998-05-11 1999-11-18 Siegfried Peter Extraction of carotenes useful as antioxidants and natural colorants in food
CA2333281A1 (en) 1998-05-22 1999-12-02 University Of Maryland Carotenoid ketolase genes and gene products, production of ketocarotenoids and methods of modifying carotenoids using the genes
US20020012979A1 (en) 1998-06-08 2002-01-31 Alan Berry Vitamin c production in microorganisms and plants
ES2379212T3 (en) 1998-07-06 2012-04-23 Dcv Inc. Doing Business As Bio-Technical Resourses Vitamin Production Procedure
EP2305825B1 (en) * 1998-07-06 2015-01-14 DCV Inc. doing business as Bio-Technical Resourses Method of vitamin production
AU4794199A (en) 1998-07-23 2000-02-14 Genset A nucleic acid encoding a geranyl-geranyl pyrophosphate synthetase (ggpps) and polymorphic markers associated with said nucleic acid
EP0982404A1 (en) 1998-08-27 2000-03-01 Wallaart, Thorvald Eelco DNA encoding amorpha-4,11-diene synthase
FR2782733B1 (en) 1998-09-01 2002-02-08 Agronomique Inst Nat Rech NON-APPROVED PROCESS OF YARROWIA LIPOLYTICA
US6166231A (en) 1998-12-15 2000-12-26 Martek Biosciences Corporation Two phase extraction of oil from biomass
DE69924005T2 (en) 1998-12-22 2006-04-13 National Research Council Canada, Ottawa TRANSGENIC PLANTS WITH CONDITIONAL LETHAL GEN
AU773353B2 (en) 1998-12-22 2004-05-20 Dow Agrosciences Llc Methods and genetic compositions to limit outcrossings and undesired gene flow in crop plants
JP4307609B2 (en) 1999-02-10 2009-08-05 株式会社カネカ Method for producing coenzyme Q10
DE19909637A1 (en) 1999-03-05 2000-09-07 Peter Beyer Process for improving the agronomic value and nutritional properties of plants
DK1035206T3 (en) 1999-03-09 2004-02-16 Hoffmann La Roche Astaxanthin synthetase
DE19916140A1 (en) 1999-04-09 2000-10-12 Basf Ag Carotene hydroxylase and process for the preparation of xanthophyll derivatives
NO309386B1 (en) 1999-04-19 2001-01-22 Norsk Hydro As Pigment
FR2792651B1 (en) 1999-04-21 2005-03-18 Centre Nat Rech Scient GENOMIC SEQUENCE AND POLYPEPTIDES OF PYROCOCCUS ABYSSI, THEIR FRAGMENTS AND USES THEREOF
DE19919751A1 (en) 1999-04-29 2000-11-09 Basf Ag Stable, aqueous dispersions and stable, water-dispersible dry powder of xanthophylls, their preparation and use
WO2000078935A1 (en) 1999-06-22 2000-12-28 Smithkline Beecham Corporation Mevalonate pathway genes
ES2157166B1 (en) 1999-08-12 2002-02-16 Antibioticos Sau PROCEDURE FOR OBTAINING LICOPEN.
SE9903336D0 (en) 1999-09-17 1999-09-17 Astacarotene Ab DNA construct and its use
CA2324625C (en) 1999-12-01 2011-09-27 F. Hoffmann-La Roche Ag Recombinant production of carotenoids, particularly astaxanthin
US20020051998A1 (en) 1999-12-08 2002-05-02 California Institute Of Technology Directed evolution of biosynthetic and biodegradation pathways
US20030157592A1 (en) 1999-12-16 2003-08-21 Jens Lerchl Moss genes from physcomitrella patens encoding proteins involved in the synthesis of tocopherols and carotenoids
CA2394414A1 (en) 1999-12-16 2001-06-21 Basf Plant Science Gmbh Moss genes from physcomitrella patens encoding proteins involved in the synthesis of tocopherols carotenoids
GB2358862B (en) 1999-12-21 2004-07-21 Fermentron Ltd Processes for Extracting Carotenoids from Biomass Carotenoid Sources
CN1423693A (en) 1999-12-24 2003-06-11 辛根塔参与股份公司 Method for the production of vitamin A
KR20080007279A (en) 2000-01-19 2008-01-17 마텍 바이오싸이언스스 코포레이션 Solventless extraction process
WO2001055100A1 (en) 2000-01-27 2001-08-02 Dsm N.V. Isolation of carotenoid crystals
EP1268752A4 (en) 2000-03-07 2004-06-30 Cargill Inc Production of lutein in microorganisms
KR100388110B1 (en) 2000-05-04 2003-06-18 해태제과식품주식회사 Process for extracting astaxanthin pigment from yeast and extracted pigment thereof
ID30360A (en) 2000-05-24 2001-11-29 Hoffmann La Roche PROCESS FOR ASTAKANTANTIN
JP4427167B2 (en) 2000-06-12 2010-03-03 新日本石油株式会社 Production of carotenoid pigments
ES2168971B1 (en) 2000-07-19 2003-11-01 Antibioticos Sau BETA-CAROTENE PRODUCTION PROCEDURE.
US6807568B1 (en) 2000-07-27 2004-10-19 Union Beach, L.P. Recipient selection of information to be subsequently delivered
US20030033626A1 (en) 2000-07-31 2003-02-13 Hahn Frederick M. Manipulation of genes of the mevalonate and isoprenoid pathways to create novel traits in transgenic organisms
US6818424B2 (en) 2000-09-01 2004-11-16 E. I. Du Pont De Nemours And Company Production of cyclic terpenoids
US6660507B2 (en) 2000-09-01 2003-12-09 E. I. Du Pont De Nemours And Company Genes involved in isoprenoid compound production
AU8791701A (en) 2000-09-22 2002-04-02 Mars Uk Ltd Food supplement
WO2002026933A2 (en) 2000-09-29 2002-04-04 Cargill Incorporated Isoprenoid production
US6645767B1 (en) * 2000-10-03 2003-11-11 Carnegie Mellon University Cells engineered to contain genes of interest without expressed bacterial sequences and materials and methods therefor
US20050260699A1 (en) 2000-11-22 2005-11-24 Desouza Mervyn L Carotenoid biosynthesis
WO2002053747A1 (en) 2000-12-28 2002-07-11 Toyota Jidosha Kabushiki Kaisha Process for producing prenyl alcohol
JP2002253284A (en) * 2000-12-28 2002-09-10 Toyota Motor Corp Method for producing geranylgeraniol and analogous compound thereof by microorganism
JP3838033B2 (en) 2000-12-28 2006-10-25 トヨタ自動車株式会社 Method for producing prenyl alcohol
JP4013535B2 (en) 2000-12-28 2007-11-28 トヨタ自動車株式会社 High production method of prenyl alcohol by microorganisms
EP1354955A4 (en) 2000-12-28 2005-01-05 Toyota Motor Co Ltd Process for producing prenyl alcohol
US7238514B2 (en) * 2001-01-05 2007-07-03 William Marsh Rice University Diterpene-producing unicellular organism
JP2002209574A (en) 2001-01-19 2002-07-30 Kanegafuchi Chem Ind Co Ltd Gene-broken yeast
AU2002227884A1 (en) 2001-01-25 2002-08-06 Evolva Biotech A/S A method for evolving a cell having desired phenotype and envolved cells
JP2004525624A (en) 2001-01-25 2004-08-26 エボルバ バイオテック アクティーゼルスカブ Cell collection library
US20050003474A1 (en) 2001-01-26 2005-01-06 Desouza Mervyn L. Carotenoid biosynthesis
WO2002079395A2 (en) 2001-01-26 2002-10-10 Cargill, Incorporated Carotenoid biosynthesis
US20040078846A1 (en) 2002-01-25 2004-04-22 Desouza Mervyn L. Carotenoid biosynthesis
US20070020625A1 (en) 2001-02-07 2007-01-25 Eric Duchaud Sequence of the photorhabdus luminescens strain tt01 genome and uses
US20030207947A1 (en) 2001-03-07 2003-11-06 Desouza Mervyn L. Production of lutein in microorganisms
EP1379666A2 (en) 2001-03-08 2004-01-14 Arnau, José Recombinant dimorphic fungal cell
US20030134353A1 (en) 2001-03-08 2003-07-17 Bioteknologisk Institut Recombinant dimorphic fungal cell
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
JP2002345469A (en) 2001-04-25 2002-12-03 Kanegafuchi Chem Ind Co Ltd Method for producing coenzyme q10
ITMI20011019A1 (en) 2001-05-17 2002-11-17 Carlo Ghisalberti FURILIC SUBSTANCES FOR TOPICAL USE
US6989257B2 (en) 2001-06-06 2006-01-24 Dsm Ip Assets B.V. Isoprenoid production
US7252964B2 (en) 2001-06-12 2007-08-07 Institut De Recherche Pour Le Developpement (I.R.D.) Isolated carotenoid biosynthesis gene cluster involved in canthaxanthin production and applications thereof
JPWO2003000902A1 (en) 2001-06-21 2004-10-21 独立行政法人 科学技術振興機構 Aphidicolin biosynthesis gene cluster
US6984523B2 (en) 2001-08-02 2006-01-10 E.I. Du Pont De Nemours And Company Carotenoid ketolase gene
US20030148319A1 (en) * 2001-08-15 2003-08-07 Brzostowicz Patricia C. Genes encoding carotenoid compounds
KR100564504B1 (en) 2001-08-23 2006-03-29 디에스엠 아이피 어셋츠 비.브이. Novel stabilized carotenoid compositions
US7635798B2 (en) 2001-08-31 2009-12-22 Dow Agrosciences, Llc Nucleic acid compositions conferring altered metabolic characteristics
US6797303B2 (en) 2001-09-04 2004-09-28 Lycored Natural Products Industries Ltd. Carotenoid extraction process
US20040077068A1 (en) * 2001-09-04 2004-04-22 Brzostowicz Patricia C. Carotenoid production from a single carbon substrate
US20030054070A1 (en) 2001-09-07 2003-03-20 Aquasearch, Inc. Edible solvent extraction of carotenoids from microorganisms
DE10145043A1 (en) 2001-09-13 2003-04-03 Degussa Process and manufacture of fine chemicals
WO2003027293A1 (en) 2001-09-26 2003-04-03 Vitatene, S.A. Biosynthetic genes of blakeslea trispora beta-carotene that code for lycopene cyclase/phytoene synthase (carrp) and phytoene dehydrogenase (carb)
US7196189B2 (en) 2001-10-09 2007-03-27 Microbia, Inc. love variant regulator molecules
US7026460B2 (en) 2001-10-09 2006-04-11 Microbia, Inc. lovE variant regulator molecules
RU2211862C2 (en) 2001-10-29 2003-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (-)-strain of heterothallic phycomycetus blakeslea trispora producing lycopin in pair with different (+)-strains of blakeslea trispora and method for micribiological synthesis of lycopin
DE50207335D1 (en) * 2001-11-05 2006-08-03 Dorma Gmbh & Co Kg HARDWARE SYSTEM
IL146449A0 (en) 2001-11-12 2002-07-25 Lycored Natural Prod Ind Ltd Method and pharmaceutical preparations for reducing the activity of cells
US7063955B2 (en) 2001-11-20 2006-06-20 E. I. Du Pont De Nemours And Company Method for production of asymmetric carotenoids
EP1318192A2 (en) 2001-12-06 2003-06-11 greenovation Biotech GmbH Prenyltransferase from Arabidopsis
ES2195758B1 (en) 2001-12-31 2005-03-01 Antibioticos, S.A.U. IMPROVED LICOPENO PRODUCTION PROCEDURE THROUGH THE FERMENTATION OF SELECTED BLISES OF BLAKESLEA TRISPORA, FORMULATIONS AND USES OF THE LICOPENO OBTAINED.
WO2003062416A1 (en) 2002-01-21 2003-07-31 Takeda Chemical Industries, Ltd. Method of screening preventive and remedy for arteriosclerosis
DE60324385D1 (en) 2002-01-25 2008-12-11 Evolva Ag SCREENING METHODS FOR MULTIPLE PARAMETERS AND DEVELOPMENT OF CELLS TO PRODUCE SMALL MOLECULES WITH MULTIPLE FUNCTIONALITIES
ES2195766B1 (en) 2002-01-29 2005-04-01 Antibioticos, S.A.U. BETA-CAROTENE PRODUCTION PROCEDURE FOR FERMENTATION IN MIXED CULTURE USING BLAPESLEA TRISPORA (+) 4 (-).
KR20040078543A (en) 2002-01-31 2004-09-10 간사이 티.엘.오 가부시키가이샤 Compositions for preventing human cancer and method of preventing human cancer
EP1474388B2 (en) 2002-02-06 2013-03-06 DSM IP Assets B.V. Astaxanthin esters
US7105634B2 (en) 2002-02-11 2006-09-12 E. I. Du Pont De Nemours And Company Genetic constructs encoding carotenoid biosynthetic enzymes
US20060068386A1 (en) 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
EP1510583A1 (en) 2002-05-10 2005-03-02 Kyowa Hakko Kogyo Co., Ltd. Process for producing mevalonic acid
WO2003097798A2 (en) 2002-05-14 2003-11-27 Martek Biosciences Corporation Carotene synthase gene and uses therefor
MXPA04012062A (en) 2002-06-21 2005-03-07 Dsm Ip Assets Bv Process for producing carotenoids.
DE10234126A1 (en) 2002-07-26 2004-02-05 Basf Ag Process for the biotransformation of carotenoids
US20050049248A1 (en) 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
WO2004011423A2 (en) 2002-07-29 2004-02-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
AU2003247270A1 (en) 2002-08-01 2004-03-03 Evolva Ltd Methods of mixing large numbers of heterologous genes
CA2496207A1 (en) 2002-08-20 2004-03-04 Sungene Gmbh & Co. Kgaa Method for the production of zeaxanthin and/or the biosynthetic intermediates and/or subsequent products thereof
WO2004022765A2 (en) 2002-08-20 2004-03-18 Sungene Gmbh & Co. Kgaa Method for hydrolysing carotenoids esters
AU2003258622A1 (en) 2002-08-20 2004-03-11 Sungene Gmbh And Co. Kgaa Method for the production of $g(b)-carotinoids
US20060121587A1 (en) 2002-09-27 2006-06-08 Tatsuo Hoshino Process for actinol production from ketoisophorone
AU2003267371A1 (en) 2002-09-27 2004-04-19 Dsm Ip Assets B.V. Production of canthaxanthin by phaffia
AU2003277902A1 (en) 2002-09-27 2004-04-19 Dsm Ip Assets B.V. Acc gene
US20060121557A1 (en) 2002-09-27 2006-06-08 Tatsuo Hoshino Production of zeaxanthin by phaffia
EP1543115B1 (en) 2002-09-27 2008-05-07 DSM IP Assets B.V. Squalene synthase (sqs) gene
CN1703392A (en) 2002-10-25 2005-11-30 普罗德麦克斯公司 Method for producing esterified astaxanthin from esterified zeaxanthin
AU2003297563A1 (en) 2002-11-25 2004-06-18 Cargill, Incorporated Production of ubiquinones
US20040219629A1 (en) 2002-12-19 2004-11-04 Qiong Cheng Increasing carotenoid production in bacteria via chromosomal integration
US7232665B2 (en) 2002-12-19 2007-06-19 E. I. Du Pont De Nemours And Company Mutations affecting carotenoid production
US7252942B2 (en) 2002-12-19 2007-08-07 E.I. Du Pont De Nemours And Company Parallel chromosomal stacking of traits in bacteria
UA55331C2 (en) 2002-12-23 2006-07-17 Товариство З Обмеженою Відповідальністю "Науково-Виробниче Підприємство "Вітан" A STRAIN (ТКSТ) BLAKESLEA TRISPORA ІМВ F-100022 PRODUCER OF 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--CAROTENE
EP1592784A1 (en) 2003-01-09 2005-11-09 Basf Aktiengesellschaft Method for the genetic modification of organisms of the genus blakeslea, corresponding organisms, and the use of the same
KR20050092739A (en) * 2003-01-09 2005-09-22 바스프 악티엔게젤샤프트 Method for producing carotenoids or their precursors using genetically modified organisms of the blakeslea genus, cartotenoids or their precursors produced by said method and use thereof
DE10300649A1 (en) 2003-01-09 2004-07-22 Basf Ag Process for the production of ketocarotenoids by cultivating genetically modified organisms
WO2004067709A2 (en) 2003-01-17 2004-08-12 Elitra Pharmaceuticals, Inc. Identification of essential genes of aspergillus fumigatus and methods of use
WO2004065555A2 (en) * 2003-01-17 2004-08-05 E.I. Du Pont De Nemours And Company Regulator/promoter for tunable gene expression and metabolite sensing
EP1591531B1 (en) * 2003-01-22 2016-03-23 Showa Denko K.K. Process for acyl-transfer enzyme reactions with acyl- coenzyme a
WO2004070035A2 (en) 2003-02-03 2004-08-19 Sungene Gmbh & Co. Kgaa Method for increasing efficiency of homologous recombination in plants
BRPI0407514A (en) 2003-02-17 2006-02-14 Metanomics Gmbh method for preparing a non-human organism, polynucleotide, method for preparing a vector, vector, host cell, polypeptide, antibody, antisense polynucleic acid, method for preparing a plant, plant cell, transgenic plant tissue, useful animal cell , useful animal or a transgenic microorganism non-human organism, transgenic microorganism, yield or a propagating material of a useful plant or animal, biomass of a microorganism, method for preparing fine chemicals, and, use of polypeptide
WO2004074490A2 (en) 2003-02-24 2004-09-02 Genoclipp Biotechnology B.V. Method for transforming blakeslea strains
WO2005014828A2 (en) 2003-08-01 2005-02-17 Basf Plant Science Gmbh Process for the production of fine chemicals in plants
AU2004235800B2 (en) 2003-05-05 2010-02-18 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
US7238482B2 (en) * 2003-05-07 2007-07-03 E. I. Du Pont De Nemours And Company Production of polyunsaturated fatty acids in oleaginous yeasts
US7125672B2 (en) * 2003-05-07 2006-10-24 E. I. Du Pont De Nemours And Company Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts
US7214491B2 (en) 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
US8313911B2 (en) * 2003-05-07 2012-11-20 E I Du Pont De Nemours And Company Production of polyunsaturated fatty acids in oleaginous yeasts
US7070952B2 (en) 2003-05-07 2006-07-04 E. I. Du Pont Nemours And Company Genes encoding carotenoid compounds
US7064196B2 (en) * 2003-05-20 2006-06-20 E. I. Du Pont De Nemours And Company Genes encoding carotenoid compounds
US20040234579A1 (en) 2003-05-22 2004-11-25 Mark D. Finke, Inc. Dietary supplements and methods of preparing and administering dietary supplements
US6929928B2 (en) * 2003-06-12 2005-08-16 E. I. Du Pont De Nemours And Company Genes encoding carotenoid compounds
DE602004020218D1 (en) 2003-06-12 2009-05-07 Dsm Ip Assets Bv FEEDBACK RESISTANT MEVALONATE KINASE
US7259255B2 (en) 2003-06-25 2007-08-21 E. I. Du Pont De Nemours And Company Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase promoters for gene expression in oleaginous yeast
US7132257B2 (en) 2003-07-10 2006-11-07 E. I. Du Pont De Nemours And Company Production or aromatic carotenoids in gram negative bacteria
EP1646713A2 (en) 2003-07-17 2006-04-19 E.I. Dupont De Nemours And Company Genes encoding carotenoid compounds
ES2308198T3 (en) 2003-07-17 2008-12-01 University Of Dundee METHODS FOR THE USE OF A COMPLEX LKB1 / STRAD / MO25.
EP1684776A1 (en) 2003-07-25 2006-08-02 Washington State University Research Foundation Natural astaxanthin extract reduces dna oxidation
DE102004007622A1 (en) 2004-02-17 2005-08-25 Sungene Gmbh & Co. Kgaa Preparation of ketocarotenoids, useful in foods and animal feeds, by growing genetically modified organism that has altered activity of ketolase and beta-cyclase
US20050071747A1 (en) * 2003-09-28 2005-03-31 Denny Jaeger Method and apparatus for performing multimedia operations
US7202356B2 (en) * 2003-11-14 2007-04-10 E. I. Du Pont De Nemours And Company Fructose-bisphosphate aldolase regulatory sequences for gene expression in oleaginous yeast
US7262257B2 (en) * 2004-02-17 2007-08-28 The Penn State Research Foundation Telechelic polymers containing reactive functional groups
WO2005085415A1 (en) * 2004-03-04 2005-09-15 Kaneka Corporation Novel transformant and process for producing polyester by using the same
JP2006134855A (en) 2004-03-11 2006-05-25 Nissan Motor Co Ltd Separator for fuel cell, fuel cell stack, fuel cell vehicle, and manufacturing method of separator for fuel cell
US7598521B2 (en) * 2004-03-29 2009-10-06 Sanyo Electric Co., Ltd. Semiconductor device in which the emitter resistance is reduced
JP4340186B2 (en) 2004-04-15 2009-10-07 カナレ電気株式会社 Adapter unit and optical plug
JP2005301156A (en) 2004-04-15 2005-10-27 Sony Corp Inspection method and apparatus for mask defect, and method for creating reference for mask inspection
JP4212509B2 (en) 2004-04-15 2009-01-21 シャープ株式会社 Liquid crystal display
JP2005301154A (en) 2004-04-15 2005-10-27 Canon Inc Image forming apparatus
JP2005301157A (en) 2004-04-15 2005-10-27 Toyoda Gosei Co Ltd Planar illuminant
JP4464184B2 (en) 2004-04-15 2010-05-19 キヤノン株式会社 Optical filter
JP2005301149A (en) 2004-04-15 2005-10-27 Ricoh Co Ltd Image forming method and image forming apparatus
JP2005301153A (en) 2004-04-15 2005-10-27 Canare Electric Co Ltd Plug
JP4120940B2 (en) 2004-04-15 2008-07-16 ソニー株式会社 Lens barrel and imaging device
JP4428121B2 (en) 2004-04-15 2010-03-10 凸版印刷株式会社 Pattern forming method and pattern forming apparatus
JP2005301148A (en) 2004-04-15 2005-10-27 Fuji Photo Film Co Ltd Heat developable photosensitive material
JP2005301151A (en) 2004-04-15 2005-10-27 Canare Electric Co Ltd Optical contact unit and optical plug
JP2005301150A (en) 2004-04-15 2005-10-27 Ricoh Co Ltd Image forming method and image forming apparatus
US7260790B2 (en) 2004-04-27 2007-08-21 International Business Machines Corporation Integrated circuit yield enhancement using Voronoi diagrams
US20050266132A1 (en) 2004-06-01 2005-12-01 Feral Temelli Supercritical carbon dioxide extraction of carotenoids from natural materials using a continuous co-solvent
US7908445B2 (en) 2004-07-19 2011-03-15 Infortrend Technology, Inc. Redundant controller dynamic logical media unit reassignment
BRPI0403102A (en) 2004-07-26 2006-03-07 Ricardo Ernesto Levy pantographic winery
WO2006014837A1 (en) 2004-07-27 2006-02-09 The Regents Of The University Of California Genetically modified host cells and use of same for producing isoprenoid compounds
JP4559151B2 (en) 2004-07-29 2010-10-06 富士通株式会社 Termination circuit, semiconductor device, and electronic device
US7145380B2 (en) 2004-09-27 2006-12-05 Etron Technology, Inc. Low power consumed and small circuit area occupied temperature sensor
US20090176287A1 (en) 2005-02-24 2009-07-09 Regents Of The University Of Minnesota Producing carotenoids
WO2006096392A2 (en) 2005-03-04 2006-09-14 Diversa Corporation Enzymes involved in astaxanthin, carotenoid and isoprenoid biosynthetic pathways, genes encoding them and methods of making and using them
JP2006008714A (en) 2005-03-17 2006-01-12 Yamaha Motor Co Ltd Matrix metalloproteinase inhibitor
EP2371967B1 (en) 2005-03-18 2015-06-03 DSM IP Assets B.V. Production of carotenoids in oleaginous yeast and fungi
JP2006008712A (en) 2005-03-24 2006-01-12 Yamaha Motor Co Ltd Neovascularization inhibitor
JP2006008713A (en) 2005-03-24 2006-01-12 Yamaha Motor Co Ltd Vascular endothelial cell growth inhibitor
JP2006008715A (en) 2005-05-17 2006-01-12 Yamaha Motor Co Ltd Phospholipase a2 inhibitor
JP2006008716A (en) 2005-05-20 2006-01-12 Yamaha Motor Co Ltd Lipoxygenase inhibitor
JP2006008717A (en) 2005-05-31 2006-01-12 Yamaha Motor Co Ltd Interleukin inhibitor
JP2006008718A (en) 2005-06-03 2006-01-12 Yamaha Motor Co Ltd Cyclooxygenase activity inhibitor
JP2006016407A (en) 2005-06-15 2006-01-19 Yamaha Motor Co Ltd Phosphodiesterase inhibitor
KR100664065B1 (en) 2005-06-20 2007-01-03 엘지전자 주식회사 Structure for fixing magnet of spm type motor
JP2006016408A (en) 2005-06-23 2006-01-19 Yamaha Motor Co Ltd Agent for reducing neutral fat in blood
JP2006008719A (en) 2005-06-23 2006-01-12 Yamaha Motor Co Ltd Blood peroxidized-lipid inhibitor
JP2006016409A (en) 2005-06-28 2006-01-19 Yamaha Motor Co Ltd Fatigue recovery agent
JP2006022121A (en) 2005-07-04 2006-01-26 Yamaha Motor Co Ltd Atopic dermatitis retarder
JP2006008720A (en) 2005-07-06 2006-01-12 Yamaha Motor Co Ltd Renal function-improving agent
WO2007095007A2 (en) 2006-02-14 2007-08-23 Albert Einstein College Of Medicine Of Yeshiva University Systematic genomic library and uses thereof
WO2008042338A2 (en) 2006-09-28 2008-04-10 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi
US8846374B2 (en) 2006-12-12 2014-09-30 E I Du Pont De Nemours And Company Carotenoid production in a recombinant oleaginous yeast
US8173405B2 (en) 2006-12-13 2012-05-08 William Marsh Rice University Nerolidol, terpene, and terpene deriviative synthesis
WO2009010826A2 (en) 2007-07-13 2009-01-22 Ocean Nutrition Canada Ltd. Novel genes and methods of producing carotenoids
US20120149886A1 (en) 2008-04-10 2012-06-14 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9909130B2 (en) 2005-03-18 2018-03-06 Dsm Ip Assets B.V. Production of carotenoids in oleaginous yeast and fungi
WO2007120423A2 (en) * 2006-03-20 2007-10-25 Microbia Precision Engineering Production of quinone derived compounds in oleaginous yeast and fungi
WO2007120423A3 (en) * 2006-03-20 2008-05-29 Microbia Prec Engineering Production of quinone derived compounds in oleaginous yeast and fungi
US8633009B2 (en) 2006-03-20 2014-01-21 Dsm Ip Assets B.V. Production of quinone derived compounds in oleaginous yeast and fungi
WO2008042338A3 (en) * 2006-09-28 2008-10-02 Microbia Prec Engineering Production of carotenoids in oleaginous yeast and fungi
US8691555B2 (en) 2006-09-28 2014-04-08 Dsm Ip Assests B.V. Production of carotenoids in oleaginous yeast and fungi
US9297031B2 (en) 2006-09-28 2016-03-29 Dsm Ip Assets B.V. Production of carotenoids in oleaginous yeast and fungi
WO2008073367A1 (en) * 2006-12-12 2008-06-19 E. I. Du Pont De Nemours And Company Carotenoid production in a recombinant oleaginous yeast
US8846374B2 (en) 2006-12-12 2014-09-30 E I Du Pont De Nemours And Company Carotenoid production in a recombinant oleaginous yeast
US8431381B2 (en) 2007-10-26 2013-04-30 Suntory Holdings Limited ATP:citrate lyase genes
RU2534560C2 (en) * 2007-10-26 2014-11-27 Сантори Холдингз Лимитед New atp:citrate liase genes
US8017375B2 (en) 2007-12-23 2011-09-13 Gevo, Inc. Yeast organism producing isobutanol at a high yield
US9926577B2 (en) 2007-12-23 2018-03-27 Gevo, Inc. Yeast organism producing isobutanol at a high yield
US8455239B2 (en) 2007-12-23 2013-06-04 Gevo, Inc. Yeast organism producing isobutanol at a high yield
US8614077B2 (en) 2007-12-23 2013-12-24 Gevo, Inc. Recovery of higher alcohols from dilute aqueous solutions
US20120149886A1 (en) * 2008-04-10 2012-06-14 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi
WO2009126890A3 (en) * 2008-04-10 2010-03-04 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi
JP2017140037A (en) * 2008-05-23 2017-08-17 ニューセリス インコーポレイテッド Production of squalene using yeast
JP2015211675A (en) * 2008-05-23 2015-11-26 ニューセリス インコーポレイテッド Production of squalene using yeast
EP3260549A1 (en) * 2008-05-23 2017-12-27 Nucelis LLC Production of squalene using yeast
JP2011520471A (en) * 2008-05-23 2011-07-21 サイバス オイルズ，エルエルシー Production of squalene using yeast
US8753842B2 (en) 2008-08-12 2014-06-17 Allylix, Inc. Method for production of isoprenoid compounds
US8481286B2 (en) 2008-08-12 2013-07-09 Allylix, Inc. Method for production of isoprenoid compounds
US8609371B2 (en) 2008-08-12 2013-12-17 Allylix, Inc. Isoprenoid compounds
US9598710B2 (en) * 2009-08-26 2017-03-21 Organobalance Gmbh Genetically modified organism for the production of lipids
US20150024009A1 (en) * 2009-08-26 2015-01-22 Organobalance Gmbh Genetically modified organism for the production of lipids
EP3219815A3 (en) * 2009-11-23 2017-11-22 Nucelis Inc. Methods and compositions for producing squalene using yeast
WO2011133610A1 (en) 2010-04-22 2011-10-27 E. I. Du Pont De Nemours And Company Method for obtaining polyunsaturated fatty acid-containing compositions from microbial biomass
WO2012027689A1 (en) 2010-08-26 2012-03-01 E. I. Du Pont De Nemours And Company Recombinant microbial host cells for high eicosapentaenoic acid production
WO2012027676A1 (en) 2010-08-26 2012-03-01 E. I. Du Pont De Nemours And Company Mutant delta-9 elongases and their use in making polyunsaturated fatty acids
WO2012027698A1 (en) 2010-08-26 2012-03-01 E.I. Du Pont De Nemours And Company Mutant hpgg motif and hdash motif delta-5 desaturases and their use in making polyunsaturated fatty acids
WO2012135773A1 (en) 2011-03-31 2012-10-04 E. I. Du Pont De Nemours And Company Yarrowia diacylglycerol acyltransferase promoter regions for gene expression in yeast
WO2012134978A2 (en) 2011-04-01 2012-10-04 Ice House America, Llc Ice bagging apparatus and methods
WO2012135777A1 (en) 2011-04-01 2012-10-04 E. I. Du Pont De Nemours And Company Yarrowia esterase/lipase promoter regions for gene expression in yeast
WO2012138613A1 (en) 2011-04-05 2012-10-11 E. I. Du Pont De Nemours And Company Yarrowia n-alkane-hydroxylating cytochrome p450 promoter regions for gene expression in yeast
WO2012138612A1 (en) 2011-04-07 2012-10-11 E. I. Du Pont De Nemours And Company Yarrowia peroxisomal 2,4-dienoyl-coa reductase promoter regions for gene expression in yeast
WO2014191205A1 (en) * 2013-05-28 2014-12-04 Wacker Chemie Ag Yeast strain and method for producing lycopene
WO2015082688A1 (en) 2013-12-06 2015-06-11 Dsm Ip Assets B.V. Biomass formulation
CN106414744B (en) * 2014-01-31 2020-11-06 帝斯曼知识产权资产管理有限公司 Promoters suitable for heterologous gene expression in yeast
WO2015116781A3 (en) * 2014-01-31 2015-11-19 Dsm Ip Assets B.V. Promoters suitable for heterologous gene expression in yeast
CN106414744A (en) * 2014-01-31 2017-02-15 帝斯曼知识产权资产管理有限公司 Promoters suitable for heterologous gene expression in yeast
EA035512B1 (en) * 2014-01-31 2020-06-29 ДСМ АйПи АССЕТС Б.В. Promoters suitable for heterologous gene expression in yeast
US10611807B2 (en) 2014-01-31 2020-04-07 Dsm Ip Assets B.V. Promoters suitable for heterologous gene expression in yeast
EP3460044A1 (en) * 2014-05-16 2019-03-27 Academia Sinica Recombinant polynucleotide sequence for producing astaxanthin and uses thereof
CN104152473A (en) * 2014-08-18 2014-11-19 中国烟草总公司郑州烟草研究院 Tobacco carotenoid isomerase gene and is application
CN104152473B (en) * 2014-08-18 2019-07-12 中国烟草总公司郑州烟草研究院 Tobacco Carotenoid isomerase gene and its application
US10308691B2 (en) 2014-12-15 2019-06-04 Temasek Life Sciences Laboratory Limited Methods for tuning carotenoid production levels and compositions in rhodosporidium and rhodotorula genera
EP3234105A4 (en) * 2014-12-15 2018-05-16 Temasek Life Sciences Laboratory Limited Methods for tuning carotenoid production levels and compositions in rhodosporidium and rhodotorula genera
US11332724B2 (en) 2015-04-21 2022-05-17 Dsm Ip Assets B.V. Microbial production of terpenoids
EP3286303A1 (en) * 2015-04-21 2018-02-28 DSM IP Assets B.V. Microbial production of terpenoids
EP3400295A4 (en) * 2016-01-08 2019-09-04 DSM IP Assets B.V. Mating type switch in yarrowia lipolytica
WO2019057999A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Production of trans-retinal
WO2019058000A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Biosynthesis of retinoids
WO2019058001A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Production of retinyl esters
US20200239924A1 (en) * 2017-09-25 2020-07-30 Dsm Ip Assets B.V. Production of retinyl esters
US11905542B2 (en) 2017-09-25 2024-02-20 Dsm Ip Assets B.V. Production of retinyl esters
WO2019057998A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Production of retinol
WO2019057996A1 (en) 2017-09-25 2019-03-28 Dsm Ip Assets B.V. Production of retinyl esters
WO2020141168A1 (en) 2018-12-31 2020-07-09 Dsm Ip Assets B.V. Novel acetyl-transferases
WO2021009194A1 (en) 2019-07-16 2021-01-21 Dsm Ip Assets B.V. Novel beta-carotene oxidases
WO2021019101A1 (en) 2019-08-01 2021-02-04 Dsm Ip Assets B.V. Beta-carotene fermentation method
WO2021136689A1 (en) 2019-12-30 2021-07-08 Dsm Ip Assets B.V. Lipase-modified strain
WO2022003130A2 (en) 2020-07-01 2022-01-06 Dsm Ip Assets B.V. Yeast expression system
WO2023006179A1 (en) 2020-07-27 2023-02-02 Dsm Ip Assets B.V. Method to produce retinyl acetate
WO2022023173A1 (en) 2020-07-27 2022-02-03 Dsm Ip Assets B.V. Reduction of fatty acid retinyl ester formation
WO2022090548A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Fermentative production of isoprenoids
WO2022090549A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. In situ two-phase extraction system
WO2022090547A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Production of carotenoids by fermentation
WO2023006851A1 (en) 2021-07-27 2023-02-02 Dsm Ip Assets B.V. Fermentative production of retinyl acetate in the presence of ethanol
WO2023067030A1 (en) 2021-10-19 2023-04-27 Dsm Ip Assets B.V. Retinoid production
WO2023148187A1 (en) 2022-02-02 2023-08-10 Dsm Ip Assets B.V. Yarrowia production process
WO2024160658A1 (en) 2023-01-30 2024-08-08 Dsm Ip Assets B.V. Novel mutants of acetyl-transferase sb-atf
WO2024160711A1 (en) 2023-01-30 2024-08-08 Dsm Ip Assets B.V. Carrp enzyme variants and their use in producing carotenoid and apocarotenoid
WO2024160712A1 (en) 2023-01-30 2024-08-08 Dsm Ip Assets B.V. Novel acetyl-transferases

Also Published As

Publication number Publication date
BRPI0609040A2 (en) 2010-01-12
US7851199B2 (en) 2010-12-14
NO20075200L (en) 2007-10-11
JP2013128497A (en) 2013-07-04
US8288149B2 (en) 2012-10-16
WO2006102342A3 (en) 2007-10-11
US20130045504A1 (en) 2013-02-21
JP2008537878A (en) 2008-10-02
UA94038C2 (en) 2011-04-11
JP2009112320A (en) 2009-05-28
KR101482081B1 (en) 2015-01-13
EA016258B1 (en) 2012-03-30
US20110021843A1 (en) 2011-01-27
EP2371967A1 (en) 2011-10-05
US20070015237A1 (en) 2007-01-18
JP2015226550A (en) 2015-12-17
ZA200707651B (en) 2011-05-25
CA2602183A1 (en) 2006-09-28
EP2371967B1 (en) 2015-06-03
CN103589650A (en) 2014-02-19
US9909130B2 (en) 2018-03-06
KR20070121679A (en) 2007-12-27
JP6267679B2 (en) 2018-01-24
CA2602183C (en) 2014-05-06
BRPI0609040B1 (en) 2018-07-31
AU2006227165B2 (en) 2011-11-10
CN101218352A (en) 2008-07-09
CN101218352B (en) 2013-09-04
EP1866428A2 (en) 2007-12-19
EA200701974A1 (en) 2008-08-29
ES2546484T3 (en) 2015-09-24
AU2006227165A1 (en) 2006-09-28
IL185713A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
US9909130B2 (en) Production of carotenoids in oleaginous yeast and fungi
US8633009B2 (en) Production of quinone derived compounds in oleaginous yeast and fungi
US11332724B2 (en) Microbial production of terpenoids
JP2008537878A5 (en)
US20120149886A1 (en) Production of carotenoids in oleaginous yeast and fungi
US8367395B2 (en) Production of sterols in oleaginous yeast and fungi
US9297031B2 (en) Production of carotenoids in oleaginous yeast and fungi
MX2007011219A (en) Production of carotenoids in oleaginous yeast and fungi

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680008816.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 185713

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 561208

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006227165

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/011219

Country of ref document: MX

Ref document number: 3439/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008502155

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2602183

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020077021286

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006227165

Country of ref document: AU

Date of ref document: 20060320

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006748522

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1200702168

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200701974

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0609040

Country of ref document: BR

Kind code of ref document: A2